As filed with the Securities and Exchange Commission on November 2, 2020

Registration No. 333-         

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form F-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

Medigus Ltd.

(Exact Name of Registrant as Specified in its Charter)

 

State of Israel   3841   Not Applicable

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Code Number)

  (I.R.S. Employer
Identification No.)

 

Tatiana Yosef

7A Industrial Park, P.O. Box 3030

Omer, 8496500, Israel

Tel: +972-73-370-4691

Fax: +972-72-260-2249

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Medigus USA LLC

1007 North Orange Street, 4th Floor,

Wilmington, DE, 19801, USA

Tel: +972-73-370-4691

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

 Dr. Shachar Hadar, Adv.

Meitar | Law Offices

16 Abba Hillel Silver Rd.

Ramat Gan 5250608, Israel

Tel: +972-3-610-3100

Email: Shacharh@meitar.com

 

Oded Har-Even, Esq.

Ron Ben-Bassat, Esq.
Sullivan & Worcester LLP

1633 Broadway

New York, NY 10019

Tel: 212.660.5000

Fax: 212.660.3001

 

Steven J. Glusband, Esq.

Guy Ben-Ami, Esq.

Carter Ledyard & Milburn LLP

2 Wall Street

New York, NY 10005

Tel: 212-238-8605

Fax: 212-732-3232

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after effectiveness of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

 

Emerging growth company ☒

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 †The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. 

 

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of each Class of Securities to be Registered   Proposed Maximum
Aggregate Offering Price(2)
    Amount of
Registration Fee(3)
 
Ordinary Shares, par value NIS 1.00 per share represented by American Depositary Shares(1)   $     $  
Total   $ 15,000,000     $ 1,636.50  

 

(1) The ordinary shares registered hereby may be represented by American Depositary Shares, or ADSs. ADSs evidenced by American depositary receipts issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-203937). Each ADS represents twenty (20) ordinary shares.

 

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, or the Securities Act.

 

(3) Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum aggregate offering price.

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

 

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

 

Subject to Completion, dated November 2, 2020

 

PRELIMINARY PROSPECTUS

 

Up to                      American Depositary Shares Representing                Ordinary Shares

 

 

We are offering up to                 American Depositary Shares, or ADSs. Each ADS represents twenty ordinary shares, par value NIS 1.00 per share, or the Ordinary Shares. We refer to the ADSs, and the underlying Ordinary Shares being offered hereby, collectively, as the Securities. See “Description of the Offered Securities” for more information.

 

Our ADSs are listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “MDGS.” On October 30, 2020, the last reported sale price of our ADSs on Nasdaq was $2.30 per ADS. Our Ordinary Shares are listed on the Tel Aviv Stock Exchange Ltd., or TASE, under the symbol “MDGS.” On November 2, 2020, the last reported sale price of our Ordinary Shares on the TASE was NIS 0.382, or $0.112 per share (based on the exchange rate reported by the Bank of Israel on such date). The actual offering price per ADS in this offering will be determined between the underwriter and us at the time of pricing, and may be at a discount to the current market price for our ADSs. We are offering all of the ADSs offered by this prospectus.

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 and are subject to reduced public company reporting requirements.

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 12 of this prospectus and other risk factors contained in the documents incorporated by reference herein for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

  

    Per ADS     Total  
Public offering price   $          $       
Underwriting discounts and commissions (1)   $       $    
Proceeds to us (before expenses)   $       $    

 

(1) For a description of the additional compensation to be received by the underwriter, see “Underwriting” beginning on page 36 for additional information regarding the underwriter compensation

 

The offering is being underwritten on a firm commitment basis. The underwriter has an option exercisable within days from the date of this prospectus to purchase up to          additional ADSs from us at the public offering price, less the underwriting discounts and commissions. If the underwriter exercises this option in full, the total underwriting discounts and commissions payable by us will be $          , and the total proceeds to us, before expenses, will be $        .

 

Delivery of the securities offered hereby is expected to be made on or about      , 2020. 

 

The date of this prospectus is                   , 2020

 

Aegis Capital Corp. 

 

 

 

 

Table of Contents

 

Prospectus Summary 1
The Offering
Summary Financial Data 10
Risk Factors 12
Cautionary Note Regarding Forward-Looking Statements 25
Use of Proceeds 26
Dividend Policy 27
Capitalization 28
Dilution 29
Description of the Offered Securities 30
Underwriting 36
Expenses Related to Offering 39
Legal Matters 39
Experts 39
Change In Registrant’s Certifying Accountant 39
Enforceability of Civil Liabilities 40
Where You Can Find Additional Information 41

 

Neither we nor the underwriter has authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus, if any, prepared by us or on our behalf. When you make a decision about whether to invest in our securities, you should not rely upon any information other than the information in this prospectus and any free writing prospectus, if any, prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of our Ordinary Shares means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or solicitation of an offer to buy these Ordinary Shares in any circumstances under which the offer or solicitation is unlawful.

 

Market data and certain industry data and forecasts used throughout this prospectus were obtained from sources we believe to be reliable, including market research databases, publicly available information, reports of governmental agencies, and industry publications and surveys. We have relied on certain data from third-party sources, including internal surveys, industry forecasts, and market research, which we believe to be reliable based on our management’s knowledge of the industry. While we are not aware of any misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” and elsewhere in this prospectus.

 

For investors outside of the United States: Neither we nor the underwriter have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.

 

Solely for convenience, some of the trademarks, service marks, and trade names referred to in this prospectus are without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies’ trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

 

i

 

 

PROSPECTUS SUMMARY

 

This summary below highlights information contained elsewhere, or incorporated by reference, in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read this summary together with the more detailed information appearing in this prospectus or incorporated by reference herein, including “Risk Factors,” “Selected Historical Financial Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Business” and our consolidated financial statements and the related notes included at the end of this prospectus or incorporated by reference herein, before making an investment in our Ordinary Shares. All references to “Medigus,” “we,” “us,” “our,” the “Company” and similar designations refer to Medigus Ltd., an Israeli company, and its consolidated subsidiaries. The terms “shekels,” “Israeli shekels” and “NIS” refer to New Israeli Shekels, the lawful currency of the State of Israel, the terms “dollar,” “US$” or “$” refer to U.S. dollars, the lawful currency of the United States. Unless derived from our consolidated financial statements or otherwise indicated, U.S. dollar translations of NIS amounts presented in this prospectus are translated using the rate of NIS 3.422 to $1.00, based on the exchange rates reported by the Bank of Israel on November 2, 2020.

 

Our Company

 

We were incorporated in the State of Israel on December 9, 1999, as a private company pursuant to the Israeli Companies Ordinance (New Version), 1983. In February 2006, we completed our initial public offering in Israel, and our Ordinary Shares have since traded on the TASE, under the symbol “MDGS”. In May 2015, we listed the ADSs on Nasdaq and since August 2015 the ADSs have been traded on Nasdaq under the symbol “MDGS”. Each ADS represents twenty (20) Ordinary Shares. Our Series C Warrants have been trading on Nasdaq under the symbol “MDGSW” since July 2018. Each Series C Warrant is exercisable into one ADS at an exercise price of $3.50 and will expire in July 2023.

 

Business Overview

 

The activities carried out by us, and our subsidiaries are focused on medical-related devices and products and on internet and other online-related technologies. Our medical related activities include miniaturized imaging equipment through Scoutcam Inc. (formerly known as Intellisense Solutions Inc.), or Scoutcam, our 49.65% held subsidiary, innovative surgical devices with direct visualization capabilities for the treatment of Gastroesophageal Reflux Disease, or GERD, by the Company using Medigus Ultrasonic Surgical Endostapler, or MUSE, and biological gels to protect patients against biological threats and prevent intrusion of allergens and viruses through the upper airways and eye cavities through our stake and licensing arrangement with Polyrizon Ltd., or Polyrizon. Our internet-related activities include ad-tech operations through our stake in Gix Internet Ltd., f/k/a Algomizer Ltd., or Gix, and its subsidiary, Linkury Ltd., or Linkury. We have also entered into agreements to acquire stakes in Eventer Technologies Ltd., or Eventer, an online event management and ticketing platform. The Eventer transaction closed on October 26, 2020.

 

The diversification of our core activity and our entry into the internet and online-related operations are in accordance with a change to our business model which we initiated in 2019. Following an analysis of our previous efforts to commercialize the MUSETM system and the ScoutCamTM portfolio, we decided to broaden our activities to include operations in fields with a shorter go-to-market pathway and increased growth potential. In accordance with this strategy, we abandoned the efforts to commercialize the MUSETM system, transferred the ScoutCamTM activity to a subsidiary, ScoutCam Ltd., and consummated a securities exchange agreement relating to ScoutCam Ltd. Since implementing these steps, we have pursued investments that have granted us substantial and controlling interests in other ventures, which we believe will provide a greater return to our shareholders.

 

1

 

 

Medical Activity Overview

 

ScoutCam Inc. – Miniaturized Imaging Equipment

 

We previously engaged in the development, production and marketing of innovative miniaturized imaging equipment known as the micro ScoutCam™ portfolio for use in medical procedures as well as various industrial applications, through our Israeli subsidiary, ScoutCam Ltd. ScoutCam Ltd. was incorporated as part of a reorganization of the Company intended to distinguish the Company’s micro ScoutCam™ portfolio from the other operations of the Company and to enable the Company to form a separate business unit with dedicated resources, focused on the promotion of our miniaturized imaging technology. After we completed the transfer of all of the Company’s assets and intellectual property related to the Company’s miniature video cameras business into ScoutCam Ltd., we consummated a securities exchange agreement with ScoutCam (formerly known as Intellisense Solutions Inc.), under which we received 60% of the issued and outstanding stock of ScoutCam in consideration for 100% of our holdings in ScoutCam Ltd. Following the aforementioned transactions, Intellisense Solutions Inc. changed its name to ScoutCam Inc. Since the securities exchange agreement, the commercialization efforts relating to the ScoutCam™ portfolio are carried out exclusively by ScoutCam. Commercially, ScoutCam has received purchase orders for its products from a Fortune 500 company in the healthcare sector and has been added to the Approved Supplier List of a leading healthcare company. ScoutCam is examining and pursuing additional applications for the micro ScoutCam™ portfolio outside of the medical device industry, including, among others, the defense, aerospace, automotive, and industrial non-destructing-testing industries, and plans to further expand the activity in these non-medical spaces.

 

Since the reorganization and spinoff of the ScoutCam activity, ScoutCam has made headway in its field both in the form of achieving commercial milestones and raising additional capital to fund its operations.

 

On March 3, 2020, ScoutCam consummated a securities purchase agreement with certain investors in connection with the sale and issuance of $948,400 worth of units, or the Units. Each Unit consisted of (i) two shares of ScoutCam’s common stock, par value $0.001 per share, or the ScoutCam Common Stock; and (ii) (a) one warrant to purchase one share of ScoutCam Common Stock with an exercise price of $0.595, or the A Warrant, and (b) two warrants to purchase one share of ScoutCam Common Stock each with an exercise price of $0.893, or the B Warrant, at a purchase price of $0.968 per Unit. In connection with the agreement, ScoutCam issued 1,959,504 shares of ScoutCam Common Stock, 979,754 A Warrants, and 1,959,504 B Warrants to purchase shares of ScoutCam Common Stock. In addition, on May 19, 2020, we announced that ScoutCam entered into and consummated a securities purchase agreement with M. Arkin (1999) Ltd. in connection with an investment of $2,000,000. Since September 14, 2020, ScoutCam’s common stock is quoted on the OTCQB Venture Market.

 

On June 23, 2020, we entered into and consummated a side letter agreement with ScoutCam, whereby the parties agreed to convert, at a conversion price of $0.484 per share, an outstanding line of credit previously extended by us to ScoutCam, which as of the date thereof was $381,136, into (i) 787,471 shares of ScoutCam Common Stock, (ii) warrants to purchase 393,736 shares of ScoutCam Common Stock with an exercise price of $0.595 with a term of twelve months from the date of issuance, and (iii) warrants to purchase 787,471 shares of ScoutCam Common Stock with an exercise price of $0.893 with a term of eighteen months from the date of issuance.

 

Our MUSE‎™‎ System

 

In addition, we have been engaged in the development, production and marketing of innovative surgical devices with direct visualization capabilities for the treatment of GERD, a common ailment, which is predominantly treated by medical therapy (e.g. proton pump inhibitors) or in chronic cases, conventional open or laparoscopic surgery. Our U.S. Food and Drug Administration, or FDA, cleared and CE-marked endosurgical system, known as the Medigus Ultrasonic Surgical Endostapler, or MUSE™ (Medigus Ultrasonic Surgical Endostapler) system, enables minimally-invasive and incisionless procedures for the treatment of GERD by reconstruction of the esophageal valve via the mouth and esophagus, eliminating the need for surgery in eligible patients. We believe that this procedure offers a safe, effective and economical alternative to the current modes of GERD treatment for certain GERD patients, and has the ability to provide results which are equivalent to those of standard surgical procedures while reducing pain and trauma, minimizing hospital stays, and delivering economic value to hospitals and payors.

 

2

 

 

GERD is a worldwide disorder, with evidence suggesting an increase in GERD disease prevalence since 1995. Treatment of GERD involves a stepwise approach. The goals are to control symptoms, to heal esophagitis and to prevent recurrent esophagitis. The most common operation for GERD is called a surgical fundoplication, a procedure that prevents reflux by wrapping or attaching the upper part of the stomach around the lower esophagus and securing it with sutures. Due to the presence of the wrap or attachment, increasing pressure in the stomach compresses the portion of the esophagus, which is wrapped or attached by the stomach, and prevents acidic gastric content from flowing up into the esophagus. Today, the operation is usually performed laparoscopically: instead of a single large incision into the chest or abdomen, four or five smaller incisions are made in the abdomen, and the operator uses a number of specially designed tools to operate under video control.

 

Our product, the MUSE™ system for transoral fundoplication is a single use innovate device for the treatment of GERD. The MUSE™ technology is based on our proprietary platform technology, experience and know-how. Transoral means that procedure is perform through the mouth, rather than through incisions in the abdomen. The MUSE™ system is used to perform a procedure as an alternative to a surgical fundoplication. The MUSE™ system offers an endoscopic, incisionless alternative to surgery. A single surgeon or gastroenterologist can perform the MUSE™ procedure in a transoral way, unlike in a laparoscopic fundoplication which requires incisions.

 

The clearance by the FDA, or ‘Indications for Use,’ of the MUSE™ system is “for endoscopic placement of surgical staples in the soft tissue of the esophagus and stomach in order to create anterior partial fundoplication for treatment of symptomatic chronic Gastro-Esophageal Reflux Disease in patients who require and respond to pharmacological therapy”. As such, the FDA clearance covers the use by an operator of the MUSE™ endostapler as described in the above paragraph. In addition, in the pivotal study presented to the FDA to gain clearance, only patients who were currently taking GERD medications (i.e. pharmacological therapy) were allowed in the study. In addition, all patients had to have a significant decrease in their symptoms when they were taking medication compared to when they were off the medication. The FDA clearance indicated that the MUSE™ system is intended for patients who require and respond to pharmacological therapy. The MUSE™ system indication does not restrict its use with respect to GERD severity from a regulatory point of view. However, clinicians typically only consider interventional treatment options for moderate to severe GERD. Therefore, it is reasonable to expect the MUSE™ system would be primarily used to treat moderate and severe GERD in practice. The system has received 510(k) marketing clearance from the FDA in the United States, as well as a CE mark in Europe.

 

On June 3, 2019, we entered into a Licensing and Sale Agreement with Shanghai Golden Grand-Medical Instruments Ltd. (Golden Grand) for the know-how licensing and sale of good relating to the MUSE™ system in China, Hong Kong, Taiwan and Macao. Under the agreement, we committed to provide a license, training services and goods to Golden Grand in consideration for $3,000,000 to be paid to us in four milestone-based installments. To date, some of these milestones have been achieved and the Company has received $1,800,000. The final milestones will be completed, and the final installment paid upon completion of a MUSE™ assembly line in China. Due to COVID-19, the implementation of certain actions required to be achieved under the milestones have been delayed, specifically due to travel restriction. In recent weeks, efforts have been renewed to achieve the next milestones.

 

3

 

 

Polyrizon Ltd. – Protective Biological Gels

 

Polyrizon Ltd. is a private company engaged in developing biological gels designed to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities.

 

In July 2020, we entered into an ordinary share purchase agreement with Polyrizon, pursuant to which we purchased 19.9% of Polyrizon’s issued and outstanding capital stock on a fully diluted basis for aggregate gross proceeds of $10,000. We also agreed to loan Polyrizon $94,000. The loan does not bear any interest and is repayable only upon a deemed liquidation event, as defined in that share purchase agreement. In addition, we have an option, or the Option, to invest an additional amount of up to $1,000,000 in consideration for shares of Polyrizon such that following the additional investment, we will own 51% of Polyrizon’s capital stock on a fully diluted basis, excluding outstanding deferred shares, as defined in the share purchase agreement. The Option is exercisable until the earlier of (i) April 23, 2023, or (ii) the consummation by Polyrizon of equity financing of at least $500,000 based on a pre-money valuation of at least $10,000,000. 

 

In addition, we entered into an exclusive reseller agreement with Polyrizon. As part of the reseller agreement, we received an exclusive global license to promote, market, and resell the Polyrizon products, focusing on a unique Biogel to protect from the COVID-19 virus. The term of the license is for four years, commencing upon receipt of sufficient FDA approvals for the lawful marketing and sale of the products globally. We also have the right to purchase the Polyrizon products on a cost-plus 15% basis for the purpose of reselling the products worldwide. In consideration of the license, Polyrizon will be entitled to receive annual royalty payments equal to 10% of our annualized operating profit arising from selling the products. To date, Poyrizon’s products have not received the requisite FDA approvals, and therefore manufacturing has not yet commenced, and commercialization efforts have not yet commenced.

 

Internet Activity Overview

 

Gix Internet Ltd.Ad-Tech and Online Advertising

 

We currently own a minority stake in Gix and its subsidiary, Linkury. Linkury operates in the field of software development, marketing, and distribution to internet users. Gix recently announced its intention to focus its efforts on Linkury, which is the primary source of Gix’s revenues and operations, with a goal of expanding its product portfolio in the field of technological solutions for advertising and media. In the coming year, Linkury plans to launch new products in the sector of advertising technologies and mobile. Furthermore, Gix continues its efforts to seek opportunities for engaging in acquisitions of companies with significant revenues and commercial potential. Gix operates through two major arms: Gix Apps, which is distributed free of charge (as browser add-ons and desktop apps) to end-users and drives revenues from the placement of advertisements, and Gix Content, a solution platform for publishers, personalized content ads and banners per users' preferences, based on Gix’s proprietary technologies.

 

Our stake in Gix was acquired pursuant to a securities purchase agreement dated June 19, 2019, or the Agreement. Pursuant to the Agreement, we are entitled, for a period of three years following the closing of the investment, to convert any and all of our Linkury shares into Gix shares with a 20% discount over the average share price of Gix on the TASE within the 60 trading days preceding the conversion. On October 14, 2020, we notified Gix of our election to convert the 793,448 ordinary shares of Linkury that we currently own into Gix’s ordinary shares in accordance with the Agreement. As a result of the conversion, we will be entitled to receive 9,858,698 ordinary shares of Gix, which will constitute approximately 33% of Gix’s issued and outstanding share capital following the conversion. Pursuant to the provisions of the Companies Law, the issuance of shares representing 25% or more of the voting rights in a public company is subject to prior shareholder approval. We have requested that Gix convene a shareholder meeting as soon as practicably possible in order to obtain the requisite approval and affect the conversion.

 

4

 

 

Eventer Technologies Ltd. – Online Event Management

 

Eventer is a technology company engaged in the development of unique tools for automatic creation, management, promotion, and billing of events and ticketing sales. Eventer seeks to tap the growing demand for enterprise and private online communication over the last year. As such, Eventer’s systems offer and enable advanced, user-friendly solutions for online events such as online concerts, enterprise events and online conferences, in addition to management and ticket sales for events carried out in offline venues. In addition, Eventer’s platform provides individuals with the ability to create and sell tickets to custom small-scale private or public events. Eventer’s revenues are derived from commissions from sales of tickets for online and offline events planned and managed through its platform.

 

On October 14, 2020, we signed a share purchase agreement and a revolving loan agreement with Eventer. The Eventer transaction closed on October 26, 2020. Pursuant to the share purchase agreement, we invested $750,000 and were issued an aggregate of 325,270 ordinary shares of Eventer, representing 50.01% of Eventer’s issued and outstanding share capital on a fully diluted basis. The share purchase agreement provides that we will invest an additional $250,000 in a second tranche, subject to Eventer achieving certain post-closing EBITDA based milestones during the fiscal years 2020 through 2023, or the Milestones. In the event that Eventer partially achieves the Milestones, the $250,000 investment will be reduced in proportion to the Milestones that were achieved.

 

In addition, we entered into a revolving loan agreement with Eventer, or the Loan Agreement, under which we committed to lend up to $1,250,000 to Eventer through advances of funds upon Eventer’s request and subject to our approval. We extended an initial advance of $250,000 upon closing the Loan Agreement, or the Initial Advance. Advances extended under the Loan Agreement may be repaid and borrowed in part or in full from time to time. The Initial Advance will be repaid in twenty-four equal monthly installments, commencing on the first anniversary of the Loan Agreement. Other advances extended under the Loan Agreement will be repaid immediately following, and in no event later than thirty days following the completion of the project or purpose for which they were made. Outstanding principal balances on the advances will bear interest at a rate equal to the higher of (i) 4% per year, or (ii) the interest rate determined by the Israeli Income Tax Ordinance [New Version] 5721-1961 and the rules and regulation promulgated thereunder. Interest payments will be made on a monthly basis.

 

5

 

 

On October 14, 2020, we entered a share exchange agreement with Eventer’s shareholders, or the Exchange Agreement, pursuant to which, during the period commencing on the second anniversary of the Exchange Agreement and ending fifty-four (54) months following the date of the Exchange Agreement, Eventer’s shareholders may elect to exchange all of their Eventer shares for ordinary shares of our company. The number of ordinary shares of the Company to which Eventer’s shareholders would be entitled pursuant to an exchange will be calculated by dividing the fair market value of each Eventer’s ordinary share, as mutually determined by our company and the shareholders, by the average closing price of an ordinary share of our company on the principal market on which its ordinary shares or ADSs are traded during the sixty days prior to the exchange date rounded down to the nearest whole number. Our board of directors may defer exchange’s implementation in the event it determines in good faith that doing so would be materially detrimental to the Company and its shareholders. In addition, the exchange may not be effected for so long as $600,000 or greater remains outstanding under the Loan Agreement, or if an event of default under the Loan Agreement has occurred.

 

Other Activities

 

Matomy Media Group Ltd.

 

We hold approximately 24.92% of the outstanding share capital of Matomy Media Group Ltd.’s, or Matomy. Matomy is dually listed on the London Stock Exchange and the TASE, and its shares are currently suspended from trading due to non-compliance with the London Stock Exchange listing rules relating to shell corporation status and maintaining an active business.

 

On September 29, 2020, Matomy announced that it has entered into a memorandum of understanding, or the Automax MOU, with Global Automax Ltd., or Automax, an Israeli private company that imports various leading car brands to Israel and Automax’s shareholders. The Automax MOU provides for a proposed merger in which the shareholders of Automax would exchange 100% of their shares in Automax for shares of Matomy, or the Proposed Merger. Under the Automax MOU, Automax and Matomy have agreed on an exclusivity period of 60 days. Save for the exclusivity period, the Automax MOU is non-binding.

 

According to the announcement, Matomy expects to sign a binding agreement for the Proposed Merger during the fourth quarter of 2020. Matomy also expects that, upon completion of the Proposed Merger, Automax shareholders would hold approximately 53% of the outstanding share capital of Matomy and potentially up to a maximum of 73%, due to additional share issuances which are subject to achievement of certain revenue and profit milestones by Matomy, or if the value of the Matomy’s shares reach specific values after the Proposed Merger. There can be no guarantee that the Proposed Merger will be completed, or a binding agreement will be signed for the Proposed Merger.

 

On October 20, 2020, Matomy held an extraordinary general meeting of shareholders and approved the cancellation of the admission of Matomy’s ordinary shares for trading on the High Growth Segment of the London Stock Exchange.

 

6

 

 

Recent Developments

 

Underwritten Public Offering

 

On May 22, 2020, we closed an underwritten public offering of (i) 575,001 ADSs at a public offering price of $1.50 per ADS, and (ii) 2,758,333 pre-funded warrants to purchase one ADS at a public offering price of $1.499. The gross proceeds from this offering were approximately $5,000,000 before deducting underwriting discounts, commissions and other offering expenses. The pre-funded warrants, which were exercisable at any time after the date of issuance upon payment of the exercise price of $0.001 per ADS, have been exercised in full.

 

GERD Patent Infringement Litigation

 

On July 13, 2020, our subsidiary, GERD IP, Inc., a Delaware corporation, filed a complaint in the United States District Court for the District of Delaware alleging infringement of two of its proprietary patents issued by the United States Patent and Trademark Office by EndoGastric Solutions, Inc. or the Defendant. On August 27, 2020 GERD IP, Inc. filed an amended complaint and on September 9, 2020 the Defendant filed an answer.

 

Smart Repair Pro, Inc. and Purex Inc. – Investment and Secondary

 

On October 8, 2020, we entered into a common stock purchase agreement with Smart Repair Pro, Inc., or Pro, Purex Inc., or Purex, and their respective stockholders, or the Purex Purchase Agreement. Pursuant to the Purex Purchase Agreement, we will acquire 50.01% of each of Pro and Purex issued and outstanding share capital on a fully diluted basis, acquired through a combination of cash investments in the companies and acquisition of additional shares from the current shareholders of the two companies in consideration for restricted ADSs of our company and a cash component. We will invest an aggregate amount of $1,250,000 in Pro and Purex, pay $150,000 in cash consideration to the current stockholders, and issue $500,000 worth of restricted ADSs to the current stockholders of such companies, with the value of restricted ADSs to be subject to downward adjustment based on the 2020 results of the two companies. In addition, the companies’ current shareholders will be entitled to additional milestone issuances of up to an aggregate $750,000 in restricted ADSs subject to the achievement by Pro and Purex of certain milestones throughout 2021. The transactions contemplated in the definitive agreements are subject to customary closing conditions.

 

The Purex Purchase Agreement provides that within 14 days following the closing of the Purchase Agreement, we and the stockholders of Pro and Purex will each extend a loan equal to $250,000 pursuant to the terms of a loan agreement provided by us, for the purpose of financing the ongoing capital requirements of the two companies.

 

Delisting from the Tel Aviv Stock Exchange Ltd.

 

On October 22, 2020, our board of directors resolved to take steps to voluntarily delist our ordinary shares from trading on the TASE. We are delisting our ordinary shares from TASE in order to be subject to one set of listing regulations instead of two, to allow greater flexibility to execute our business and financing strategy and to reduce administrative costs, in order to maximize shareholder value in the medium and long term.

 

Following the delisting in Israel, our ADSs will continue to trade on the Nasdaq Stock Market. We are urging the holders of our ordinary shares to convert their shares into ADSs through their banks and brokers. Every twenty (20) ordinary shares are convertible into one (1) ADS.

 

Under applicable Israeli law, including Section 35BB of the Israeli Securities Law, the delisting of our ordinary shares from trading on the TASE will take place three months after the date of this announcement. The last trading day of our ordinary shares on the TASE will be January 21, 2021, and our ordinary shares will be delisted from TASE on January 25, 2021. During the interim period, our ordinary shares will continue to be traded on the TASE. Following the delisting, the Company will continue to file public reports and make public disclosures in accordance with the rules and regulations of the SEC and Nasdaq.

 

Corporate Information

 

We are a public limited liability company and operate under the provisions of Israel’s Companies Law, 5759-1999, as amended, or the Companies Law. Our registered office and principal place of business are located at Omer Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel and our telephone number in Israel is +972-73-370-4691. Our website address is www.medigus.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this prospectus. Our registered agent in the United States is Medigus USA LLC. The address of Medigus USA LLC is 1007 North Orange Street, 4th Floor, Wilmington, DE, 19801, USA.

 

7

 

 

THE OFFERING

 

ADSs offered by us in the offering  

      ADSs representing               Ordinary Shares.

   
Total number of Ordinary Shares outstanding immediately before this offering  

             Ordinary Shares.

     
Total number of Ordinary Shares outstanding immediately after this offering                Ordinary Shares.
     
The ADSs  

Each ADS represents twenty (20) Ordinary Shares. The ADSs will be evidenced by American Depositary Receipts, or ADRs, executed and delivered by The Bank of New York Mellon, as Depositary.

 

The Depositary, as depositary, will be the holder of the Ordinary Shares underlying your ADSs and you will have rights as provided in the Deposit Agreement, among us, The Bank of New York Mellon, as Depositary, and all owners and holders from time to time of ADSs issued thereunder, or the Deposit Agreement, a form of which has been filed as Exhibit 1 to the Registration Statement on Form F-6 filed by The Bank of New York Mellon with the SEC on May 7, 2015.

  

The Depositary will charge you fees for such exchanges pursuant to the Deposit Agreement.

 

To better understand the terms of the ADSs, you should carefully read the section in this prospectus entitled “Description of the Offered Securities.” We also encourage you to read the Deposit Agreement, which is incorporated by reference as an exhibit to the registration statement that includes this prospectus.

     
Offering Price  

The offering price is $        per ADS. The actual offering price per ADS in this offering will be determined between us and the underwriter at the time of pricing, and may be at a discount to the current market price for our ADSs. 

     
Use of proceeds  

We expect to receive approximately $     million in net proceeds from the sale of ADSs offered by us in this offering (approximately $      million if the underwriter exercises its over-allotment option in full), based upon an assumed public offering price of $      per ADS, the last reported sale price of our ADSs on Nasdaq on     , 2020. The actual offering price per share in this offering will be determined between us and the underwriter at the time of pricing, and may be at a discount to the current market price.

 

We will use the net proceeds that we receive from the sale of the securities offered by this prospectus for general corporate purposes and working capital. See “Use of Proceeds” for additional information. 

 

8

 

 

Risk factors   Investing in our securities involves a high degree of risk. Before deciding to invest in our securities, you should carefully consider the risks related to our business, the offering and our securities, and our location in Israel. See “Risk Factors” and “Item 3. - Key Information – D. Risk Factors in our 2019 Annual Report on Form 20-F filed with the SEC, on April 21, 2020 incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors you should carefully consider before investing in our securities.
     
Listing   Our ADSs are listed on Nasdaq under the symbol “MDGS” and our Ordinary Shares currently trade on the TASE in Israel under the symbol “MDGS.”
     
Depositary   The Bank of New York Mellon.

 

The number of our ADSs and Ordinary Shares to be outstanding immediately after this offering as shown above assume that all of the ADSs offered hereby are sold and is based on 153,177,438 Ordinary Shares outstanding as of October 28, 2020, and excludes:

 

  5,913,630 Ordinary Shares issuable upon the exercise of outstanding options at a weighted average exercise price of NIS 0.71 per share or $0.21 per share (based on the exchange rate reported by the Bank of Israel on such date), equivalent to 295,682 ADSs at a weighted average exercise price of $4.20 per ADS; and

 

85,988,240 Ordinary Shares issuable upon the exercise of warrants to purchase up to an aggregate of 4,299,412 ADSs at a weighted average exercise price of $5.26 per ADS.

 

Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options or warrants described above.

 

9

 

 

Summary Financial Data

 

The following consolidated statement of operations data for the years ended December 31, 2019, 2018 and 2017 is derived from our audited consolidated financial statements incorporated by reference herein. The consolidated statement of operations data for the period of six months ended June 30, 2019 and 2020 is derived from our unaudited interim condensed consolidated financial statements as of June 30, 2020 also incorporated by reference herein. The consolidated balance sheet data as of June 30, 2020 is derived from our unaudited interim condensed consolidated financial statements as of June 30, 2020 also incorporated by reference herein. These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as set forth by the International Accounting Standard Board. The selected consolidated financial data set forth below should be read in conjunction with and are qualified by reference to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and notes thereto and other financial information included elsewhere in this registration statement or incorporated by reference herein. 

 

    Year Ended December 31,     Six Months Ended
June 30,
 
    2017     2018     2019     2019     2020  
    Audited     Unaudited  
    (U.S. Dollars, in thousands, except per share and weighted
average shares data)
 
Consolidated Statements of Loss and Other Comprehensive Loss      
Revenues   $ 467     $ 436     $ 273     $ 144     $ 73  
Cost of revenues                                        
Products and services     219       279       455       242       276  
Inventory impairment     297       328       -       -       -  
Gross loss     (49 )     (171 )     (182 )     (98 )     (203 )
Research and development expenses     (2,208 )     (1,809 )     (609 )     (471 )     (356 )
Sales and marketing expenses     (846 )     (1,354 )     (326 )     (232 )     (213 )
General and administrative expenses     (3,005 )     (3,338 )     (3,081 )     (1,168 )     (2,639 )
Net change in fair value of financial assets at fair value through profit or loss     -       -       92       -       (323 )
Share of net loss of associate accounted for using the equity method     -       -       (216 )     -       (138 )
Amortization of excess purchase price of an associate     -       -       -       -       (546 )
Listing expenses     -       -       (10,098 )             -  
Operating loss     (6,108 )     (6,672 )     (14,420 )     (1,969 )     (4,418 )
Changes  in fair value of warrants issued to investors     3,502       148       142       7       789  
Financing income (expenses), net     54       (54 )     99       154       30  
Loss before taxes on income     (2,552 )     (6,578 )     (14,179 )     (1,808 )     (3,599 )
Tax benefit (Taxes on income)     7       (20 )     1       4       -  
Loss for the period   $ (2,545 )   $ (6,598 )   $ (14,178 )   $ (1,804 )   $ (3,599 )
Other comprehensive loss for the period, net of tax     -       -       (41 )     -       4  
Total comprehensive loss for the period   $ (2,545 )   $ (6,598 )   $ (14,219 )   $ (1,804 )   $ (3,595 )
Basic loss per ordinary share(1)   $ (0.20 )   $ (0.16 )   $ (0.18 )   $ (0.02 )   $ (0.04 )
Diluted loss per ordinary share(1)   $ (0.23 )   $ (0.16 )   $ (0.18 )   $ (0.02 )   $ (0.04 )
Weighted average number of Ordinary Shares outstanding used to compute (in thousands) (1):                                        
Basic loss per share     12,569       41,988       78,124       75,932       90,416  
Diluted loss per share     12,969       41,988       78,124       75,932       90,416  

 

(1) Adjusted to reflect: a 1-for-10 reverse share split of our Ordinary Shares effected on July 13, 2018, together with a change in the ratio of Ordinary Shares per ADSs, such that after the reverse share split was implemented each ADS represents 20 post- reverse share split Ordinary Shares, instead of 50 pre- reverse share split Ordinary Shares.

 

10

 

 

    As of June  30, 2020  
    Unaudited  
    Actual           As
Adjusted(1)
 
    (U.S. Dollars in thousands)  
Consolidated Balance Sheet Data:                  
Cash and cash equivalents   $ 10,172                $        
Total assets     17,898                  
Total non-current liabilities     58                  
Accumulated deficit     (79,210 )                
Total shareholders’ equity     13,437                  

 

(1) As adjusted gives further effect to the issuance and sale in this offering of                 ADSs representing      Ordinary Shares at the assumed public offering price of $       per ADS, the last reported sales price of our ADSs on the Nasdaq on           , 2020, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

11

 

  

RISK FACTORS

 

An investment in our securities involves significant risks. Before making an investment in our securities, you should carefully read all of the information contained in this prospectus and in the documents incorporated by reference herein, including the risk factors contained in our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the SEC on April 21, 2020. For a discussion of risk factors that you should carefully consider before deciding to purchase any of our securities, please review the additional risk factors disclosed below and the information under the heading “Risk Factors” in the accompanying prospectus. The risks and uncertainties described below are not the only risks facing us. Please note that additional risks not currently known to us or that we currently deem immaterial also may adversely affect our business, results of operations, financial condition and prospects. Our business, financial condition, results of operations and prospects could be materially and adversely affected by these risks, and you may lose all or part of your original investment.

 

Risks Related to Our Business and the Business of our Subsidiaries

 

We made material changes to our business strategy during 2019, which we continued to implement in 2020. We cannot guarantee that any of these changes will result in any value to our shareholders.

 

Since 2019, we have materially changed our business model, adjusted our exclusive focus on the medical device industry to include other industries, abandoned our strategy to commercialize the MUSE system, transferred our ScoutCam™ activity into our subsidiary, ScoutCam Ltd., and consummated a securities exchange agreement in relation to ScoutCam Ltd. As a result of these changes, we have acquired substantial stakes in a number of ventures, including but not limited to online business activities such as ad-tech and online event management. We cannot guarantee that these strategic decisions will derive the anticipated value to our shareholders, or any value at all and us.

 

We have had a history of losses and our ability to grow sales and achieve profitability are unpredictable.

 

We have incurred losses since our incorporation. As of June 30, 2020, we had an accumulated deficit of $79.2 million and incurred total comprehensive losses of approximately $14.2 million, $6.6 million and $3.6 million in the years ended December 31, 2019 and 2018 and the six months ended June 30, 2020, respectively. Our ability to reach profitability depends on many factors, which include:

 

  successfully implementing our business strategy;

  

  increasing revenues; and

  

  controlling costs

 

There can be no assurance that we will be able to successfully implement our business plan, meet our challenges and become profitable in the future.

 

Changes in laws and regulations related to the Internet or changes in the Internet infrastructure itself may diminish the demand for our products and services and could harm our business.

 

The future success of the online businesses of our subsidiaries depends upon the continued use of the internet as a primary medium for commerce, communication, and business applications. Federal, state, or foreign government bodies or agencies have in the past adopted, and may in the future adopt, laws or regulations affecting the use of the Internet as a commercial medium. The adoption of any laws or regulations that could reduce the growth, popularity, or use of the Internet, including laws or practices limiting Internet neutrality, could decrease the demand for, or the usage of, services provided by Eventer and Gix increase the cost of doing business and harm our results of operations. Changes in these laws or regulations could require our subsidiaries and us to modify our offerings, or certain aspects of them, in order to comply with these changes. In addition, government agencies or private organizations have imposed and may impose additional taxes, fees, or other charges for accessing the Internet or commerce conducted via the Internet. These laws or charges could limit the growth of Internet-related commerce or communications generally, or result in reductions in the demand for Internet-based products such as those of our subsidiaries. In addition, the use of the Internet as a business tool could be harmed due to delays in the development or adoption of new standards and protocols to handle increased demands of Internet activity, security, reliability, cost, ease-of-use, accessibility, and quality of service. Further, the applicability and demand for services and products offered by our subsidiaries and us depend on the quality of our users’ access to the Internet. Certain features of our offerings, and specifically those of Eventer, may require significant bandwidth and fidelity to work effectively. Internet access is frequently provided by companies that have significant market power that could take actions that degrade, disrupt, or increase the cost of access to our services, which would negatively impact our results. The Internet's performance and its acceptance as a business and commerce tool have been harmed by “viruses,” “worms” and similar malicious programs, and the Internet has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure. If the Internet’s use is adversely affected by these issues, demand for the services provided by our subsidiaries and us could decline.

 

12

 

  

The global outbreak of COVID-19 (coronavirus) may negatively impact the global economy in a significant manner for an extended period of time, and also adversely affect our operating results in a material manner. 

 

The COVID-19 pandemic, including the efforts to combat it, has had and may continue to have a widespread effect on our business. In response to the pandemic, public health authorities and local and national governments have implemented measures that have and may continue to impact our business, including voluntary or mandatory quarantines, restrictions on travel and orders to limit the activities of non-essential workforce personnel. As of the date of this registration statement, the COVID-19 (coronavirus) pandemic had made a significant impact on global economic activity, with governments around the world, including Israel, having closed office spaces, public transportation and schools, and restricting travel. These closures and restrictions, if continued for a sustained period, could trigger a global recession that could negatively impact our business in a material manner. We are actively monitoring the pandemic and we are taking any necessary measures to respond to the situation in cooperation with the various stakeholders.

 

In light of the evolving nature of the pandemic and the uncertainty it has produced around the world, we do not believe it is possible to predict with precision the pandemic’s cumulative and ultimate impact on our future business operations, liquidity, financial condition and results of operations. For example, travel restrictions have adversely affected our ability to timely achieve certain milestones included in our Golden Grand Agreement and has delayed the recognition revenues deriving therefrom. These travel restrictions have also impacted our sales and marketing efforts and those of our subsidiaries.

 

The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration of the spread of the outbreak and any future “waves” of the outbreak, globally and specifically within Israel and the United States. In addition, the extent of the impact on capital and financial markets, foreign currencies exchange and governmental or regulatory orders that impact our business are highly uncertain and cannot be predicted. If economic conditions generally or in the industries in which we operate specifically, worsen from present levels, our results of operations could be adversely affected and our financial condition will depend on future developments that are highly uncertain and cannot be predicted, including new government actions or restrictions, new information that may emerge concerning the severity, longevity and impact of the COVID-19 pandemic on economic activity.

 

Additionally, concerns over the economic impact of the pandemic have caused extreme volatility in financial markets, which has adversely impacted and may continue to adversely impact our share price and our ability to access capital markets. To the extent the pandemic or any worsening of the global business and economic environment as a result adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section and the risk factors in our Annual Report on Form 20-F for the year ended December 31, 2019. 

 

If our subsidiaries fail to offer high-quality support to customer service, their brand and reputation could suffer.

 

Eventer’s clients rely on the platform to plan and manage online and offline events and expect a high level of user experience and customer service relating to both the event management functions of the platform as well as ticket sales. Providing such quality service is imperative for ensuring customer success, sustaining sales growth, and developing Eventer’s business. To the extent that Eventer cannot provide real-time support for users of its platforms, the platform may become less attractive to potential users, and their results of operations may be harmed.

 

Unfavorable conditions in the industry of our subsidiaries and the global economy in general could limit their ability to grow their business and negatively affect their operations results.

 

The results of operations of our subsidiaries may vary based on the impact of changes in the industry or the global economy on their customers or the subsidiaries. Our subsidiaries’ businesses revenue growth and potential profitability and our subsidiaries depend on the demand for our services and products, including the demand online and offline events and advertising. Current or future economic uncertainties or downturns could adversely affect our business and results of operations. Negative conditions in the global economy or individual markets, including changes in gross domestic product growth, financial and credit market fluctuations, political turmoil, natural catastrophes, warfare and terrorist attacks in Israel, the United States or elsewhere, could cause a decrease in business investments, leisure related spending, event organization and organization spend on marketing and advertising which could negatively affect our business.

 

Gix and Eventer each rely on key employees and highly skilled personnel, and, if they are unable to attract, retain or motivate qualified personnel, they may not be able to operate its business effectively.

 

The success of Gix and Eventer depends largely on the continued employment of their senior management and key personnel who can effectively operate its business and its ability to attract and retain skilled employees. Competition for highly skilled management, technical, research and development, and other employees is intense, and Gix and Eventer may not be able to attract or retain highly qualified personnel in the future. If any of the key employees of Gix and Eventer leave or are terminated, and such companies fail to manage a transition to new personnel effectively, or if they fail to attract and retain qualified and experienced professionals on acceptable terms, the business, financial condition and results of operations of Gix and Eventer could be adversely affected.

 

13

 

 

We, and our subsidiaries, are subject to stringent and changing laws, regulations, standards, and contractual obligations related to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could harm our business.

 

Our subsidiaries and we receive, collect, store, process, transfer, and use personal information and other data relating to users of our products, our employees and contractors, and other persons. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of certain data, including personal information. We are subject to numerous federal, state, local, and international laws, directives, and regulations regarding privacy, data protection, and data security and the collection, storing, sharing, use, processing, transfer, disclosure, and protection of personal information and other data, the scope of which are changing, subject to differing interpretations, and may be inconsistent among jurisdictions or conflict with other legal and regulatory requirements. We are also subject to certain contractual obligations to third parties related to privacy, data protection and data security. We strive to comply with our applicable policies and applicable laws, regulations, contractual obligations, and other legal obligations relating to privacy, data protection, and data security to the extent possible. However, the regulatory framework for privacy, data protection and data security worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and it is possible that these or other actual or alleged obligations may be interpreted and applied in a manner that we do not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other legal obligations or our practices. Further, any significant change to applicable laws, regulations or industry practices regarding the collection, use, retention, security or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of users or other data subjects for the collection, use, retention or disclosure of such data must be obtained, could increase our costs and require us to modify our services and features, possibly in a material manner, which we may be unable to complete, and may limit our ability to store and process user data or develop new services and features.

 

If our subsidiaries or we were found in violation of any applicable laws or regulations relating to privacy, data protection, or security, our business may be materially and adversely affected and we would likely have to change our business practices and potentially the services and features available through our platform. In addition, these laws and regulations could impose significant costs on us and could constrain our ability to use and process data in manners that may be commercially desirable. In addition, if a breach of data security were to occur or to be alleged to have occurred, if any violation of laws and regulations relating to privacy, data protection or data security were to be alleged, or if we had any actual or alleged defect in our safeguards or practices relating to privacy, data protection, or data security, our solutions may be perceived as less desirable, and our business, prospects, financial condition, and results of operations could be materially and adversely affected.

 

We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions. For example, the data protection landscape in the European Union (“EU”) is currently evolving, resulting in possible significant operational costs for internal compliance and risks to our business. The EU adopted the General Data Protection Regulation or GDPR, which became effective in May 2018, and contains numerous requirements and changes from previously existing EU laws, including more robust obligations on data processors and heavier documentation requirements for data protection compliance programs by companies. Among other requirements, the GDPR regulates the transfer of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. Failure to comply with the GDPR could result in penalties for noncompliance (including possible fines of up to the greater of €20 million and 4% of our global annual turnover for the preceding financial year for the most serious violations, as well as the right to compensation for financial or non-financial damages claimed by individuals under Article 82 of the GDPR).

 

In addition to the GDPR, the European Commission has another draft regulation in the approval process that focuses on a person’s right to conduct a private life. The proposed legislation, known as the Regulation of Privacy and Electronic Communications, or ePrivacy Regulation, would replace the current ePrivacy Directive. Originally planned to be adopted and implemented at the same time as the GDPR, the ePrivacy Regulation is still being negotiated.

 

Additionally, in June 2018, California passed the California Consumer Privacy Act, or CCPA, which provides new data privacy rights for California consumers and new operational requirements for covered companies. Specifically, the CCPA provides that covered companies must provide new disclosures to California consumers and afford such consumers new data privacy rights that include the right to request a copy from a covered company of the personal information collected about them, the right to request deletion of such personal information, and the right to request to opt-out of certain sales of such personal information. The CCPA became operative on January 1, 2020. The California Attorney General can enforce the CCPA, including seeking an injunction and civil penalties for violations. The CCPA also provides a private right of action for certain data breaches expected to increase data breach litigation. The CCPA may require us to modify our data practices and policies and to incur substantial costs and expenses in order to comply. A new privacy law, the California Privacy Rights Act, or CPRA, was recently certified by the California Secretary of State to appear on the ballot for the November 3, 2020 election. If this initiative is approved by California voters, the CPRA would significantly modify the CCPA, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. More generally, some observers have noted the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. Further, in March 2017, the United Kingdom (“U.K.”) formally notified the European Council of its intention to leave the EU pursuant to Article 50 of the Treaty on European Union (“Brexit”). The U.K. ceased to be an EU Member State on January 31, 2020, but enacted a Data Protection Act substantially implementing the GDPR, effective in May 2018, which was further amended to align more substantially with the GDPR following Brexit. It is unclear how U.K. data protection laws or regulations will develop in the medium to longer-term and how data transfers to and from the U.K. will be regulated. Some countries also are considering or have enacted legislation requiring local storage and processing of data that could increase the cost and complexity of delivering our services.

 

14

 

 

In addition, failure to comply with the Israeli Privacy Protection Law 5741-1981, and its regulations as well as the guidelines of the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including class actions), and in certain cases, criminal liability. Current pending legislation may result in a change in the current enforcement measures and sanctions.

 

Any failure or perceived failure by our subsidiaries or by us to comply with our posted privacy policies, our privacy-related obligations to users or other third parties, or any other legal obligations or regulatory requirements relating to privacy, data protection, or data security may result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our users to lose trust in us, and otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations, other obligations, and policies that are applicable to the businesses of our users may limit the adoption and use of, and reduce the overall demand for, our platform. Additionally, if third parties we work with violate applicable laws, regulations, or contractual obligations, such violations may put our users’ data at risk, could result in governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our users to lose trust in us, and otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection practices, even if unrelated to our business, industry, or operations, may lead to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities, which may increase our costs and risks.

 

Risks Related to the Business of Eventer Technologies Ltd.

 

Eventer’s business is highly sensitive to public tastes. It is dependent on its ability to secure popular artists and other live music events. Eventer’s ticketing clients may be unable to anticipate or respond to consumer preferences changes, which may result in decreased demand for its services.

 

Eventer’s business is highly sensitive to rapidly changing public tastes and is dependent on the availability of popular artists and events. Eventer’s live entertainment business depends on its ability to anticipate the tastes of consumers and offer events that appeal to them. Since Eventer relies on unrelated parties to create and perform at live music events as well as online events, any lack of availability of popular artists could limit its ability to generate revenue. If artists do not choose to perform, or if Eventer cannot secure performances and events to be managed and ticketed through its platform, Eventer’s business would be adversely affected. Furthermore, Eventer’s business could be adversely affected if artists utilizing its platform do not tour or perform as frequently as anticipated, or if such tours or performances are not as widely attended by fans as anticipated due to changing tastes, general economic conditions or otherwise.

 

Eventer faces intense competition in the online and offline event and ticketing industries. It may not be able to maintain or increase its current revenue, which could adversely affect its business, financial condition, and operations results.

 

Eventer is active in highly competitive industries, and it may not be able to maintain or increase its current revenue due to such competition. Online and offline leisure events compete with other entertainment forms for consumers’ discretionary spending and within this industry, Eventer faces competition from other promoters and venue operators. Eventer’s competitors compete for relationships with popular music artists and other service providers who have a history of being able to book artists for concerts and events. These competitors may engage in more extensive development efforts, undertake more far-reaching marketing campaigns, adopt more aggressive pricing policies and make more attractive offers to existing and potential artists. Due to increasing artist influence and competition to attract and maintain artist clients for events managed on Eventer’s platform, it may enter into agreements on terms that are less favorable to it, which could negatively impact the number of commissions collected from ticket sales which may adversely affect its financial results. Eventer’s competitors may develop services and advertising options equivalent to or superior to those they provide or achieve greater market acceptance and brand recognition than it achieves. Across the live music and entertainment industry, it is possible that new competitors may emerge and rapidly acquire significant market share.

 

Eventer’s business faces significant competition from other ticketing service providers to continuously secure new and retain existing clients. Additionally, it faces significant and increasing challenges from companies that sell self-ticketing systems and clients who choose to self-ticket by integrating such systems into their existing operations or the acquisition of primary ticket services providers. The advent of new technology, particularly as it relates to online ticketing, has amplified this competition. The intense competition that Eventer faces in the ticketing industry could cause the volume of ticketing services to decline.

 

15

 

 

The success of Eventer’s event management and ticketing solutions and other operations depends, in part, on the integrity of its systems and infrastructure, as well as affiliate and third-party computer systems, Wi-Fi, and other communication systems. System interruption and the lack of integration and redundancy in these systems and infrastructure may have an adverse impact on its business, financial condition, and operations results.

 

System interruption and the lack of integration and redundancy in the information systems and infrastructure, utilized for Eventer’s platform as well as other computer systems and third-party software, Wi-Fi and other communications systems service providers on which Eventer relies, may adversely affect its ability to operate the platform, process and fulfill transactions, respond to customer inquiries and generally maintain cost-efficient operations. Such interruptions could occur by virtue of natural disasters, malicious actions such as hacking or acts of terrorism or war, or human error. In addition, the loss of some or all of certain key personnel could require Eventer to expend additional resources to continue to maintain its software and systems and could subject it to systems interruptions. The infrastructure required to operate Eventer’s platform requires an ongoing investment of time, money, and effort to maintain or refresh hardware and software and ensure it remains at a level capable of servicing the demand and volume of business it receives. Failure to do so may result in system instability, degradation in performance, or unfixable security vulnerabilities that could adversely impact both the business and the consumers utilizing Eventer’s services.

 

While Eventer has backup systems for certain aspects of its operations, disaster recovery planning by its nature cannot be sufficient for all eventualities. In addition, Eventer may not have adequate insurance coverage to compensate for losses from a major interruption. If any of these adverse events were to occur, it could adversely affect Eventer’s business, financial condition, and operations results.

 

Eventer’s success depends, in significant part, on entertainment and leisure events and economic and other factors adversely affecting such events could have a material adverse effect on its business, financial condition and results of operations.

 

A decline in attendance at or reduction in the number of entertainment and leisure events may have an adverse effect on Eventer’s revenue and operating income. In addition, during periods of economic slowdown and recession, many consumers have historically reduced their discretionary spending and advertisers have reduced their advertising expenditures. The impact of economic slowdowns on Eventer’s business is difficult to predict, but they may result in reductions in ticket sales and the ability to generate revenue. The risks associated with Eventer’s businesses may become more acute in periods of a slowing economy or recession, which may be accompanied by a decrease in attendance at entertainment and leisure events. Many of the factors affecting the number and availability of entertainment and leisure events are beyond Eventer’s control. For example, COVID-19 has led to lockdowns and governmental restrictions on live entertainment and leisure events as well as restrictions regarding the attendance of such events. Although Eventer’s platform supports the management and ticketing of online events, there is no assurance that online events will generate demand on par with live events, which could adversely affect Eventer’s operations results.

 

Eventer’s business depends on discretionary consumer and enterprise spending. Many factors related to corporate spending and discretionary consumer spending, including economic conditions affecting disposable consumer income such as unemployment levels, fuel prices, interest rates, changes in tax rates and tax laws that impact companies or individuals, and inflation can significantly impact Eventer’s operating results. Business conditions, as well as various industry conditions, including corporate marketing and promotional spending and interest levels, can also significantly impact Eventer’s operating results. These factors can affect attendance at online and offline events, advertising, and spending, as well as the financial results of venues, events, and the industry. Negative factors such as challenging economic conditions and public concerns over terrorism and security incidents, particularly when combined, can impact corporate and consumer spending and one negative factor can result in more than another. There can be no assurance that consumer and corporate spending will not be adversely impacted by current economic conditions or by any future deterioration in economic conditions, thereby possibly impacting Eventer’s operating results and growth.

 

16

 

 

If Eventer fails to maintain and improve the quality of its platform, it may not be able to attract clients seeking to manage their online and offline events or facilitate ticket sales for events.

 

To satisfy both clients seeking to manage online and offline events through Eventer’s platform, Eventer needs to continue to improve the user experience and innovate and introduce features and services that both event managers and ticket purchasers find useful cause them to use Eventer’s platform more frequently. In addition, Eventer needs to adapt, expand and improve its platform and user interfaces to keep up with changing user preferences. Eventer invests substantial resources in researching and developing new features and enhancing its platform by incorporating these new features, improving the functionality, and adding other improvements to meet users’ evolving demands. The success of any enhancements or improvements to Eventer’s platform or any new features depends on several factors, including timely completion, adequate quality testing, integration with technologies on the platform and overall market acceptance. Because further development of Eventer’s platform is complex, challenging, and dependent upon an array of factors, the timetable for the release of new features and enhancements to Eventer’s platform is difficult to predict, and it may not offer new features as rapidly as users of its platform require or expect.

 

It is difficult to predict the problems Eventer may encounter in introducing new features to its platform. Eventer may need to devote significant resources to creating, supporting, and maintaining these features. Eventer provides no assurance that its initiatives to improve the user experience will be successful. Eventer also cannot predict whether users will well receive any new features or whether improving its platform will be successful or sufficient to offset the costs incurred to offer these new features. If Eventer is unable to improve or maintain its platform's quality, its business, prospects, financial condition, and results of operations could be materially and adversely affected.

 

Errors, defects, or disruptions in Eventer’s platform could diminish its brand, subject it to liability, and materially and adversely affect its business, prospects, financial condition, and operations results.

 

Any errors, defects, or disruptions in Eventer’s platform or other performance problems with its platform could harm its brand and may damage the businesses of artists and clients that manage events on its platform. Eventer’s online systems, including its website and mobile apps, could contain undetected errors, or “bugs,” that could adversely affect their performance. Additionally, Eventer regularly updates and enhances its website, platform, and other online systems and introduces new versions of its software products and apps. These updates may contain undetected errors when first introduced or released, which may cause disruptions in its services and may, as a result, cause Eventer to lose market share, and its brand, business, prospects, financial condition and results of operations could be materially and adversely affected.

 

Eventer is subject to escrow, payment services, and money transmitter regulations that may materially and adversely affect its business.

 

Eventer relies on third-party to collect funds from ticket purchasers, remit payments to clients that manage events on its platform, and hold funds in connection with ticket purchases. Although Eventer believes that by working with third parties, its operations comply with existing applicable laws and regulatory requirements related to escrow, money transmission, handling or moving of money, existing laws or regulations may change, and interpretations of existing laws regulations may also change.

 

As a result, Eventer could be required to be licensed as an escrow agent or a money transmitter (or other similar licensees) in jurisdictions in which it is active or may choose to obtain such a license even if not required. As a result, Eventer may be required to register as a money services business under applicable laws and regulations. It is also possible that Eventer could become subject to regulatory enforcement or other proceedings in those jurisdictions with escrow, money transmission, or other similar statutes or regulatory requirements related to the handling or moving of money, which could, in turn, have a significant impact on its business, even if we were to ultimately prevail in such proceedings. Any developments in the laws or regulations related to escrow, money transmission, or the handling or moving of money or increased scrutiny of its business may lead to additional compliance costs and administrative overhead.

 

17

 

 

Eventer faces payment and fraud risks that could materially and adversely affect its business.

 

Requirements applicable to Eventer’s platform relating to user authentication and fraud detection are complex. If Eventer’s security measures do not succeed, Eventer’s business may be adversely affected. In addition, bad actors worldwide use increasingly sophisticated methods to engage in illegal activities involving personal data, such as unauthorized use of another’s identity or payment information, unauthorized acquisition or use of credit or debit card details, and other fraudulent use of another’s identity or information. This could result in any of the following, each of which could adversely affect Eventer’s business:

 

Eventer may be held liable for the unauthorized use of a credit card or bank account number by ticket purchasers and be required by card issuers or banks to pay a chargeback or return fee, and if chargeback or return rate becomes excessive, credit card networks may also require Eventer to pay fines or other fees;

   

Eventer may be subject to additional risk and liability exposure, including negligence, fraud or other claims, if employees or third-party service providers misappropriate user information for their own gain or facilitate the fraudulent use of such information;

   

Eventer may suffer reputational damage as a result of the occurrence of any of the above.

 

Despite measures taken by Eventer to detect and reduce the risk of this kind of conduct, it cannot ensure that any of its measures will stop illegal or improper uses of its platform. Eventer may receive complaints from users and other third parties concerning misuse of its platform in the future. Even if these claims do not result in litigation or are resolved in Eventer’s favor, these claims, and the time and resources necessary to resolve them, could divert the resources of Eventer’s management and materially and adversely affect its business, prospects, financial condition and results of operations.

 

Eventer uses open source software, which could negatively affect its ability to offer its platform and subject it to litigation or other actions.

 

Eventer uses substantial amounts of open source software in its platform and may use more open source software in the future. From time to time, there have been claims challenging both the ownership of open source software against companies that incorporate open source software into their products and whether such incorporation is permissible under various open source licenses. U.S. and Israeli courts have not interpreted the terms of many open source licenses, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on its ability to commercialize its platform. As a result, Eventer could be subject to lawsuits by parties claiming ownership of what we believe to be open source software, or breach of open source licenses. Litigation could be costly for Eventer to defend, have a negative effect on its results of operations and financial condition, or require it to devote additional research and development resources to change its platform. In addition, if Eventer were to combine its proprietary source code or software with open source software in a certain manner, it could, under certain of the open source licenses, be required to release the source code of its proprietary software to the public. This would allow its competitors to create similar products with less development effort and time. If Eventer inappropriately uses open source software or the license terms for open source software that its uses change, Eventer may be required to re-engineer its platform, or certain aspects of it, incur additional costs, discontinue the availability of certain features, or take other remedial actions.

 

In addition to risks related to license requirements, open source software usage can lead to greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or assurance of title or controls on origin of the software. In addition, many of the risks associated with usage of open source software, such as the lack of warranties or assurances of title, cannot be eliminated and could, if not properly addressed, negatively affect Eventer’s business. Eventer has established processes to help alleviate these risks, but it cannot be sure that all of its use of open source software is in a manner that is consistent with its current policies and procedures or will not subject Eventer to liability.

 

18

 

 

To the extent Eventer’s security measures are compromised, its platform may be perceived as not being secure. This may result in customers curtailing or ceasing their use of Eventer’s platform, its reputation being harmed, Eventer incurring significant liabilities, and adverse effects on its results of operations and growth prospects.

 

Eventer’s operations involve the storage and transmission of artist and ticket purchaser data or information. Cyberattacks and other malicious internet-based activity continue to increase, and cloud-based platform providers of services are expected to continue to be targeted. Threats include traditional computer “hackers,” malicious code (such as viruses and worms), employee theft or misuse and denial-of-service attacks. Sophisticated nation-states and nation-state supported actors now engage in such attacks, including advanced persistent threat intrusions. The ticket sales solution included in Eventer’s platform stores credit card data and other customer personal information. Hackers and malicious actors may target Eventer in order to obtain credit card information. Despite significant efforts to create security barriers to such threats, it is virtually impossible for Eventer to entirely mitigate these risks. If Eventer’s security measures are compromised as a result of third-party action, employee or customer error, malfeasance, stolen or fraudulently obtained log-in credentials, or otherwise, Eventer’s reputation could be damaged, its business may be harmed, and it could incur significant liability. Eventer may be unable to anticipate or prevent techniques used to obtain unauthorized access or to compromise its systems because they change frequently and are generally not detected until after an incident has occurred. As Eventer relies on third-party and public-cloud infrastructure, it will depend in part on third-party security measures to protect against unauthorized access, cyberattacks, and the mishandling of customer data. A cybersecurity event could have significant costs, including regulatory enforcement actions, litigation, litigation indemnity obligations, remediation costs, network downtime, increases in insurance premiums, and reputational damage. Many companies that provide cloud-based services have reported a significant increase in cyberattack activity since the beginning of the COVID-19 pandemic.

 

Risks Related to Gix Internet Ltd.’s Business and Industry

 

Gix’s advertising customers may reduce or terminate their business relationship with Gix at any time. If customers representing a significant portion of Gix’s revenue reduce or terminate their relationship with Gix, it could have a material adverse effect on Gix’s business, its results of operations and financial condition.

 

Gix generally does not enter into long-term contracts with its advertising customers, and such customers do business with Gix on a non-exclusive basis. In most cases, Gix’s customers may terminate or reduce the scope of their agreements with little or no penalty or notice. Accordingly, Gix’s business is highly vulnerable to adverse economic conditions, market evolution, development of new or more compelling offerings by Gix’s competitors and development by Gix’s advertising customers of in-house replacement services. Any reduction in spending by, or loss of, existing or potential advertisers by Gix would negatively impact Gix’s revenue and operating results.

 

Due to rapid changes in the Internet and the nature of services, it is difficult to accurately predict Gix’s future performance and may be difficult to increase revenue or profitability.

 

As the digital advertising ecosystem is dynamic, seasonal and challenging, it is hard to predict Gix’s future performance and make predictions, particularly regarding the effect of Gix’s efforts to aggressively increase the distribution and profitability of its services and products. If Gix is unable to continuously improve its systems and processes, adapt to the changing and dynamic needs of its customers and align its expenses with the revenue level, it will impair Gix’s ability to structure its offerings to be compelling and profitable.

 

Increased availability of advertisement-blocking technologies could limit or block the delivery or display of advertisements by Gix solutions, which could undermine Gix’s business's viability.

 

Advertisement-blocking technologies, such as mobile apps, anti-virus software or browser extensions that limit or block the delivery or display of advertisements, are currently available for desktop and mobile users. Furthermore, new browsers and operating systems, or updates to current browsers or operating systems, offer native advertisement-blocking technologies to their users. The more such technologies become widespread, Gix’s ability to serve advertisements to users may be impeded, and its business financial condition and results of operations may be adversely affected.

 

19

 

 

Large and established internet and technology companies, such as Google and Facebook, play a substantial role in the digital advertising market and may significantly impair Gix’s ability to operate in this industry.

 

Google and Facebook are substantial players in the digital advertising market and account for a large portion of the digital advertising budgets, along with other smaller players. Such high concentration subjects Gix to unilateral changes with respect to advertising on their respective platforms, which may be more lucrative than alternative methods of advertising or partnerships with other publishers that are not subject to such changes. Furthermore, Gix could have limited ability to respond to, and adjust for, changes implemented by such players.

 

These companies, along with other large and established Internet and technology companies, may also leverage their power to make changes to their web browsers, operating systems, platforms, networks or other products or services in a way that impacts the entire digital advertising marketplace.

 

The consolidation among participants within the digital advertising market could have a material adverse impact on Gix and accordingly, its business and results of operations.

 

The digital advertising industry has experienced substantial evolution and consolidation in recent years and Gix expects this trend to continue, increasing the capabilities and competitive posture of larger companies, particularly those that are already dominant in various ways, and enabling new or stronger competitors to emerge. This consolidation could adversely affect Gix’s business in a number of ways, including: (i) Gix’s customers or partners could acquire or be acquired by Gix’s competitors causing them to terminate their relationship with Gix; (ii) Gix’s competitors could improve their competitive position or broaden their offerings through strategic acquisitions or mergers.

 

The advertising industry is highly competitive. If Gix cannot compete effectively in this market, Gix’s revenues are likely to decline.

 

Gix faces intense competition in the marketplace. Gix operates in a dynamic market that is subject to rapid development and introduction of new technologies, products and solutions, changing branding objectives, evolving customer demands and industry guidelines, all of which affect Gix’s ability to remain competitive. There are a large number of digital media companies and advertising technology companies that offer products or services similar to Gix’s and that compete with Gix for finite advertising budgets and for limited inventory from publishers. There is also a large number of niche companies that are competitive with Gix, as they provide a subset of the services that Gix provides. Some of Gix’s existing and potential competitors may be better established, benefit from greater name recognition may offer solutions and technologies that Gix does not offer or that are more evolved than Gix, and may have significantly more financial, technical, sales, and marketing resources than Gix does. In addition, some competitors, particularly those with a larger and more diversified revenue base and a broader offering, may have greater flexibility than Gix does to compete aggressively on the basis of price and other contract terms as well as respond to market changes. Additionally, companies that do not currently compete with Gix in this space may change their services to be competitive if there is a revenue opportunity, and new or stronger competitors may emerge through consolidations or acquisitions. If Gix’s digital advertising platform and solutions are not perceived as competitively differentiated or Gix fails to develop adequately to meet market evolution, Gix could lose customers and market share or be compelled to reduce Gix’s prices and harm Gix’s operational results.

 

If the demand for digital advertising does not continue to grow or customers do not embrace Gix’s solutions, this could have a material adverse effect on Gix’s business and financial condition.

 

If customers do not embrace Gix’s solutions, or if Gix’s integration with advertising networks is not successful, or if there is a reduction in general demand for digital advertising, in spend for certain channels or solutions, or the demand for Gix’s specific solutions and offerings is decreased, Gix’s revenues could decline or otherwise, Gix’s business may be adversely affected.

 

20

 

 

Gix’s business is susceptible to seasonality, unexpected changes in campaign size, and prolonged cycle time, which could affect its business, results of operations and ability to repay indebtedness when due.

 

The revenue of Gix’s advertising business is affected by a number of factors, and, as a result, Gix’s profit from these operations is seasonal, including:

 

Product and service revenues are influenced by political advertising, which generally occurs every two years;

 

In any single period, product and service revenues and delivery costs are subject to significant variation based on changes in the volume and mix of deliveries performed during such period;

 

Revenues are subject to the changes in brand marketing trends, including when and where brands choose to spend their money in a given year;

 

  Advertising customers generally retain the right to supplement, extend, or cancel existing advertising orders at any time prior to their completion, and Gix has no control over the timing or magnitude of these revenue changes; and

 

Relative complexity of individual advertising formats, and the length of the creative design process.

 

Gix’s advertising business depends on Gix’s ability to collect and use data, and any limitation on the collection and use of this data could significantly diminish the value of Gix’s solutions and cause Gix to lose customers, revenue and profit.

 

In most cases, when Gix delivers an advertisement, Gix is often able to collect certain information about the content and placement of the ad, the relevancy of such ad to a user, and the interaction of the user with the ad, such as whether the user viewed or clicked on the ad or watched a video. As Gix collects and aggregates data provided by billions of ad impressions and third-party providers, Gix analyzes the data in order to measure and optimize the placement and delivery of Gix’s advertising inventory and provide cross-channel advertising capabilities.

 

Gix publishers or advertisers might decide not to allow Gix to collect some or all of this data or might limit Gix’s use of this data. Gix’s ability to either collect or use data could be restricted by new laws or regulations, including the General Data Protection Regulation (the “GDPR”), in the European Union, which entered into effect in May 2018, and presumably broaden the definition of personal data to include location data and online identifiers, which are commonly used and collected parameters in digital advertising, and impose more stringent user consent requirements, changes in technology, operating system restrictions, requests to discontinue using certain data, restrictions imposed by advertisers and publishers, industry standards or consumer choice.

 

If this happens, Gix may not be able to optimize ad placement for the benefit of Gix’s advertisers and publishers, which could render Gix’s solutions less valuable and potentially result in loss of clients and a decline in revenues. For more information on privacy regulation and compliance, see also – “We are subject to stringent and changing laws, regulations, standards, and contractual obligations related to privacy, data protection, and data security. Our or our subsidiaries' actual or perceived failure to comply with such obligations could harm our business”.

 

Risks Related to an Investment in Our Securities and this Offering

 

The market price for our securities may be volatile.

 

The stock market in general and the market prices of our Ordinary Shares on TASE, and the ADSs on Nasdaq, in particular, are or will be subject to fluctuation, and changes in these prices may be unrelated to our operating performance. We anticipate that the market prices of our securities will continue to be subject to wide fluctuations. The market price of our securities is, and will be, subject to a number of factors, including:

 

  announcements of technological innovations or new products by us or others;
     
  announcements by us of significant acquisitions, strategic partnerships, in-licensing, out-licensing, joint ventures or capital commitments;
     
  expiration or terminations of licenses, research contracts or other collaboration agreements;
     
  public concern as to the safety of the equipment we sell;
     
  the volatility of market prices for shares of medical devices companies generally;

 

21

 

 

  developments concerning intellectual property rights or regulatory approvals;
     
  variations in our and our competitors’ results of operations;
     
  changes in revenues, gross profits and earnings announced by the company;
     
  changes in estimates or recommendations by securities analysts, if our Ordinary Shares or the ADSs are covered by analysts;
     
  fluctuations in the share price of our publicly traded subsidiaries;
     
  changes in government regulations or patent decisions; and
     
  general market conditions and other factors, including factors unrelated to our operating performance.

 

These factors may materially and adversely affect the market price of our securities s and result in substantial losses by our investors.

 

We will have broad discretion in the use of the net proceeds of this offering and may not use them effectively.

 

We intend to use the net proceeds from this offering for general corporate purposes and working capital. As a result, our management will retain broad discretion in the allocation and use of the net proceeds of this offering, and investors will be relying on the judgment of our management with regard to the use of these net proceed, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our ADSs. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our ADS to decline and delay the development of our Company.

 

We will need additional capital in the future. If additional capital is not available, we may not be able to continue to operate our business pursuant to our business plan or we may have to discontinue our operations entirely. 

 

Regardless of the success of this offering, we will require additional capital in the future. We have incurred losses in each year since our inception. If we continue to use cash at our historical rates of use we will need significant additional financing, which we may seek through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us. 

 

You may experience immediate dilution in book value of any ADSs you purchase. 

 

Because the price per ADS being offered is substantially higher than our net tangible book value per ADS, you may suffer substantial dilution in the net tangible book value of any ADSs you purchase in this offering. After giving effect to the sale by us of ADSs in this offering, based on an aggregate public offering price of $      per ADS and after deducting the estimated underwriting discounts and commissions and offering expenses payable by us, our as adjusted net tangible book value of our ADSs would be approximately $       million, or approximately $       per ADS, as of                     , 2020. If you purchase ADSs in this offering, you may suffer immediate and substantial dilution of our as adjusted net tangible book value of approximately $      per ADS. To the extent outstanding options or warrants are exercised, you will incur further dilution. See “Dilution” on page 29 for a more detailed discussion of the dilution you may incur in connection with this offering.

  

22

 

 

ADSs representing a substantial percentage of our outstanding shares may be sold in this offering, which could cause the price of our ADSs and Ordinary Shares to decline.

 

Pursuant to this offering, we may sell up to             ADSs representing             Ordinary Shares, or approximately       %, of our outstanding Ordinary Shares as of      , 2020. This sale and any future sales of a substantial number of ADSs in the public market, or the perception that such sales may occur, could materially adversely affect the price of our ADSs and Ordinary Shares. We cannot predict the effect, if any, that market sales of those ADSs or the availability of those ADSs for sale will have on the market price of our ADSs and Ordinary Shares.

  

Raising additional capital by issuing securities may cause dilution to existing shareholders.

 

We are currently authorized to issue 1,000,000,000 Ordinary Shares. As of               , 2020, we had            Ordinary Shares issued and outstanding, and            Ordinary Shares reserved for future issuance under outstanding options and warrants and under our 2013 Share Option and Incentive Plan.

 

We may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us.

 

Future sales of our Ordinary Shares or the ADSs could reduce the market price of our Ordinary Shares and the ADSs.

 

Substantial sales of our Ordinary Shares or the ADSs, either on the TASE or on Nasdaq, may cause the market price of our Ordinary Shares or ADSs to decline. All of our outstanding Ordinary Shares are registered and available for sale in Israel. Sales by us or our security holders of substantial amounts of our Ordinary Shares or ADSs, or the perception that these sales may occur in the future, could cause a reduction in the market price of our Ordinary Shares or ADSs. 

 

The issuance of any additional Ordinary Shares, any additional ADSs, or any securities that are exercisable for or convertible into our Ordinary Shares or ADSs, may have an adverse effect on the market price of our Ordinary Shares and the ADSs and will have a dilutive effect on our existing shareholders and holders of ADSs.

 

We do not know whether a market for the ADSs will be sustained or what the trading price of the ADSs will be and as a result it may be difficult for you to sell your ADSs.

 

Although our ADSs trade on Nasdaq and our Ordinary Shares trade on TASE (which will continue until our Ordinary Shares cease to trade on the TASE on January 21, 2021), an active trading market for the ADSs or Ordinary Shares may not be sustained. It may be difficult for you to sell your ADSs or Ordinary Shares without depressing the market price for the ADSs or Ordinary Shares. As a result of these and other factors, you may not be able to sell your ADSs or Ordinary Shares. Further, an inactive market may also impair our ability to raise capital by selling ADSs and Ordinary Shares and may impair our ability to enter into strategic partnerships or acquire companies or products by using our Ordinary Shares as consideration.

 

Our securities are traded on different markets and this may result in price variations.

 

Our Ordinary Shares have been traded on TASE since February 2006 and our ADSs have been traded on Nasdaq since August 5, 2015. Trading in our securities on these markets takes place in different currencies (U.S. dollars on the Nasdaq and NIS on the TASE), and at different times (resulting from different time zones, different trading days and different public holidays in the United States and Israel). The trading prices of these securities on these two markets (which will continue until our Ordinary shares cease to trade on the TASE on January 21, 2021) may differ due to these and other factors. Any decrease in the price of our securities on one of these markets could cause a decrease in the trading price of our securities on the other market.

 

23

 

 

We have no plans to pay dividends on our Ordinary Shares, and you may not receive funds without selling the ADSs or Ordinary Shares.

 

We have not declared or paid any cash dividends on our Ordinary Shares, nor do we expect to pay any cash dividends on our Ordinary Shares for the foreseeable future. We currently intend to retain any additional future earnings to finance our operations and growth and, therefore, we have no plans to pay cash dividends on our Ordinary Shares at this time. Any future determination to pay cash dividends on our Ordinary Shares will be at the discretion of our board of directors and will be dependent on our earnings, financial condition, operating results, capital requirements, any contractual restrictions, and other factors that our board of directors deems relevant. Accordingly, you may have to sell some or all of the ADSs or Ordinary Shares in order to generate cash from your investment. You may not receive a gain on your investment when you sell the ADSs or Ordinary Shares and may lose the entire amount of your original investment.

 

Holders of ADSs may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, you may not receive dividends or other distributions on our Ordinary Shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.

 

The Depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on Ordinary Shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of Ordinary Shares your ADSs represent. However, the Depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act of 1933, as amended, or the Securities Act, but that are not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that was part of a dividend made in respect of deposited Ordinary Shares may require the approval or license of, or a filing with, any government or agency thereof, which may be unobtainable. In these cases, the Depositary may determine not to distribute such property and hold it as “deposited securities” or may seek to effect a substitute dividend or distribution, including net cash proceeds from the sale of the dividends that the Depositary deems an equitable and practicable substitute. We have no obligation to register under U.S. securities laws any ADSs, Ordinary Shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, Ordinary Shares, rights or anything else to holders of ADSs. In addition, the Depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges to the extent the Depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.

 

Holders of ADSs must act through the Depositary to exercise their rights as shareholders of our company.

 

Holders of our ADSs do not have the same rights of our shareholders and may only exercise the voting rights with respect to the underlying Ordinary Shares in accordance with the provisions of the Deposit Agreement. Under Israeli law and our articles of association, the minimum notice period required to convene a shareholders meeting is no less than 21 or 35 calendar days, depending on the proposals on the agenda for the shareholders meeting. When a shareholder meeting is convened, holders of ADSs may not receive sufficient notice of a shareholders’ meeting to permit them to withdraw their Ordinary Shares to allow them to cast their vote with respect to any specific matter. In addition, the Depositary and its agents may not be able to send voting instructions to holders of ADSs or carry out their voting instructions in a timely manner. We will make all reasonable efforts to cause the Depositary to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct the Depositary to vote their Ordinary Shares underlying the ADSs. Furthermore, the Depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of our ADSs may not be able to exercise their right to vote and they may lack recourse if their Ordinary Shares underlying the ADSs are not voted as they requested. In addition, in the capacity as a holder of ADSs, they will not be able to call a shareholders’ meeting.

 

24

 

  

CAUTIONARY Note Regarding Forward-Looking Statements

 

This prospectus and the information incorporated by reference herein may include forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. In addition, certain sections of this prospectus and the information incorporated by reference herein contain information obtained from independent industry and other sources that we have not independently verified. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.

 

Our ability to predict our operating results or the effects of various events on our operating results is inherently uncertain. Therefore, we caution you to consider carefully the matters described under the caption “Risk Factors” above, and certain other matters discussed in this prospectus and the information incorporated by reference herein, and other publicly available sources. Such factors and many other factors beyond our control could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by the forward-looking statements.

 

Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

 

  recent material changes in our strategy;
     
  our ability to sell or license our MUSE™ technology;
     
  ScoutCam’s commercial success in commercializing the ScoutCam™ system;
     
  projected capital expenditures and liquidity;
     
  the overall global economic environment as well as the direct and indirect impact of the coronavirus strain COVID-19 on us;
     
  the impact of competition and new technologies;
     
  general market, political, reimbursement and economic conditions in the countries in which we operate;
     
  government regulations and approvals;
     
  litigation and regulatory proceedings; and
     
  those factors referred to in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects”, in our Annual Report on Form 20-F for the year ended December 31, 2019, which is incorporated by reference in this prospectus.

 

We caution you to carefully consider these risks and not to place undue reliance on our forward-looking statements. Except as required by law, we assume no responsibility for updating any forward-looking statements.

 

25

 

 

Use of Proceeds

 

We estimate that the net proceeds from this offering will be approximately $       million (approximately $     million if the underwriter exercises its over-allotment option in full), based upon an assumed public offering price of $       per ADS, the last reported sales price of our ADSs on Nasdaq on       , 2020, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

A $0.10 increase (decrease) in the assumed aggregate public offering price of $      per ADS, would increase (decrease) the net proceeds we receive from this offering by $      , assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ADS we are offering.

 

A 100,000 ADS increase in the number of ADSs and together with a concomitant $0.10 increase in the assumed aggregate public offering price of $      per ADS would increase the net proceeds we receive from this offering by $      , after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Conversely, a 100,000 ADS decrease in the number of ADSs together with a concomitant $0.10 decrease in the assumed aggregate public offering price of $       per ADS would decrease the net proceeds we receive from this offering by $     , after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

We currently intend to use the net proceeds from this offering for working capital and general corporate purposes. As a result, our management will retain broad discretion in the allocation and use of the net proceeds of this offering, and investors will be relying on the judgment of our management with regard to the use of these net proceeds. The precise amount use and timing of the application of such proceeds will depend upon our funding requirements and the availability and cost of other capital. Pending application of the net proceeds for the purposes as described above, we expect to invest the net proceeds in short-term, interest-bearing securities, investment grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government.

 

26

 

 

Dividend Policy

 

We have never declared or paid any cash dividends to our shareholders. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.

 

The distribution of dividends may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due.

 

Payment of dividends may be subject to Israeli withholding taxes. For additional information, see “Item 10. Additional Information—E. Taxation—Israeli Tax Considerations and Government Programs” included in our Annual Report on Form 20-F for the year ended December 31, 2019, which is incorporated by reference herein.

 

 

27

 

 

Capitalization

 

The following table sets forth our capitalization:

 

  on an actual basis as of June 30, 2020; and

 

  on an as adjusted basis, to give effect to the issuance and sale in this offering of                  ADSs representing           Ordinary Shares at the assumed public offering price of $       per ADS, the last reported sales price of our ADSs on Nasdaq on               , 2020, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

The information set forth in the following table should be read in conjunction with, and is qualified in its entirety by, reference to our audited and unaudited financial statements and the notes thereto incorporated by reference herein.

 

    As of June 30, 2020  
    Actual     As adjusted  
    (U.S. Dollars, in thousands)  
Cash and cash equivalents     10,172               
Total Liabilities     4,461          
Equity:                
Ordinary Shares, par value NIS 1.00 per share: 250,000,000 ordinary shares authorized (actual and as adjusted); 128,818,758 Ordinary Shares issued and outstanding (actual);                Ordinary Shares outstanding (as adjusted)     36,014          
Share premium     38,210          
Other capital reserves     13,430          
Warrants     1,802          
Accumulated deficit     (79,210 )        
Equity attributable to owners of Medigus Ltd.     10,246          
Non-controlling interests     3,191          
Total equity     13,437          
Total capitalization and indebtedness     17,898          

 

A $0.10 increase (decrease) in the assumed aggregate public offering price of $      per ADS, would increase (decrease) the as adjusted amount of each of cash and cash equivalents and total shareholders’ equity by approximately $        , assuming that the number of ADSs, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A 100,000 ADS increase in the number of ADSs offered by us together with a concomitant $0.10 increase in the assumed aggregate public offering price of $      per ADS would increase our as adjusted cash and cash equivalents by approximately $      after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Conversely, a 100,000 ADS decrease in the number of ADSs offered by us together with a concomitant $0.10 decrease in the assumed aggregate public offering price of $      per ADS would decrease our as adjusted cash and cash equivalents by approximately $     after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

The preceding table excludes as of June 30, 2020: (i) 6,193,880 Ordinary Shares issuable upon the exercise of outstanding options at a weighted average exercise price of NIS 0.79 per share or $0.23 per share (based on the exchange rate reported by the Bank of Israel on such date), equivalent to 309,694 ADSs at a weighted average exercise price of $4.56 per ADS; and (ii) 110,361,780 Ordinary Shares issuable upon the exercise of warrants to purchase up to an aggregate of 5,518,089 ADSs at a weighted average exercise price of $4.10 per ADS.

 

28

 

 

Dilution

 

If you invest in our securities in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per ADS and the as adjusted net tangible book value per ADS after this offering.

 

Our net tangible book value as of June 30, 2020, was approximately $0.08, or approximately $1.59 per ADS. Our net tangible book value per ADS represents the amount of our total tangible assets less total liabilities divided by the total number of our Ordinary Shares outstanding as of June 30, 2020, and multiplying such amount by 20 (one ADS represents 20 Ordinary Shares).

 

After giving effect to the issuance and sale in this offering of         ADSs at an assumed public offering price of $       per ADS, the last reported sales price of our ADSs on Nasdaq on       , 2020, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value on June 30, 2020, would have been approximately $       million, or $       per ADS. This represents an immediate dilution in the as adjusted net tangible book value of $       per ADS to investors purchasing our ADSs in this offering.

 

The following table illustrates this calculation on a per share basis:

 

Assumed offering price per ADS           $          
Net tangible book value per ADS   $ 1.59          
Decrease in net tangible book value per ADS attributable to the offering   $              
                 
As-adjusted net tangible book value per ADS after giving effect to the offering           $    
                 
Dilution in net tangible book value per ADS to new investors           $    

 

The preceding table excludes as of June 30, 2020: (i) 6,193,880 Ordinary Shares issuable upon the exercise of outstanding options at a weighted average exercise price of NIS 0.79 per share or $0.23 per share (based on the exchange rate reported by the Bank of Israel on such date), equivalent to 309,694 ADSs at a weighted average exercise price of $4.56 per ADS; and (ii) 110,361,780 Ordinary Shares issuable upon the exercise of warrants to purchase up to an aggregate of 5,518,089 ADSs at a weighted average exercise price of $4.10 per ADS.

 

The above illustration of dilution per share to investors participating in this offering assumes no exercise of outstanding options to purchase our Ordinary Shares or outstanding warrants to purchase our ADSs or Ordinary Shares. To the extent outstanding options or warrants are exercised, you may incur further dilution.

 

A $0.10 increase (decrease) in the assumed aggregate public offering price of $      per ADS would increase (decrease) our as adjusted net tangible book value per ADS after this offering by $       and the dilution per ADS to new investors by $       , assuming the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ADSs we are offering. A 100,000 ADS increase in the number of ADSs offered by us together with a concomitant $0.10 increase in the assumed aggregate public offering price of $       per ADS would increase our as adjusted net tangible book value per ADS after this offering by $       and the dilution per ADS to new investors by $       , after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Conversely, a 100,000 ADS decrease in the number of ADSs offered by us together with a concomitant $0.10 decrease in the assumed aggregate public offering price of $       per ADS would decrease our as adjusted net tangible book value per ADS after this offering by $       and the dilution per ADS to new investors by $      , after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

29

 

 

DESCRIPTION OF THE OFFERED SECURITIES

AMERICAN DEPOSITARY SHARES TO BE ISSUED AS PART OF THIS OFFERING

 

General

 

The following is a summary description of our ADSs and does not purport to be complete. Each of our ADSs represents twenty (20) Ordinary Shares (or a right to receive twenty (20) Ordinary Shares) deposited with the principal Tel Aviv office of either of Bank Hapoalim or Bank Leumi, as custodian for the Bank of New York Mellon as the Depositary. Each ADS also represents any other securities, cash or other property which may be held by the Depositary. The Depositary’s office at which the ADSs will be administered is located at 240 Greenwich Street, New York, New York 10286. The Bank of New York Mellon’s principal executive office is located at One Wall Street, New York, New York 10286.

 

You may hold ADSs either (A) directly (i) by having an American Depositary Receipt, or ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

 

Registered holders of uncertificated ADSs will receive statements from the Depositary confirming their holdings. As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Israeli law governs shareholder rights. The Depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the Depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the Depositary. New York law governs the deposit agreement and the ADSs.

 

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR.

 

Dividends and Other Distributions

 

How will you receive dividends and other distributions on the shares?

 

The Depositary has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after deducting its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent.

 

Cash. The Depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the Depositary to distribute the NIS only to those ADS holders to whom it is possible to do so. It will hold the NIS it cannot convert for the account of the ADS holders who have not been paid. It will not invest the NIS and it will not be liable for any interest.

 

Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. For more information see “Item 10. – Additional Information – E. Taxation – Israeli Tax Considerations and Government Programs” in our in our Annual Report on Form 20-F for the year ended December 31, 2019, which is incorporated by reference herein. The Depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the Depositary cannot convert the NIS, you may lose some or all of the value of the distribution.

 

Shares. The Depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The Depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the Depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The Depositary may sell a portion of the distributed shares sufficient to pay its fees and expenses in connection with that distribution (or ADSs representing those shares).

 

30

 

 

Rights to purchase additional shares. If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the Depositary may make these rights available to ADS holders. If the Depositary decides it is not legal and practical to make the rights available but that it is practical to sell the rights, the Depositary will use reasonable efforts to sell the rights and distribute the proceeds in the same way as it does with cash. The Depositary will allow rights that are not distributed or sold to lapse. In that case, you will receive no value for them.

 

If the Depositary makes rights available to ADS holders, it will exercise the rights and purchase the shares on your behalf. The Depositary will then deposit the shares and deliver ADSs to the persons entitled to them. It will only exercise rights if you pay it the exercise price and any other charges the rights require you to pay.

 

U.S. securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For example, you may not be able to trade these ADSs freely in the United States. In this case, the Depositary may deliver restricted depositary shares that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions in place.

 

Other Distributions. The Depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the Depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the Depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The Depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. 

 

The Depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.

 

Deposit, Withdrawal and Cancellation

 

How are ADSs issued?

 

The Depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the Depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.

 

How can ADS holders withdraw the deposited securities?

 

You may surrender your ADSs at the Depositary’s office. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the Depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the Depositary will deliver the deposited securities at its office, if feasible.

 

How do ADS holders interchange between certificated ADSs and uncertificated ADSs?

 

You may surrender your ADR to the Depositary for the purpose of exchanging your ADR for uncertificated ADSs. The Depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Alternatively, upon receipt by the Depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the Depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.

 

31

 

 

Voting Rights 

 

How do you vote?

 

ADS holders may instruct the Depositary how to vote the number of deposited shares their ADSs represent. The Depositary will notify ADS holders of shareholders’ meetings and arrange to deliver our voting materials to them if we ask it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the Depositary how to vote. For instructions to be valid, they must reach the Depositary by a date set by the Depositary. Otherwise, you won’t be able to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares.

 

The Depositary will try, as far as practical, subject to the laws of Israel, and of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt to vote as instructed.

 

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your shares are not voted as you requested.

 

In order to give you a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to deposited securities, if we request the Depositary to act, we agree to give the Depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days in advance of the meeting date.

 

Each of our American Depositary Shares, or ADSs, represents twenty of our Ordinary Shares. The ADSs trade on Nasdaq.

 

The form of the deposit agreement for the ADSs and the form of American Depositary Receipt (ADR) that represents an ADS as filed as exhibits to the Company’s registration statement on Form F-6 with the SEC on May 7, 2015. Copies of the deposit agreement are available for inspection at the principal office of the Bank of New York Mellon, located at 101 Barclay Street, New York, New York 10286, and at the principal office of our custodians Bank Hapoalim B.M., 104 Hayarkon Street, Tel Aviv 63432, Israel. 

 

Fees and Expenses

 

Persons depositing or withdrawing shares or ADS holders must pay:   For:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)   ●     Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
    ●     Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
$.05 (or less) per ADS   ●     Any cash distribution to ADS holders
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs   ●     Distribution of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders
$.05 (or less) per ADS per calendar year   ●     Depositary services
Registration or transfer fees   ●     Transfer and registration of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares
Expenses of the Depositary  

●     Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)

●     converting foreign currency to U.S. dollars

Taxes and other governmental charges the Depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes   ●     As necessary
Any charges incurred by the Depositary or its agents for servicing the deposited securities   ●     As necessary

 

32

 

 

The Depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The Depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The Depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

 

From time to time, the Depositary may make payments to us to reimburse and/or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the Depositary may use brokers, dealers or other service providers that are affiliates of the Depositary and that may earn or share fees or commissions.

 

Payment of Taxes

 

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The Depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the Depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes. 

 

Reclassifications, Recapitalizations and Mergers

 

If we:   Then:

●     Change the nominal or par value of our Ordinary Shares

 

●     Reclassify, split up or consolidate any of the deposited securities

 

●     Distribute securities on the shares that are not distributed to you

 

●     Recapitalize, reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action

 

The cash, shares or other securities received by the Depositary will become deposited securities. Each ADS will automatically represent its equal share of the new deposited securities.

 

The Depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.

 

Amendment and Termination

 

How may the deposit agreement be amended? 

 

We may agree with the Depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the Depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the Depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended

 

33

 

 

How may the deposit agreement be terminated? 

 

The Depositary will terminate the deposit agreement at our direction by mailing notice of termination to the ADS holders then outstanding at least 30 days prior to the date fixed in such notice for such termination. The Depositary may also terminate the deposit agreement by mailing notice of termination to us and the ADS holders if 60 days have passed since the Depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment.

 

After termination, the Depositary and its agents will do the following under the deposit agreement but nothing else: collect distributions on the deposited securities, sell rights and other property, and deliver shares and other deposited securities upon cancellation of ADSs. Four months after termination, the Depositary may sell any remaining deposited securities by public or private sale. After that, the Depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability for interest. The Depositary’s only obligations will be to account for the money and other cash. After termination our only obligations will be to indemnify the Depositary and to pay fees and expenses of the Depositary that we agreed to pay.

 

Limitations on Obligations and Liability

 

Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs

 

The deposit agreement expressly limits our obligations and the obligations of the Depositary. It also limits our liability and the liability of the Depositary. We and the Depositary: 

 

  are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith;
     
  are not liable if we are or it is prevented or delayed by law or circumstances beyond our or its control from performing our or its obligations under the deposit agreement;
     
  are not liable if we or it exercises discretion permitted under the deposit agreement;
     
  are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;
     
  have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;
     
  are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and
     
  may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person.

 

In the deposit agreement, we and the Depositary agree to indemnify each other under certain circumstances.

 

Requirements for Depositary Actions

 

Before the Depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the Depositary may require: 

 

  payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;

 

34

 

  

  satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and
     
  compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

 

The Depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the Depositary or our transfer books are closed or at any time if the Depositary or we think it advisable to do so.

 

Right to Receive the Shares Underlying your ADSs

 

ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:

 

  when temporary delays arise because: (i) the Depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our shares;
     
  when you owe money to pay fees, taxes and similar charges; or
     
  when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.

 

This right of withdrawal may not be limited by any other provision of the deposit agreement.

 

Pre-release of ADSs

 

The deposit agreement permits the Depositary to deliver ADSs before deposit of the underlying shares. This is called a pre-release of the ADSs. The Depositary may also deliver shares upon cancellation of pre-released ADSs (even if the ADSs are canceled before the pre-release transaction has been closed out). A pre-release is closed out as soon as the underlying shares are delivered to the Depositary. The Depositary may receive ADSs instead of shares to close out a pre-release. The Depositary may pre-release ADSs only under the following conditions: (1) before or at the time of the pre-release, the person to whom the pre-release is being made represents to the Depositary in writing that it or its customer owns the shares or ADSs to be deposited; (2) the pre-release is fully collateralized with cash or other collateral that the Depositary considers appropriate; and (3) the Depositary must be able to close out the pre-release on not more than five business days’ notice. In addition, the Depositary will limit the number of ADSs that may be outstanding at any time as a result of pre-release, although the Depositary may disregard the limit from time to time if it thinks it is appropriate to do so.

 

Direct Registration System

 

In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to uncertificated ADSs upon acceptance thereof to DRS by the Depository Trust Company, or DTC. DRS is the system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of ADSs, to direct the Depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the Depositary of prior authorization from the ADS holder to register that transfer.

 

In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the Depositary’s reliance on and compliance with instructions received by the Depositary through the DRS/Profile System and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the Depositary.

 

Shareholder communications; inspection of register of holders of ADSs

 

The Depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The Depositary will send you copies of those communications if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.

 

35

 

 

UNDERWRITING

 

Aegis Capital Corp., or Aegis, is acting as the representative of the underwriters and the book-running manager of this offering. Under the terms of an underwriting agreement, which is filed as an exhibit to the registration statement, each of the underwriters named below has severally agreed to purchase from us the respective number of shares of common stock shown opposite its name below:

 

Underwriters   Number of ADSs  
Aegis Capital Corp.               
     
Total        

 

The underwriting agreement provides that the underwriters’ obligation to purchase ADSs depends on the satisfaction of the conditions contained in the underwriting agreement including:

 

the representations and warranties made by us to the underwriters are true;

 

there is no material change in our business or the financial markets; and

 

we deliver customary closing documents to the underwriters.

 

Commissions and Expenses

 

The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.

 

    Per ADS     Total with no Over-Allotment     Total with
Over-Allotment
 
Public offering price   $                                   
Underwriting discount (%)   $                    
Non-accountable expense allowance(1)   $                    
Proceeds, before expenses, to us   $                    

  

(1) We have agreed to pay a non-accountable expense allowance to the representative of up to $100,000.

 

We paid an advance of $25,000 to the representative, which will be applied against actual out-of-pocket accountable expenses and reimbursed to the Company to the extent any portion thereof is not actually incurred in compliance with FINRA Rule 5110(f)(2)(C).

 

The representative has advised us that the underwriters propose to offer the ADSs directly to the public at the public offering price on the cover of this prospectus and to selected dealers, which may include the underwriters, at such offering price less a selling concession not in excess of $0. per ADS. After the offering, the representatives may change the offering price and other selling terms.

 

The expenses of this offering that are payable by us are estimated to be approximately $ (excluding estimated underwriting discounts and commissions). We have also agreed to reimburse the underwriters for certain of their expenses, in an amount up to $100,000, including for road show, diligence, and reasonable legal fees, as set forth in the underwriting agreement.

 

Option to Purchase Additional Shares

 

We have granted the underwriters an option exercisable for 45 days after the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of ADSs from us at the public offering price less underwriting discounts and commissions. To the extent that this option is exercised, each underwriter will be obligated, subject to certain conditions, to purchase its pro rata portion of these additional shares based on the underwriter’s percentage underwriting commitment in this offering as indicated in the table at the beginning of this Underwriting Section.

 

36

 

 

Lock-Up Agreements

 

We, all of our directors and executive officers have agreed that, for a period of sixty (60) days after the date of this prospectus subject to certain limited exceptions, we and they will not directly or indirectly, without the prior written consent of Aegis, (i) offer for sale, sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future of) any Securities of the Company (including, without limitation, Ordinary Shares and ADSs that may be deemed to be beneficially owned by us or them in accordance with the rules and regulations of the SEC and Ordinary Shares and ADSs that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Ordinary Shares or ADSs, (ii) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of Ordinary Shares or ADSs, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Ordinary Shares or ADSs or other securities, in cash or otherwise, (iii) make any demand for or exercise any right or file or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Ordinary Shares and ADSs or securities convertible into or exercisable or exchangeable Ordinary Shares or ADSs or any of our other securities, or (iv) publicly disclose the intention to do any of the foregoing.

 

Aegis, in its sole discretion, may release the Ordinary Shares and ADSs and other securities subject to the lock-up agreements described above in whole or in part at any time. When determining whether or not to release common stock and other securities from lock-up agreements, Aegis will consider, among other factors, the holder’s reasons for requesting the release, the number of Ordinary Shares or ADSs and other securities for which the release is being requested and market conditions at the time.

 

Right of First Refusal

 

Pursuant to the terms of the underwriting agreement, Aegis will have the right of first refusal for a period of six months after the closing of this offering to act as sole book-running manager for all future public equity offerings by us, or any successor to or subsidiary of our Company, during such period.

 

Indemnification

 

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make for these liabilities.

  

Stabilization, Short Positions and Penalty Bids

 

The representatives may engage in stabilizing transactions, short sales and purchases to cover positions created by short sales, and penalty bids or purchases for the purpose of pegging, fixing or maintaining the price of the ADSs, in accordance with Regulation M under the Exchange Act:

 

Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.

 

A short position involves a sale by the underwriters of ADSs in excess of the number of ADSs the underwriters are obligated to purchase in the offering, which creates the syndicate short position. This short position may be either a covered short position or a naked short position. In a covered short position, the number of ADSs involved in the sales made by the underwriters in excess of the number of ADSs they are obligated to purchase is not greater than the number of ADSs that they may purchase by exercising their option to purchase additional ADSs. In a naked short position, the number of ADSs involved is greater than the number of shares in their option to purchase additional ADSs. The underwriters may close out any short position by either exercising their option to purchase additional ADSs and/or purchasing ADSs in the open market. In determining the source of ADSs to close out the short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through their option to purchase additional ADSs. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase ADSs in the offering.

 

Syndicate covering transactions involve purchases of the ADSs in the open market after the distribution has been completed in order to cover syndicate short positions.

 

Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the ADSs originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

 

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our ADSs or preventing or retarding a decline in the market price of the ADSs. As a result, the price of the ADSs may be higher than the price that might otherwise exist in the open market. These transactions may be effected on the Nasdaq or otherwise and, if commenced, may be discontinued at any time.

 

37

 

 

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the ADSs. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these stabilizing transactions or that any transaction, once commenced, will not be discontinued without notice.

 

Electronic Distribution

 

A prospectus in electronic format may be made available on the Internet sites or through other online services maintained by one or more of the underwriters and/or selling group members participating in this offering, or by their affiliates. In those cases, prospective investors may view offering terms online and, depending upon the particular underwriter or selling group member, prospective investors may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ADSs for sale to online brokerage account holders. Any such allocation for online distributions will be made by the representatives on the same basis as other allocations.

 

Other than the prospectus in electronic format, the information on any underwriter’s or selling group member’s web site and any information contained in any other web site maintained by an underwriter or selling group member is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter or selling group member in its capacity as underwriter or selling group member and should not be relied upon by investors.

 

Listing on The Nasdaq Capital Market

 

Our ADSs trade on the Nasdaq under the symbol “MDGS.”

 

Discretionary Sales

 

The underwriters have informed us that they do not expect to sell more than 5% of the ADSs in the aggregate to accounts over which they exercise discretionary authority.

 

Other Relationships

 

Certain of the underwriters and their affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which they may in the future receive customary fees.

 

Offer restrictions outside the United States

 

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

 

38

 

 

Expenses Related to Offering

 

The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offer and sale of Ordinary Shares in this offering. All amounts listed below are estimates except the SEC registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee.

 

Itemized expense   Amount  
SEC registration fee   $ 1,636.50  
FINRA filing fee        
Printing and engraving expenses        
Legal fees and expenses        
Transfer agent and registrar fees        
Accounting fees and expenses        
Miscellaneous        
Total   $        

 

Legal Matters

 

The validity of the securities offered hereby and certain matters of Israeli law will be passed upon for us by Meitar | Law Offices, Ramat Gan, Israel. Certain matters of United States federal securities law relating to this offering will be passed upon for us by Sullivan & Worcester, LLP, New York, New York. Certain legal matters of United States federal securities law related to the offering will be passed upon for the underwriter by  Carter Ledyard & Milburn, LLP, New York, New York

 

Experts

 

The financial statements incorporated in this prospectus by reference to the Annual Report on Form 20-F for the year ended December 31, 2019, except as they relate to Algomizer Ltd. (currently named Gix Internet Ltd.), have been audited by Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm. Such financial statements, except as they relate to Algomizer Ltd. (currently named Gix Internet Ltd.) have been incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company’s ability to continue as a going concern as described in Note 1(b) to the financial statements) of such independent registered public accounting firm given on the authority of said firm as experts in auditing and accounting.

 

The audited financial statements of Gix, an 8% equity investment of the Company, as of and for the period from September 4, 2019 through December 31, 2019, which are reflected in the consolidated financial statements of the Company for that period, which are not separately presented in this Prospectus, have been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, an independent registered public accounting firm, whose report thereon is incorporated in this prospectus by reference. The audited financial statements of the Company, to the extent they relate to Gix have been incorporated in reliance on the report of such independent registered public accounting firm by reference, given on the authority of said firm as experts in auditing and accounting.

 

Change in Registrant’s Certifying Accountant

 

On May 17, 2020, following discussion and recommendation of the Company’s audit committee and board of directors, the Company notified Kesselman & Kesselman of its dismissal from its position as independent auditor of the Company.

 

On July 9, 2020, following the approval of the Company’s board of directors and audit committee, the Company’s shareholders approved the appointment of Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as the Company’s independent auditors of the Company for the year ending December 31, 2020 and to serve until the annual general meeting of shareholders to be held in 2021.

 

39

 

 

Kesselman & Kesselman’s report on the financial statements of the Company for the two years ended December 31, 2018 and 2019 did not contain an adverse opinion or a disclaimer of opinion nor was it qualified or modified as to uncertainty, audit scope, or accounting principles, except for, an explanatory paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern in the year ended December 31, 2019.

 

During the two years ended December 31, 2018 and 2019 and in the subsequent interim period through May 17, 2020, there were (i) no “disagreements” (as such term is defined in Item 16F of Form 20-F) between Kessleman & Kesselman and the Company on any matters of accounting principles or practices, financial statement disclosure or auditing scope or procedures, any of which, if not resolved to Kesselman & Kesselman’s satisfaction, would have caused Kesselman & Kesselman to make reference thereto in their reports and (ii) no “reportable events” (as such term is defined in Item 16F of Form 20-F), except for the material weakness in our internal control over financial reporting related to complex accounting matters, including for the reverse recapitalization transaction conducted with regard to ScoutCam Ltd. which was accounted for in our consolidated financial statements as a transaction with non-controlling interest as of December 31, 2019.

 

The Company provided Kesselman & Kesselman with a copy of the disclosures made pursuant to this Item 16F of Form 20-F and requested that Kesselman & Kesselman furnish a letter addressed to the SEC, which is attached hereto as Exhibit 16.1, stating whether it agrees with such disclosures, and if not, stating the respects in which it does not agree.

 

Enforceability of Civil Liabilities

 

We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States

 

We have irrevocably appointed Medigus USA LLC as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. The address of our agent is 1007 North Orange Street, 4th Floor, Wilmington, DE, 19801, USA.

 

We have been informed by our legal counsel in Israel, Meitar | Law Offices, that it may be difficult to initiate an action with respect to U.S. securities law in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law.

 

Subject to certain time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that:

 

  the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;

 

40

 

 

  the judgment may no longer be appealed;

 

  the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and

 

  the judgment is executory in the state in which it was given.

 

Even if these conditions are met, an Israeli court will not declare a foreign civil judgment enforceable if:

 

  the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases);

 

  the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel;

 

  the judgment was obtained by fraud;

 

  the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court;

 

  the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel;

 

  the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or

 

  at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel.

 

If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

 

Where You Can Find Additional Information

 

We are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements we file reports with the SEC. Those other reports or other information are available at the SEC’s website noted above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we file with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and submit to the SEC, on Form 6-K, unaudited financial information for the first 6 months of each fiscal year within 60 days after the end of each such 6 month period, or such applicable time as required by the SEC.

 

We maintain a website at www.medigus.com. Information contained in or accessible through our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings of our shareholders.

 

41

 

 

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

 

We are allowed to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this prospectus. We incorporate by reference in this prospectus the documents listed below, and any future Annual Reports on Form 20-F or Reports on Form 6-K (to that extent that such Form 6-K indicates that it is intended to be incorporated by reference herein) filed with the SEC pursuant to the Exchange Act prior to the termination of the offering.

 

The following documents are incorporated by reference into this document:

 

  (1) our annual report on Form 20-F for the year ended December 31, 2019, filed with the SEC on April 21, 2020;
     
  (2) our reports on Form 6-K, furnished to the SEC on May 20, 2020, May 22, 2020, June 4, 2020, July 9, 2020, August 31, 2020 (including the financial statement exhibits filed as Exhibits 99.2 and 99.2 therein); October 26, 2020, and October 26, 2020 (both with respect to the Company’s delisting from TASE);
     
  (3) the description of our Ordinary Shares, par value NIS 1.00 per share, and the American Depositary Shares representing the Ordinary Shares, contained in our Registration Statement on Form 20-F filed with the SEC on May 7, 2015, including any subsequent amendment or any report filed for the purpose of updating such description.

 

As you read the above documents, you may find inconsistencies in information from one document to another. If you find inconsistencies between the documents and this prospectus, you should rely on the statements made in the most recent document. All information appearing in this prospectus is qualified in its entirety by the information and financial statements, including the notes thereto, contained in the documents incorporated by reference herein.

 

We will provide to each person, free of charge, including any beneficial owner, to whom this prospectus is delivered, a copy of these filings, at no cost, upon written or oral request to us at the following address:

 

Omer Industrial Park, No. 7A, P.O. Box 3030

Omer 8496500, Israel

Tel: +972-73-370-4691

Attention: Tatiana Yosef, Chief Financial Officer

 

You should rely only on the information contained or incorporated by reference in this prospectus, the accompanying prospectus and any free writing prospectus we have authorized for use in connection with this offering. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, or such earlier date, that is indicated in this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

 

42

 

 

 

 

 

 

 

 

 

Up to                   American Depositary Shares Representing               Ordinary Shares

 

 

 

 

MEDIGUS LTD.

 

 

 

 

 

PRELIMINARY PROSPECTUS

 

 

 

 

 

 

, 2020  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Part II

 

Information Not Required in Prospectus

 

Item 6. Indemnification of Office Holders (including Directors).

 

Under the Companies Law, a company may not exculpate an office holder from liability for a breach of a fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our articles of association include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.

 

Under the Companies Law and the Securities Law, 5738-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:

 

  a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator’s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking will detail the abovementioned foreseen events and amount or criteria;

 

  reasonable litigation expenses, including reasonable attorneys’ fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;

 

  reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent;

 

  a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law;

 

  expenses incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys’ fees; and

 

  any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.

 

II-1

 

 

An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.

 

Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company’s articles of association:

 

  a breach of a fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;

 

  a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;

  

  a monetary liability imposed on the office holder in favor of a third party;

 

  a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and

 

  expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys’ fees.

 

Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:

 

  a breach of fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;

 

  a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;

 

  an act or omission committed with intent to derive illegal personal benefit; or

 

  a civil or administrative fine, monetary sanction or forfeit levied against the office holder.

 

Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which such controlling shareholders have a personal interest, also by the shareholders.

 

Our articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors’ and officers’ liability insurance policy.

 

As of the date of this registration statement on Form F-1, no claims for directors’ and officers’ liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought.

 

We have entered into agreements with each of our current director and officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our directors and officers based on such indemnification agreement is equal to 25% of our shareholders’ equity pursuant to our latest audited or unaudited consolidated financial statements, as applicable, as of the date of the indemnification payment. Such indemnification amounts are in addition to any insurance amounts. Each director or officer who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.

 

II-2

 

 

Item 7. Recent Sales of Unregistered Securities.

 

Set forth below are the sales of all securities by the Company during the three years preceding this offering, which were not registered under the Securities Act.

 

On September 3, 2019, we issued to Gix 333,334 ADSs through equity exchange by issuing Gix ADSs at a price of $3 per ADS in consideration for Gix shares based on a price per Gix share of NIS 4.15. In addition, we issued Gix warrants to purchase our ADSs in an amount equal to the ADSs issued to Gix, at an exercise price of $4 per ADS.  

 

In July 2018, we issued and sold to H.C. Wainwright & Co., as underwriter for our public offering, 425,651 Series C Warrants to purchase 425,651 ADSs, representing 8,513,020 Ordinary Shares, at a price of $0.01 per warrant, as part of the consideration for its services as underwriter. We also undertook to issue the underwriter an additional 198,637 Underwriter Warrants to purchase 198,637 ADSs, representing 3,972,740 Ordinary Shares, at an exercise price of $4.375 per ADS for a period of five years once we increased our authorized share capital. We subsequently issued those Underwriter Warrants to the underwriter.

 

In November 2017, we issued investors warrants to purchase up to a total of 202,500 ADSs representing 4,050,000 Ordinary Shares at an exercise price of $8 per ADS.

 

In November 2017, we issued H.C. Wainwright & Co. warrants to purchase up to a total of 14,177 ADSs representing 283,540 Ordinary Shares at an exercise price of $10 per ADS as part of the consideration for its services as placement agent.

 

The foregoing issuances of warrants to purchase ADSs in 2017 and 2018 were offered pursuant to Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act, and the issuance of ADS in 2019 was made in reliance on an exemption pursuant to Regulation S, promulgated under the Securities Act.

 

The foregoing issuances, with the exclusion of Gix, were adjusted to reflect (i) a 1-for-10 reverse share split of our Ordinary Shares effected on July 13, 2018, together with a change in the ratio of Ordinary Shares per ADSs, such that after the reverse share split was implemented each ADS represents 20 post- reverse share split Ordinary Shares, instead of 50 pre-reverse share split Ordinary Shares, (ii) change in the ratio of Ordinary Shares per ADS from five Ordinary Shares per ADS to 50 Ordinary Shares per ADS effected on March 15, 2017, and (iii) 1-for-10 reverse share split of our Ordinary Shares and the change in the ratio of Ordinary Shares per ADS to five deposited Ordinary Shares per ADS effected on November 6, 2015.

 

Item 8. Exhibits and Financial Statement Schedules.

 

  (a) The Exhibit Index is hereby incorporated herein by reference.
     
  (b) Financial Statement Schedules.

 

All Financial Statement Schedules have been omitted because either they are not required, are not applicable or the information required therein is otherwise set forth in the Registrant’s consolidated financial statements and related notes thereto.

 

II-3

 

 

Item 9. Undertakings.

 

  (a) The undersigned Registrant hereby undertakes:

 

  (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

  i. To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

 

  ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

 

  iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

  (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

  (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

  (4) To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.

 

  (5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

  i. If the registrant is relying on Rule 430B:

 

  A. Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

 

II-4

 

 

  B. Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness of the date of the first contract or sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

 

  ii. If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

  (6) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell securities to such purchaser:

 

  i. Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
     
  ii. Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
     
  iii. The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
     
  iv. Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

II-5

 

 

(c) The undersigned registrant hereby undertakes that:

 

(1) That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

(2) That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-6

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Omer, State of Israel on November 2, 2020.

 

  Medigus Ltd.
   
  By: /s/ Liron Carmel
  Name:  Liron Carmel
  Title:  Chief Executive Officer

  

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints Liron Carmel and Tatiana Yosef, and each of them, as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act, and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of securities of the registrant, including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-1 (the “Registration Statement”) to be filed with the Securities and Exchange Commission with respect to such securities, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement, and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signatures   Title   Date
         
/s/ Liron Carmel   Chief Executive Officer   November 2, 2020
Liron Carmel        
         
/s/ Tatiana Yosef   Chief Financial Officer   November 2, 2020
Tatiana Yosef        
         
/s/ Eliyahu Yoresh   Chairman of the Board of Directors    November 2, 2020
Eliyahu Yoresh        
         
/s/ Ronen Rosenbloom   Director   November 2, 2020
Ronen Rosenbloom        
         
/s/ Eli Cohen   Director   November 2, 2020
Eli Cohen        
         
/s/ Kineret Tzedef    Director   November 2, 2020
Kineret Tzedef        

 

II-7

 

 

Signature of authorized representative in the United States

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant’s duly authorized representative has signed this registration statement on Form F-1 in on this 2nd day of November 2020.

 

  Medigus USA LLC
   
  Authorized U.S. Representative
   
  By: /s/ Liron Carmel
  Name:  Liron Carmel
  Title:  Chief Executive Officer

 

II-8

 

 

EXHIBIT INDEX

 

Exhibit
No.
  Description
1.1   Form of Underwriting Agreement(1)
3.1   Articles of Association of Medigus Ltd., as amended(9)
4.1   Form of Deposit Agreement between the Registrant, The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs issued thereunder, including the Form of American Depositary Shares(2)
5.1   Opinion of Meitar | Law Offices, Israeli counsel to the Registrant, as to the validity of the ordinary shares(1)
10.1   2013 Share Option and Incentive Plan(2)
10.2   Compensation Policy of Medigus Ltd.(9)
10.3   Form of Indemnification and Exculpation Undertaking(2)
10.4   Common Stock Purchase Agreement by and between the Registrant, Smart Repair Pro, Inc., Purex, Inc, each of Smart Repair Pro, Inc. and Purex, Inc. respective stockholders and Vicky Hacmon dated October 8, 2020(9)*
10.5   Share Purchase Agreement by and between the Registrant and Eventer Technologies Ltd., dated October 14, 2020(9)*
10.6   Revolving Loan Agreement by and between the Registrant and Eventer Technologies Ltd., dated October 14, 2020(9)*
10.7   Share Exchange Agreement by and between the Registrant and the shareholders of Eventer Technologies Ltd., dated October 14, 2020(9)
10.8   Addendum No. 1 to Amended and Restated Asset Transfer Agreement by and between the Registrant and ScoutCam Ltd., dated July 27, 2020(9)*
10.9   Underwriting Agreement by and between the Registrant and ThinkEquity, a division of Fordham Financial Management, Inc., dated May 19, 2020(3)
10.10   Amended and Restated Inter Company Services Agreement by and between the Registrant and ScoutCam Ltd. dated April 20, 2020(4)
10.12   Asset Transfer Agreement by and between the Registrant and GERD, IP, Inc., dated April 19, 2020(4)*
10.12   Founders Agreement by and between the Registrant and Kfir Zilberman, dated January 12, 2020(4)
10.13   Amended and Restated Asset Transfer Agreement by and between the Registrant and ScoutCam Ltd., dated December 1, 2019(4)*
10.14   Patent License Agreement by and between the Registrant and ScoutCam Ltd., dated December 1, 2019(3)*
10.15   Securities Purchase Agreement by and between the Registrant, Algomizer Ltd. and Linkury Ltd., dated June 19, 2019(4)*
10.16   Know-How License and Sale of Goods Agreement By and between the Registrant and Shanghai MUSE Medical Science and Technology Co., Ltd., dated June 2, 2019(4)*
10.17   Form of Series C Warrant Agent Agreement between the Registrant and Computershare Inc., as warrant agent, including Form of Series C Warrant(5)
10.18   Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares issued in connection with the November 24, 2017, Securities Purchase Agreement(6)
10.19   Form of Placement Agent Warrant to purchase Ordinary Shares Represented by American Depositary Shares issued in connection with the March 2017 Securities Purchase Agreement(7)
10.20   Form of Series A Warrant to purchase Ordinary Shares Represented by American Depositary Shares issued in connection with the March 2017 Securities Purchase Agreement(7)
10.21   Form of Warrant to purchase Ordinary Shares Represented by American Depositary Shares issued in connection with the November 2016 Securities Purchase Agreements(8)
16.1   Letter from Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, dated November 2, 2020(9)
21.1   List of Subsidiaries(8)
23.1   Consent of Kesselman & Kesselman, Certified Public Accountant (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm(9)
23.2   Consent of Brightman Almagor Zohar & Co., Certified Public Accountant (Isr.), a firm in the Deloitte Global Network(9)
23.3   Consent of Meitar | Law Offices, Israeli counsel to the Registrant (included in Exhibit 5.1)(1)
24.1   Power of Attorney (included in the signature page of the Registration Statement)

 

(1) To be filed by amendment.

 

II-9

 

 

(2) Previously filed with the Securities and Exchange Commission on May 7, 2015, as an exhibit to the Registrant’s annual report on Form 20-F (File No 001-37381) and incorporated by reference herein.
(3) Previously filed with the Securities and Exchange Commission on May 22, 2020, as an exhibit to the Registrant’s report on Form 6-K (File No 001-37381) and incorporated by reference herein.
(4) Previously filed with the Securities and Exchange Commission on April 22, 2020, as an exhibit to the Registrant’s annual report on Form 20-F (File No 001-37381) and incorporated by reference herein.
(5) Previously filed with the Securities and Exchange Commission on July 18, 2018, as an exhibit to the Registrant’s registration statement on Form F-1 (File 333-2225610) and incorporated by reference herein.
(6) Previously filed with the Securities and Exchange Commission on November 24, 2017, as an exhibit to the Registrant’s report on Form 6-K (File No 001-37381) and incorporated by reference herein.
(7) Previously filed with the Securities and Exchange Commission on March 23, 2017, as an exhibit to the Registrant’s registration statement on Form F-1 (File No 333-216155) and incorporated by reference herein.
(8) Previously filed with the Securities and Exchange Commission on December 1, 2016, as an exhibit to the Registrant’s report on Form 6-K (File No 001-37381) and incorporated by reference herein.
(9) Filed herewith.

 

* Certain confidential information contained in this exhibit, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit.

 

 

II-10

 

Exhibit 3.1

 

AMENDED AND RESTATED

ARTICLES OF ASSOCIATION

OF

MEDIGUS LTD., AS AMENDED

 

Interpretation

 

Article 1:

 

In these Articles the following terms shall bear the meaning ascribed to them below:

 

Person   shall include a corporation;
     
Shareholder   shall mean a Registered Shareholder or Unregistered Shareholder. Where an effective date, as defined in Section 182 of the Companies Law, is in effect, a Shareholder shall mean such Registered Shareholder or Unregistered Shareholder as of the Effective Date;
     
Registered Shareholder   shall mean a Person registered in the Register;
     
Unregistered Shareholder   shall mean a Person in whose favor a share is registered with a stock exchange member, and such share is also registered in the Register under a nominee company’s name;
     
Stock Exchange   shall mean the Tel Aviv Stock Exchange Ltd.
     
The “Board   shall mean the Company’s Board of Directors as appointed in accordance with the Law and these Articles;
     
Director   shall mean a member of the Board, or any other person or entity serving, de-facto, as a Director, even if referred to otherwise;
     
The “Companies Law   shall mean the Israeli Companies Law, 5759 – 1999, as amended from time to time, and all the rules and regulations promulgated thereunder;
     
The “Law   shall mean the Companies Law, the Israeli Securities Law, 5728-1968, as amended from time to time and its regulations or regulation prescribed by Law, and any other companies-related law applicable to the company at the time;
     
The “Company   shall mean the company referred to above;
     
Administrative Enforcement Proceeding   shall mean administrative enforcement proceeding under Chapter 8-C, 8-D or 9-1 to the Israeli Securities Law, 5728-1968, and proceeding under Article D, Chapter 4 of part 9 of the Companies Law, 5759-1999;
     
Register   shall mean a register of shareholders as required under Section 127 of the Companies Law, and any additional register of shareholders maintained by the Company outside of Israel;
     
The “Office   shall mean the registered office of the Company, as shall be from time to time in accordance with the Board’s discretion;
     
In Writing   shall mean print, lithography, photo, telegram, telex, facsimile, electronic mail, or any other visual expression or imprinting of words;
     
Securities   shall include shares, debentures, capital notes, certificates and other documents granting the right to sell or convert them as such;
     
The “Companies Ordinance   shall mean the Israeli Companies Ordinance [New Version], 5743- 1983;
     
The “Articles   shall mean the articles of association contained in the Articles, as originally registered and as may be amended from time to time.

 

 

 

 

Article 2: 

 

Sections 2, 3, 4, 5, 6, 7, 8 and 10 of the Interpretation Law, 5741-1981, shall apply, mutatis mutandis, to the interpretation of these Articles herein, unless otherwise provided herein or unless the matter at hand, or its context, does not conform to such application.  

 

Article 3:

 

Except for this Article 3 herein, all terms and expressions used in these Articles herein shall have the same meaning as provided in the Companies Law, unless such meaning is in contradiction to the relevant matter at hand or its context.

 

Article 4:

 

Provisions which may be conditioned shall apply the Company, unless otherwise provided in these Articles herein, and in any contradiction between the provisions of these Articles herein and those of the Companies Law, the provisions of these Articles herein shall prevail.

 

Article 5:

 

Where these Articles refer to provisions of the Companies Law which were amended or canceled, such provision shall apply as if already stipulated in these Articles herein, unless otherwise prohibited by law.

 

Article 6:

 

Unless otherwise stipulated in these Articles herein, resolutions shall be adopted by the Company’s general meeting of its shareholders or by the Board by an ordinary majority. Notwithstanding anything in these Articles to the contrary, the provisions of Articles 6, 83, 84, 87, 88, 91, 92, 93 and 159 may only be amended by a resolution at the general meeting of the Company’s shareholders, provided however, that such amendment was also approved by a resolution of at least 75% of the members of the Board then in office, at a session of the Board which has taken place prior to the general meeting.

 

The Company’s Name

 

Article 7:

 

The name of the Company shall be as follows:

 

In Hebrew: מדיגוס בע”מ

 

In English: Medigus Ltd.

 

The Company’s Objectives

 

Article 8:

 

The Company may undertake any lawful activity, subject to the provisions stipulated in its Memorandum of Association.

 

The Company’s Purpose

 

Article 9:

 

The purpose of the Company is to operate in accordance with commercial considerations with the intention of generating profits. However, the Company may donate reasonable amounts for any suitable purpose even if such contributions do not fall within the business considerations of the Company, as the Board may determine in its discretion.

 

2

 

 

The Registered Share Capital

 

Article 10:

 

A) The Company’s registered share capital is NIS 1,000,000,000 divided into 1,000,000,000 ordinary shares of the Company, par value NIS 1.00 each (hereinafter: the “Shares”).

 

B) All ordinary Shares shall have equal rights for any matter or purpose, and holders of fully paid ordinary shares shall be entitled to the following rights with respect to each such ordinary share held by them:

 

1. A right to be invited to and participate in, all the general meetings of the Company’s shareholders, and a right to one vote per each ordinary share he holds, in every voting, in every general meeting of the Company’s shareholders he participates in.

 

2. A right to participate in dividends’ distribution, if and when distributed, and a right to be granted with bonus shares, if and when granted.

 

3. A right to participate in the Company’s liquidation distribution in the event of its liquidation.

 

Liability of Shareholders

 

Article 11:

 

The shareholders’ liability is limited. Every shareholder’s liability is limited to the payment of the par value of his Shares. Where the Company allocated Shares for less than their par value, the liability of every shareholder so allocated shall be limited to the lower par value of such Shares.

 

Public Company

 

Article 12:

 

Subject to the Companies Law, and for as long as the Shares are listed for trade in the Stock Exchange or have been offered to the public under a prospectus, as such term is defined in the Securities Law, 1968, or have been offered to the public outside of Israel under an applicable public offer instrument as required by applicable law outside of Israel, and are held by the public, the Company shall qualify as a Public Company. Prior to the date of becoming a Public Company and upon the date the date of ceasing to be a Public Company (if at all), the Company shall then be a Private Company.1

 

Shares

 

Article 13:

 

Without prejudice to any special rights previously granted to holders of existing Shares, the Company may issue or allot Shares or other Securities consisting preference or deferred rights, or to issue from its unissued share capital redeemable Securities, or to issue shares consisting other special limited rights or limitations regarding dividend distribution rights, voting rights, or other matters, as shall be resolved from time to time by a special majority resolution of the general meeting of the Company’s shareholders.

 

Article 14:

 

If at any time, the Company’s share capital shall be divided into different classes, the general meeting of the Company’s shareholders may resolve by an ordinary majority, unless otherwise stipulated by the issuance terms of the relevant class of shares, to convert, extend, add or to otherwise amend the rights, privileges, benefits, limitations and provisions related or unrelated at that time to the relevant class of shares, or as shall otherwise be resolved by an ordinary majority of the Company’s shareholders holding the relevant class of shares, at the general meeting of the Company’s shareholders.

 

 

 

 

1 For the avoidance of doubt, it is hereby clarified that any Articles specifically referring to a Private Company shall not apply for as long as the Company is as a Public Company.

 

3

 

 

Article 15:

 

The special rights attached to issued shares or classes of shares, including preference rights shares or other special rights shares, shall not be considered to be amended by creating or issuing additional shares of an equal rank, unless otherwise stipulated by the issuing terms of such shares. The provisions regarding general meetings of the Company’s shareholders stipulated in these Articles herein shall apply, mutatis mutandis, on any class meetings.

 

Article 16:

 

The Company’s unissued share capital shall be subject to the Board’s supervision, which may allocate it to those Persons for cash or such other consideration, under the same terms and conditions, at a higher par value, equal par value or lower par value (in accordance with the provisions of the Companies Law), and at those dates determined by the Board, and the Board shall be authorized to demand payment for any such shares from any Person, equal, higher or lower than their par value, during such period and for such consideration, terms and conditions as the Board may determine.

 

Article 17:

 

Upon allocation of shares, the Board may distinguish between shareholders regarding payment amounts and payment dates.

 

Article 18:

 

If any allocation terms stipulate that the consideration for the shares so allocated shall be, in whole or in part, in installments, each such installment shall be paid by the Person registered as the shareholder at the time of payment, or by his legal guardians.

 

Article 19:

 

The Company may pay at any time any Person, for providing underwriting services or for his consent to provide underwriting services, either conditionally or unconditionally, for any of the Company’s Securities, including debentures and debentures stock, or for his consent to obtain signatures, either conditionally or unconditionally, for any of the Company’s securities, debentures or debentures stock. Any commission may be paid or removed in cash, Securities, debentures or debentures stock.

 

Share Certificate; Share Deed

 

Article 20:

 

Subject to and in accordance with the provisions of the Companies Law, each share certificate evidencing proprietary right in the Shares shall carry the Company’s seal or its printed name, along with one of the signatures of one of the company’s members of the Board and Company secretary, or as otherwise shall be determined by the Board.

 

Article 21:

 

Every registered shareholder (including a nominee company), is entitled to receive from the Company, as requested, one share certificate evidencing all of the Shares registered under his name, or, if so approved by the Board (upon payment of the amounts determined by the Board from time to time), several share certificates, each for one or more such Shares; each share certificate shall denote the number of Shares represented by such certificate, the serial number of such Shares and their par value, all subject to the Companies Law.

 

Article 22:

 

Share certificate registered jointly under the names of two Persons or more shall be delivered to the Person whose name is listed first among other such Persons in the Register, unless otherwise instructed in writing by such joint registered Persons.

 

4

 

 

Article 23:

 

A) Where the consideration for Shares is fully paid, the Company may provide a share deed entitling its holder with rights to the Shares denoted in the share deed and the right to transfer it by transferring the Share, and the provisions regarding Share transfers stipulated in these Articles herein shall not apply.

 

B) Shareholder lawfully holding a share deed is entitled to return such share deed to the Company to be cancelled and converted to a registered Share; Such shareholder is further entitled, upon payment of a fee determined by the Board, to be registered in the Register as the holder of the Shares so represented by the share deed returned to the Company, and to receive a share certificate representing such Shares.

 

C) Holder of a share deed may deposit his share deed in the Office, and for as long as it is so deposited, such depositor shall have the right to request for the general meeting of the Company’s shareholders to convene, in accordance with and subject to the Companies Law and these Articles herein, to attend it, to vote in it and to uphold all further rights granted to a shareholder in a general meeting of the Company’s shareholders convened pursuant to his request 48 hours pursuant to such deposit, as though his name was registered in the Register as the holder of those Shares represented by the deed. Only one Person shall be acknowledged as the share deed depositor, and the Company must return the share deed to its depositor if so requested by him, in writing, at least two days in advance.

 

Where a share deed was not deposited in accordance with the above, its holder shall not have the rights stated in subsection C above, and shall have, subject to these Articles herein, all other rights granted to the Company’s shareholders.

 

Article 24:

 

If a share certificate or share deed are lost, damaged or defected, the Board may issue a new share certificate or share deed to replace them, provided that such share certificate or share deed were not canceled by the Company, or upon proving to the Board’s satisfaction such loss or destruction, and the Company was provided with guarantees against any possible damage to the Board’s satisfaction, all for the consideration determined by the Board. Articles 20-23 above shall apply, mutatis mutandis, in connection with the issuance of a new share certificate.

 

Calls on Shares

 

Article 25:

 

The Board may, from time to time, in its discretion, make calls upon to perform payment of any amount of the consideration of their Shares not yet paid, and which, according to the allocation terms of such Shares are not to be paid in definite dates, and all such shareholder shall pay the calls so made upon him at the time(s) and place(s) designated in such call. A call may contain a demand for payment in installments. The date of the Board’s resolution approving such call shall be deemed as the date of such call.

 

Article 26:

 

A call shall be delivered to the relevant shareholder not less than fourteen (14) days prior to the date of payment stipulated therein, and shall specify the installments and the designated place of payment. Notwithstanding the above, prior to the due date stipulated in the call the Board may, by delivering a written notice to the relevant shareholder, revoke such call or extend the payment period, subject to such revoking being approved prior to the payment of the call.

 

Article 27:

 

The joint holders of a Share shall be bound jointly and severally to pay all calls in respect thereof.

 

5

 

 

Article 28:

 

If, according to the terms of issuance of any Share, any amount is due at a definite date or in installments in definite dates, such amount(s) shall be paid on same date(s) as though due call had been delivered to the shareholder by the Board, and provisions regarding calls provided in these Articles herein shall apply such call.

 

Article 29:

 

Any amount not paid by the shareholder of the respective Share, when due or prior to that, shall bear an interest from its due date until its actual payment at a rate determined by the Board from time to time, or as prescribed by law at the date of call,, unless otherwise prescribed by the Board.

 

Article 30:

 

The Board may agree to accept prepayment by any shareholder of any amount yet due with respect to his Shares or any part thereof. The Board may direct the payment of interest for such prepayment or any part thereof, until the date of such prepayment at a rate as may be agreed upon between the Board and the shareholder so prepaying.

 

Forfeiture and Lien of Shares

 

Article 31:

 

The Board may require any shareholder failing to pay any due amount on account of his Shares or any part thereof, to pay the unpaid due amount, including accrued interest and all expenses incurred by the Company with respect to the collection of such payment, on the date and in the terms so prescribed, by delivering a notice to such shareholder.

 

Article 32:

 

The notice shall specify a date, which date shall be not less than 14 days following the delivery date of such notice, and a place(s) where such payment, including the accrued interest and expenses thereon, is to be paid. Same notice shall specify that, in the event of failure to pay the entire amount due within the period stipulated in the notice, same failure may cause, ipso facto, the forfeiture of such Shares.

 

Article 33:

 

By Shareholder’s failure to meet the demands included in the abovementioned, the Board may, at any time thereafter and prior to the payment of all due amounts specified in the notice or payment of all expenses and accrued interest to which the company is entitled with respect to such shareholder’s Shares, resolve to forfeit such Shares. Such forfeiture shall include all dividends declared with respect thereof and not actually paid to the date of forfeiture thereof.

 

Article 34:

 

Any Share so forfeited shall be deemed as the Company’s property, and the Board may resolve, subject to the provisions of these Articles herein, to resell it, reissue it or otherwise transfer it as it deems fit, all subject to the provisions of the Companies Law. 

 

Article 35:

 

Shares so forfeited and yet to be resold shall be deemed dormant Shares, and shall not have any rights attached to them for as long as they are held by the Company.

 

6

 

 

Article 36:

 

The Board may, at any time prior to the resell, reissuance or otherwise disposal of an aforesaid forfeited Share, nullify the forfeiture on such conditions as it deems fit.

 

A) Any shareholder whose Shares have been so forfeited shall cease to be a holder of such forfeited Shares, but shall nevertheless continue to be obligated to pay the Company all amounts at the time of forfeiture due to the Company with respect thereof, including accrued interest and expenses as aforesaid until actual repayment, and including the interest to be paid for the aforesaid amounts from the time of forfeiture until the actual repayment, at the maximal interest rate prescribed by law, unless such Shares have been resold and the Company received the full amount owed by the shareholder, including all expenses incurred by the Company with respect to the sale of such Shares thereof.

 

B) If the consideration received by the Company for the sale of the forfeited Shares shall exceed the amounts owed by the shareholder of whose Shares have been forfeited, such shareholder shall be entitled to receive the partial consideration paid by him to the Company with respect to such Shares, if so paid, subject to the allocation agreement, provided that the total remaining consideration shall not be less than the total obligations of such shareholder, including any sell-related expenses.

 

Article 37:

 

Provisions of these Articles herein regarding forfeiture of Shares shall also apply to failure to pay due known amounts in accordance with the allocation agreement, as if such amount was due to be repaid in accordance with a duly delivered payment notice.

 

Article 38:

 

The Company shall have a first and paramount lien upon all the Shares registered in the name of each shareholder on the Register, excluding fully paid Shares, and upon proceeds from their sale for repayment of such shareholder’s debts and obligations to the Company, whether joint or several, matured or un-matured, regardless of the origins of such debts and obligations, and no equitable rights for any such Shares shall be constituted. The abovementioned lien shall apply upon all the declared dividends from time to time with respect to such Shares.

 

Article 39:

 

The Board may sell any of the Shares subject to the abovementioned lien, in any manner it deems fit in accordance with its discretion, for the purpose of enforcing the abovementioned lien; however, such sale may be executed only where the period specified in Article 32 thereof has passed and a written notice specifying the Company’s intention to sell such Shares have been delivered to the shareholder in question (or to the one entitled to such notice following his departure or his bankruptcy, liquidation or receivership), and the shareholder or any other Person so entitled to the Share has failed to fully pay his abovementioned debts or obligations within fourteen (14) days following the delivery of such notice. 

 

Article 40:

 

The net proceeds of any such sale, after payment of the sale expenses, shall be used for the full payment of the respective shareholder’s debts and obligations (including the debts, obligations and engagements yet to be due), and the provisions of Article 36(b) herein shall apply, mutatis mutandis.

 

Article 41:

 

Upon the sale of forfeited Shares or enforcement of a lien, the Board may appoint any Person to execute a Share transfer deed of the sold Shares and register the purchaser of such Shares in the Register as the holder of such Shares, and after such registration in the Register, the validity of such sale shall not be rebutted, and any Person damaged by such sale shall be entitled to claim monetary damages solely from the Company.

 

7

 

 

Transfer of Shares

 

Article 42:

 

Any transfers of Shares registered in the Register by a registered shareholder, including transfer by or to the nominee company, shall be executed in writing, provided that the Share transfer deed shall be signed by or on behalf of the transferor and the transferee, or by their respective representatives, and by witnesses to their signatures, and the transferor shall be deemed the holder of such Shares until the registration of the transferee in the Register with respect to the Shares so transferred. Subject to the provisions of the Companies Law, transfer of Shares shall not be registered unless the Company was provided with the Share transfer deed, as described above.

 

The Share transfer deed shall be drawn-up and filled as below or in a manner as similar as possible or in an ordinary and accepted manner so approved by the chairman of the Board

 

I, the undersigned  , of   (the “Transferor”), for consideration of   NIS paid to me by  of  (the “Transferee”) do hereby transfer to the Transferee   Shares  par value NIS _______ each, numbered  through    (inclusive) of __________ Ltd., to be held by the Transferee, the administrators of his estate, his guardians and his representatives, in accordance with the terms and conditions by which they were held by me on the date of signing this Share transfer deed herein, and I, the Transferee, do hereby accept the transfer of these Shares in accordance with those terms and conditions.”

 

In witness whereof we have we have signed this Share transfer deed in this ___ day of __________.

 

     
     
The Transferor     The Transferee

 

     
     
     
Witness to the Transferor’s Signature   Witness to the Transferee’s Signature

 

Article 43:

 

The Company may close the Register for a period as the Board deems fit, provided that such period shall not exceed thirty (30) days per year. The Company shall notify the shareholders of the closing of the Register as stipulated in these Articles herein in connection the delivery of notices to shareholders.

 

Article 44:

 

A) Every Share transfer deed shall be submitted to the Office for registration along with the Share certificates to be transferred, if such Share certificates have been issued, and all such other evidencing instruments as the Board may deem required. Such registered Share transfer deeds shall remain in the Company’s possession. However, Share transfer deeds which the Board refused to register shall be returned, on demand, to their respective submitter, along with the Share certificates (if submitted). Where the Board refuses to approve Share transfers, it shall notify the transferor no later than thirty (30) days following the date in which it received the Share transfer deed.

 

B) The Company may require payment of a fee for the registration of the transfer of Share, as shall be determined by the Board from time to time.

 

Article 45:

 

Upon the departure of a registered shareholder, the Company shall recognize the guardians, administrators of the estate, executors of the will, and in the absence of such persons, the inheritors of the deceased shareholder, as the only holders of rights in the deceased shareholder’s registered Shares.

 

Article 46:

 

In the event of the deceased shareholder being a registered shareholder of a Share held jointly with others, the surviving shareholder(s) shall be deemed the sole holder(s) of rights in such Shares, but such rights will not dismiss the deceased shareholder’s estate from any liability relating to such Shares held jointly. Each joint holder or registered Shares may transfer his rights in such Shares.

 

Article 47:

 

Any Person acquiring rights in Shares by virtue of a shareholder’s departure, shall be entitled, upon provision of a due will or appointment of legal guardian or issuance of order of probate, evidencing his rights in such Shares, to be registered as a shareholder of the respective Shares, or to transfer such Shares in accordance with the provisions of these Articles herein.

 

8

 

 

Article 48:

 

The Company may recognize an official receiver or liquidator of a shareholder which is a corporate in dissolution proceedings, or trustee in liquidation proceedings, or any receiver of a bankrupt shareholder, as the acquirer of the rights in the registered Shares of such shareholder.

 

Article 49:

 

Subject to the Board’s approval (which may refuse to provide such approval without providing any reason), a Person acquiring a right to a Share by virtue of being an official receiver, liquidator or trustee in liquidation proceedings regarding a corporate shareholder, or any official receiver of a bankrupt shareholder, may be registered as the shareholder of the respective Share or transfer such Share in accordance with the provisions of these Articles herein, subject to the provision of such proof of entitlement as the Board may deem necessary.

 

Article 50:

 

All the abovementioned provisions regarding transfer of Shares shall apply to transfer of any other of the Company’s Securities, mutatis mutandis.

 

Redeemable Securities

 

Article 51:

 

Subject to the provisions of these Articles herein regarding issuance of Securities, the Company may issue or allot redeemable Securities.

 

Article 52:

 

Where the Company had issued redeemable Securities, it may redeem them without being subject to such limitations as prescribed under Chapter Two of Part Seven of the Companies Law.

 

Article 53:

 

Where the Company had issues redeemable Securities, it may attach them with similar rights to those attached to Shares, including voting rights and rights to participate in the distribution of dividends.

 

Alteration of Share Capital

 

Article 54:

 

The Company may, from time to time, by an ordinary majority resolution of the general meeting of the Company’s shareholders, increase the registered share capital of the Company in classes of shares, as it may determine.

 

Article 55:

 

Unless otherwise resolved in the abovementioned resolution approving the increase of registered share capital, all newly issued Shares shall be subject to these Articles herein.

 

Article 56:

 

The Company may, by ordinary majority resolution of the general meeting of the Company’s shareholders:

 

A) Consolidate and redistribute its Share capital, or any part thereof, into Shares par higher value than the par value of its already issued Shares, and if the already issued Shares have no par value - into a Share capital comprised of a smaller number of Shares, provided that the proportional holdings of the existing shareholders shall not be retained.

 

9

 

 

For the purpose of executing any such resolution, the Board may settle any difficulty arising as it deems fit, including issuance of Share certificates for fractional Shares or issuance of several Share certificates for several shareholders which shall include fractional Shares.

 

Without derogating from the above generality of the Board’s authority, if the consolidation of the Shares results in fractional Shares, the Board may, subject to an ordinary majority approval of the general meeting of the Company’s shareholders:

 

1) sell all the fractional Shares, and for that purpose, assign to a trustee on whose name Share certificates including the fractional Shares  shall be issued, who will sell them, and the net proceeds of any such sale, after deducting commissions and other sale related expenses, shall be distributed to those eligible; or

 

2) issue each shareholder holding fractional Shares due to the consolidation, fully paid Shares of the same class of Shares which existed prior to the consolidation, in such number that would constitute one whole Share, and such issuance shall be deemed to take effect immediately prior to the consolidation; or

 

3) resolve that shareholders shall not be entitled to receive a consolidated Share due to fractional consolidated Shares, resulting from consolidation of half or less of the number of Shares which consolidation results one whole consolidated Share, and shall be entitled to receive one consolidated Share due to fractional consolidated Shares resulting from of more than half of the number of Shares which consolidation constitutes one whole Share;

 

Where actions under paragraphs (2) and (3) above require the additional issuance of Shares, such Shares may be redeemed in the manner by which preferred Shares may be redeemed. The abovementioned consolidation and division shall not change the rights attached to the Shares so consolidated or divided.

 

B) Redistribute all or any of its Share capital through the redistribution of all or any of its existing Shares into shares of a lower par value, and where its Shares have no par value, into issued Share capital comprised of a larger number of Shares, provided, however, that the proportional holdings of the existing shareholders is retained.

 

C) Cancel registered Share capital yet to be issued, provided that the Company did not undertake (conditionally or otherwise), to issue such Share capital.

 

D) Reduce the Shares in its issued Share capital in such manner that the reduced Shares shall be cancelled and any payment made with respect to their par value shall be registered in the Company’s financial statements as a capital fund which shall be treated as a premium paid for the Shares remaining in the Company’s issued  Share capital.

 

E) Consolidate any or all of its Share capital into one class of Shares, and the Company may resolve to reimburse any or all of its shareholders for such consolidation, by means of issuing preferred Shares to such shareholders.

 

General Meetings of the Company’s Shareholders

 

Article 57:

 

An annual meeting of the Company’s shareholders shall be held once in every calendar year, within a period of not more than fifteen (15) months after the previous annual meeting of the Company’s shareholders. All general meetings of the Company’s shareholders other than those annual meetings shall be referred to as “Extraordinary Meetings”.

 

Article 58:

 

The agenda at the annual meeting of the Company’s shareholders shall include the following matters:

 

A) a discussion on the Company’s audited financial statements and the Board’s report on the state of the Company’s affairs, which shall be submitted to the general meeting of the Company’s shareholders;

 

B) appointment of directors;

 

10

 

 

C) appointment of an auditor and receiving the Board’s report on the auditor’s remuneration;

 

D) other matters brought for discussion and resolution by the Board.

 

Article 59:

 

For as long as the Company is a Private Company, the Board may convene an Extraordinary Meeting at its discretion and following the request of each of the following:

 

A) a member of the Board;

 

B) One or more shareholders, holding at least 10 percent (10%) of the Company’s issued Share capital and at least one percent (1%) of the Company’s voting rights, or one or more shareholders holding at least ten percent (10%) of the Company’s voting rights.

 

Article 60:

 

Notwithstanding the above, if the Company becomes a Public Company, the Board may convene an Extraordinary Meeting pursuant to a Board resolution, and must convene such meeting if request is received from two members of the Board or one-fourth of the then serving members of the Board or one or more shareholders holding at least five percent (5%) of the Company’s issued Share capital and at least one percent (1%) of the Company’s voting rights or one or more shareholders holding at least five percent (5%) of the Company’s voting rights.

 

If the Board is requested to convene an Extraordinary Meeting, it shall so convene it within twenty one (21) days pursuant to such request being submitted to it, at such date resolved in the notice of the Extraordinary Meeting, as provided in Article 63(B) therein, provided that if the Company is a Public Company, such meeting shall not be held later than thirty five (35) days from the date such notice was published, all subject to the provisions of the Law.2

 

Article 61:

 

If the Board does not convene a duly requested Extraordinary Meeting as stipulated in Articles 59 and 60 thereof, the Person so requesting such meeting to be convened, and in the case of shareholders – any of them holding more than one half of their voting rights, may convene the meeting himself, provided that it shall not be held more than three (3) months after the date upon which such was submitted, and it shall be convened, insofar as possible, in the same manner by which meetings are convened by the Board.

  

Article 62:

 

A) A general meeting’s agenda shall be determined by the Board and will include the matters for which an Extraordinary Meeting is requested to be convened pursuant to Articles 59 and 60 of these Articles herein, as well as matters requested in accordance with sub-Article (b) below.

 

B) One or more shareholders holding at least one percent (1%) of the Company’s voting rights may request matters to be included on the agenda by the Board, provided that such matters are suitable for discussion at a general meeting of the Company’s shareholders.

 

C) A request as mentioned in article b) above shall be submitted to the Company in writing no less than seven (7) days prior to the date on which a notice of the convening of the general meeting of the Company’s shareholders is given, and shall include the language of the proposed resolution.

 

Article 63:

 

A) If the Company is to become a Public Company, notice of a general meeting of the Company’s shareholders shall be published in no less than two (2) daily Hebrew-language newspapers with a wide circulation at the date prescribed by Law, and the Company shall not be obligated to provide any other notice of such general meeting of its shareholders to any registered shareholders.

 

 

 

 

2 Provisions of this Article herein shall not be in effect for as long as the Company is a Private Company, as such term is defined in the Companies Law.

 

11

 

 

B) Notice of a general meeting of the Company’s shareholders shall include the type of meeting and the place, date and time at which such meeting shall convene and shall further include the agenda, a summary of the proposed resolutions, the majority required for the approval of the proposed resolutions and the determining date for the purpose of eligibility to vote in the such general meeting. If a differed general meeting is adjourned at a different day, time or place in the following week, the notice must specify the details of such adjourned meeting.

 

Article 64:

 

Notwithstanding the above, for as long as the Company is a Private Company: (a) a notice of a general meeting of the Company’s shareholders shall be delivered to all those eligible to participate in the meeting no later than seventy two (72) hours prior to the date of the meeting, provided that such notice shall not be delivered earlier than 45 days prior to the date of meeting; (b) the general meeting of the Company’s shareholders may be convened on a shorter notice, if so approved by all those  eligible to receive such notice. Waiver may be retroactively submitted in writing even after such general meeting was convened.

 

Article 65:

 

The general meeting of the Company’s shareholders may assume powers conferred on another organ. Where the general meeting assumed powers conferred by law on the Board, the shareholders shall be liable and bound by the liability and duties of Directors regarding the exercise of such powers, mutatis mutandis, including, among other things and taking into consideration their holdings in the Company, their participation in the general meeting and the manner in which they vote, the provisions of Chapters 3, 4 and 5 of Part Six of the Companies Law.

 

Article 66:

 

A bona fide flaw in convening the general meeting of the Company’s shareholders or in the conduct thereof, including a flaw deriving from non-compliance with a provision or condition stipulated by the Law or these Articles herein, including in connection with the manner by which the meeting is to convene or to be conducted, shall not cause any resolutions adopted by such general meeting to be invalid and shall not impair discussions held thereat, subject to the provisions of any law.

 

Voting Rights

 

Article 67:

 

A shareholder wishing to vote at a general meeting of the Company’s shareholders shall provide evidence of his ownership in his Shares, as required by any applicable law.

 

Article 68:

 

If, and when, the Company becomes a Public Company, it may set an effective date for the purpose of eligibility to participate and vote at the general meeting of its shareholders, provided that such date will not be less than twenty one (21) days or will exceed four (4) days prior to the date such general meeting is to  convene.

 

Article 69:

 

A Shareholder who is a minor or shareholder who is legally incapacitated by a court of competent jurisdiction may exercise his right to vote by his custodian, and such custodian may vote by proxy.

 

Article 70:

 

Subject to the provisions of any applicable law, where Shares are held jointly, each shareholder so holding the Shares may vote at any meeting, in person or by proxy, in relation to such Shares, as though he were the sole owner of such Shares. If more than one such shareholders attend a meeting, in person or by proxy, the vote shall be made by the joint shareholder whose name appears first in the Register in relation to such Shares, or in an applicable deed or certificate evidencing the ownership of such Shares as determined by the Board for such purpose. Several guardians or administrators of the estate of a deceased registered shareholder shall be deemed as joint shareholders of such Shares for the purposes of this Article herein.

 

12

 

 

Article 71:

 

A Shareholder may vote in the general meeting of the Company’s shareholders in person or by proxy, subject to the conditions stipulated hereunder.

 

Article 72:

 

A corporate body being a shareholder of the Company and entitled to attend and vote at a general meeting of the Company’s shareholders may exercise such rights by authorizing any Person, whether in general or for such specific general meeting, to be present and/or vote on its behalf. Such representative may exercise, on behalf of such corporate body, the rights of the corporate body, as if the corporate body was a single shareholder. Upon the request of the chairman of such general meeting, a reasonable evidence of such authorization and its validity shall be furnished thereto as a requirement for the participation of such representative in such general meeting.

 

It is hereby clarifies that Articles 73 through 77 hereunder with respect to a letter of appointment shall not apply an authorized representative of the corporate body, but shall only apply to its proxy.

 

Article 73:

 

A proxy’s letter of appointment (hereinafter: “Letter of Appointment”) shall be in writing and shall be signed by the appointer or by such other duly authorized Person. If the appointer is a corporate body, the Letter of Appointment shall be in writing and signed by the corporate body’s approved signatory, accompanied by the corporate seal or signed by its authorized representative.

 

Article 74:

 

The Letter of Appointment, or a suitable copy thereof to the Board’s satisfaction, shall be deposited in the Office or in any other place in which the general meeting of the Company’s shareholders is to convene, not less than forty eight (48) hours prior to the commencement of the meeting at which the Person appointed by the Letter of Appointed is to vote. Notwithstanding the aforesaid, the chairman of such meeting may waive such requirement with respect to all the participants in a general meeting and accept a Letter of Appointment upon the commencement of such meeting.

 

Article 75:

 

A Shareholder holding more than one Share may appoint more than one proxy, subject to the following provisions:

 

A) The Letter of Appointment shall specify the class and number of Shares for which it is issued;

 

B) If the Letter of Appointment specifies a number of Shares higher than the number of Shares held by the relevant shareholder, all Letters of Appointment issued by such shareholder with respect to the excess Shares shall be void, without derogating from the validity of the Letters of Appointment issued with respect to the Shares duly held by such shareholder;

 

C) If the Letter of Appointment does not specify the number and class of Shares in respect of which it is being issued, such Letter of Appointment shall be deemed to have been given in respect of all the shareholder’s registered Shares as of the date he submitted the Letter of Appointment to the Company or submitted it to the chairman of the general meeting of the Company’s shareholders, as the case may be. If the Letter of Appointment is issued in respect of fewer Shares than the ones held by the shareholder, then the shareholder shall be deemed to have abstained from voting in respect of the remaining Shares held by him and the Letter of Appointment shall be valid only in respect of the number of Shares specified therein.

 

13

 

 

Article 76:

 

The Letter of Appointment shall be drawn up in the following form of wording or in a form of wording as similar thereto as possible:

 

I ____________, of ____________, as a shareholder of __________ Ltd. (the “Company”), hereby appoint ______________ of _____________ whose identity number is ____________ or in his absence _____________ of  ____________________  whose identity number is _____________ as my proxy, to vote in my name and stead in respect of  ____________number of shares of ______________ class which are held by me, at the annual/Extraordinary Meeting of the Company’s shareholders to be held on the __________  day of __________  year__________  and at any deferred meeting thereof.

 

In witness whereof I have signed this Letter of Appointment in this ___ day of __________. 

 

   
   
Signature”  

  

Article 77:

 

Voting by virtue of a Letter of Appointment shall be valid even if prior to such voting the appointer had died or the Letter of Appointment had been cancelled or the Share in respect of which it was given was transferred, unless a written notice regarding such death, cancellation or transfer was received in the Office prior to the respective meeting.

 

Discussions and Adoption of Resolutions in the General Meetings

 

Article 78:

 

Discussions are no to be held unless a quorum is present within half an hour of the time scheduled for the respective meeting. Unless otherwise stipulated by the Companies Law or these Articles herein, a legal quorum is the presence, in person or by proxy, of at least two (2) shareholders holding at least ten percent (10%) of the voting rights in the Company.

 

Article 79:

 

If a quorum is not present within half an hour from the time set for the respective meeting’s commencement, the meeting shall be adjourned for the following week, at the same day, time and place, without it being necessary to notify the shareholders of such adjournment, or to another date if such is stated in the notice of the meeting, at which the agenda shall be of the first meeting. If a quorum is not present at the adjourned meeting within half an hour of the time set for its commencement, the adjourned meeting shall then commence at the presence of any number of shareholders (it is hereby clarified that the provisions of this Article 79 are also applicable to meetings convened upon a Shareholder’s request).

 

Article 80:

 

A general meeting chairman shall be appointed at every general meeting of the Company’s shareholders. Such chairman shall be appointed at the commencement of every such general meeting, subject to the presence of the required quorum, by the Company Secretary or by a Shareholder authorized by him for that purpose.

 

Article 81:

 

The chairman of a general meeting of the Company’s shareholders may, with the consent of the respective meeting in which a quorum is present, adjourn the meeting or adjourn the discussion or the adoption of a resolution on a particular matter on the agenda to that time place as resolved by the meeting, and is obliged to so adjourn such meeting, discussion or resolutions at the general meeting’s demand. No matter shall be discussed at an adjourned meeting save for a matter that was on the agenda and which were not discussed or which discussion did not end in the meeting so decided to be adjourned.

 

Article 82:

 

Subject to the provisions of any applicable law, any resolution shall be adopted by a vote in which every Share shall entitle its respective holder to one vote. In case of equal votes, the resolution shall be deemed to have been rejected.

 

14

 

 

Article 83:

 

Resolution in the general meeting of the Company’s shareholders shall be adopted by an ordinary majority, unless otherwise required by Law or these Articles herein. Notwithstanding anything in these Articles to the contrary, the provisions of Articles 6, 83, 84, 87, 88, 91, 92, 93 and 159 may only be amended by a resolution at the general meeting of the Company’s shareholders, provided however, that such amendment was also approved by a resolution of at least 75% of the members of the Board then in office, at a session of the Board which has taken place prior to the general meeting.

 

Article 84:

 

In addition to any matters to be resolved by the general meeting of the Company’s shareholders in accordance with the Law and these Articles herein, the following matters shall be resolved by ordinary majority in general meeting of the Company’s shareholders:

 

A) amending these Articles (provided that the provisions of Articles 6, 83, 84, 87, 88, 91, 92, 93 and 159 may only be amended by a resolution at the general meeting of the Company’s shareholders, provided however, that such amendment was also approved by a resolution of at least 75% of the members of the Board then in office, at a session of the Board which has taken place prior to the general meeting);

 

B) exercising the Board’s powers by the general meeting of the Company’s shareholders, if the Board is unable to exercise such powers and the exercise of any of its powers is essential for the Company’s adequate management as stipulated in Section 52(a) of the Companies Law;

 

C) appointment of the Company’s auditor and the termination of his service;

 

D) appointment and dismissal of the Company’s directors;

 

E) appointment of the chairman of the Company’s Board;

 

F) appointment of the Company’s general manager;

 

G) approval of actions and transactions requiring the general meeting of the Company’s shareholders’ approval;

 

H) increase or reduction of the Companies authorized share capital; and

 

I) merger.

 

Article 85:

 

Declaration of the chairman of the general meeting of the Company’s shareholder’s that a resolution by the general meeting has been adopted unanimously or in a certain majority or denied, shall constitute evidence prima facie of the minutes of such meeting.

 

Article 86:

 

The Board may, from time to time, determine which of the resolutions of the general meeting of the Company’s shareholders may be adopted by means of voting paper. Unless otherwise determined by the Board and subject to the provisions of the Companies Law and the regulations thereunder, the general meeting of the Company’s shareholders may vote by means of voting paper on the following matters:

 

A) appointment and removal of Directors;

 

B) approval of transactions requiring the approval of the general meeting of the Company’s shareholders in accordance with the provisions of Sections 255 and 268 through 275 of the Companies Law;

 

C) approval of a merger in accordance with Section 320 of the Companies Law;

 

D) such other matters prescribed by the Minister in accordance with Section 89 of the Companies Law.

 

15

 

 

Article 86A:

 

For as long as the Company is a Private Company, a resolution in writing, signed by all of the Company’s Shareholders, shall be, subject to the provisions of the Law, valid and binding, as any resolution of a duly convened general meeting of the Company’s shareholders in accordance with these Articles herein.

 

Article 86B:

 

For as long as the Company is a Private Company, the Company may hold a general meeting of its shareholders by using any means of communication, provided that all shareholders so participating in the meeting are able hear each other simultaneously.

 

The Board of Directors

 

Article 87:

 

The number of Directors shall be prescribed in accordance with the provisions of these Articles, from time to time, by an ordinary majority resolution of the general meeting of the Company’s shareholders, or by an ordinary majority resolution of the Board, provided such number shall not be less than three (3) nor more than six (6) Directors (not including external Directors appointed as required under applicable law).

 

Article 88:

 

A) The Directors (excluding the External Directors, if any were elected), shall be classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I, Class II and Class III. The Board may assign members of the Board already in office to such classes at the time such classification becomes effective.

 

i. The term of office of the Class I directors shall expire at the first annual general meeting of the Company’s shareholders to be held in 2020 and when their successors are elected and qualified,

 

ii. The term of office of the initial Class II directors shall expire at the first annual general meeting of the Company’s shareholders following the Annual General Meeting referred to in clause (i) above and when their successors are elected and qualified, and

 

iii. The term of office of the initial Class III directors shall expire at the first annual general meeting of the Company’s shareholders following the annual general meeting of the Company’s shareholders referred to in clause (ii) above and when their successors are elected and qualified.

 

B) At each annual general meeting of the Company’s shareholders, commencing with the annual general meeting of the Company’s shareholders to be held in 2020, each of the successors elected to replace the Directors of a class whose term shall have expired at such annual general meeting of the Company’s shareholders shall be elected to hold office until the third annual general meeting of the Company’s shareholders next succeeding his or her election and until his or her respective successor shall have been elected and qualified.  Notwithstanding anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as such Director’s office is vacated.

 

C) If the number of Directors (excluding External Directors, if any were elected) that consists the Board is hereafter changed, any newly created directorships or decrease in directorships shall be so apportioned by the Board among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors constituting the Board shall shorten the term of any incumbent Director.

 

D) Director’s term of service shall commence on the date of appointment, but the general meeting of the Company’s shareholders may determine a different date for such commencement of service.

 

E) Prior to every annual general meeting of the Company’ shareholders, and subject to clause (A) of this Article, the Board (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board (or such Committee), a number of Persons to be proposed to the Shareholders for election as Directors at such annual general meeting of the Company’ shareholders (the “Nominees”).

 

16

 

 

F) Any Proposing Shareholder requesting to include on the agenda of an annual general meeting of the Company’ shareholders a nomination of a Person to be proposed to the Shareholders for election as Director (such person, an “Alternate Nominee”), may so request provided that it complies with this Article 88(F) and Article 62 and applicable law. In addition to any information required to be included in accordance with applicable law, such a proposal request shall include information required pursuant to Article 62 and applicable law, and shall also set forth: (i) the name, address, telephone number, fax number and email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements, relations or understandings between the proposing shareholder(s) or any of its affiliates and each Alternate Nominee; (iii) a declaration signed by the Alternate Nominee that he or she consents to be named in the Company’s notices and proxy materials relating to the general meeting of the Company’s shareholders, if provided or published, and, if elected, to serve on the Board and to be named in the Company’s disclosures and filings, (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure requirements under Form 20-F or any other applicable form prescribed by the U.S. Securities and Exchange Commission); (v) a declaration made by the Alternate Nominee of whether he meets the criteria for an independent director and/or External Director of the Company under the Companies Law and/or under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required at the time of submission of the proposal request by applicable law, regulations or stock exchange rules. In addition, the proposing shareholder shall promptly provide any other information reasonably requested by the Company. The Board may refuse to acknowledge the nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided by a proposing shareholder pursuant to this Article 88(F) and Article 62, and the proposing shareholder shall be responsible for the accuracy and completeness thereof.

 

G) The Nominees or Alternate Nominees shall be elected by a resolution adopted at the general meeting of the Company’s shareholders at which they are subject to election.

 

Article 89:

 

A) Director may, at any time, appoint an alternate director on his behalf (hereinafter: “Alternate Director”). Person who is not qualified to be appointed as a Director or who is serving as a Director or Alternate Director shall not be appointed to serve as an Alternate Director, unless otherwise permitted by any applicable law. An Alternate Director may be appointed to serve on a committee of the Board, provided that such Alternate Director does not serve as a member of another committee of the Board.

 

B) For as long as the appointment of the Alternate Director is in effect, the Alternate Director is entitled to receive notices to all of the Board meetings (without such right derogating from the Director’s right to receive such notices) and to participate and vote in every such Board meeting in which the appointing Director is absent.

 

C) Subject to the provisions of the letter of appointment by which he was appointed, an Alternate Director shall be vested with all of the rights of the appointing Director and shall be deemed a Director for all purposes.

 

D) Appointing Director may terminate his appointment of an Alternate Director at any time thereafter. The appointment of an Alternate Director shall terminate by delivery of notice regarding the termination of such appointment by the appointing Director to the Company, or by the appointing Director’s resignation, or by termination of service of the appointing Director in any other way.

 

E) Notice of the appointment or termination of appointment of an Alternate Director must be submitted in writing to the Company.

 

Article 90:

 

Director whose service was terminated may be reappointed to serve as Director.

 

17

 

 

Article 91:

 

Director’s office shall be vacated on the occurrence of any of the following:

 

A) he resigns or is removed from office, as stipulated in Sections 229 through 231 (inclusive) of the Companies Law, provided that any resolution of the general meeting of the Company’s shareholders in this respect shall be adopted by a majority of at least 50% of the voting power in the Company.

 

B) he is convicted in a felony specified in Section 232 of the Companies Law.

 

C) a competent court orders his termination of service, as stipulated in Section 233 of the Companies Law.

 

D) he is declared bankrupt, and in the case of a corporation – has declared its voluntary dissolution or was given a dissolution order.

 

E) upon death.

 

F) he is declared legally incapacitated.

 

Article 92:

 

If a Director’s office becomes vacant, the remaining serving Directors may continue to act in any manner, provided that their number is of the minimal number specified above. If the number of serving Directors is lower than their minimal one, the Board shall not be permitted to act, other than for the purpose of convening a general meeting of the Company’s shareholders for the purpose of appointing additional Directors.

 

Article 93:

 

The Directors may appoint, immediately or of a future date, additional Director(s), provided that the number of Directors shall not exceed six (6) Directors (not including external Directors). The Directors shall determine at the time of appointment the class pursuant to Article 88 to which the additional Director shall be assigned. Directors may be elected only at annual general meetings.

 

Article 94:

 

Subject to the approvals required by any applicable law, the Directors shall be entitled to remuneration by the Company for their services as Directors. In addition, every Director shall be entitled to reimbursement of his reasonable travel expenses and other expenses related to his participation at the Board’s meetings and the service as a Director.

 

Article 95:

 

If and when so required by any applicable law, not less than 2 external Directors shall serve on the Board, and the provisions stipulated in the Companies Law regarding their qualifications, service and remuneration shall apply.

 

The Board of Directors’ Powers and Duties

 

Article 96:

 

The Board shall set the policy and guidelines for the Company’s operations and shall supervise the performance of the general manager’s position, and shall be vested with residual authority not vested or granted to any other organ.

 

Article 97:

 

Subject to the provisions of the Companies Law, the Board may delegate any of its powers to the general manager or to one of the Board’s committees.

 

18

 

 

Article 98:

 

A) The Board may resolve by an ordinary majority that powers vested with the general manager shall be transferred to it, for a particular matter or for a particular period of time.

 

B) Without derogating from the above, the Board may instruct the general manager how to act in a particular matter. Should the general manager fail to follow such instruction, the Board may exercise the power required to execute such instruction in his stead.

 

C) Should the general manager be unable to exercise his powers, the Board may exercise them in his stead.

 

Board Meetings

 

Article 99:

 

The Board shall convene in accordance with the Company’s needs and not less than once every three (3) months.

 

Article 100:

 

The chairman of the Board may convene a meeting of the Board at any time. In addition, any Director may request the Board to convene for the purpose of any matter to be specified.

 

Article 101:

 

A) Notice of a Board meeting may be delivered  orally, by telephone, in writing (including via e-mail or facsimile) or by telegram, at least twenty four (24) hours prior to the scheduled time of the meeting, or with a shorter prior notice or without notice, if so agreed by all Directors or Alternate Directors (if appointed).

 

B) Director exiting the borders of Israel (hereinafter: “Absent Director”) who wishes to receive notices during the time of his absence, shall provide the Company corporate secretary with sufficient contact details for such purpose (an Absent Director who provided such contact details as well as any Directors who are present in Israel shall be collectively referred to hereinafter as: “Directors Entitled to Receive Notices”).

 

C) An Absent Director who did not provide the above contact details, shall not be entitled to receive notices during his absence, unless he requested to deliver the notices to an Alternate Director representing him, who was duly appointed in accordance with these Articles herein.

 

D) A written memorandum signed by the Company Secretary shall be deemed conclusive evidence of providing notice to the Absent Director which is a Director Entitled to Receive Notices.

 

Article 102:

 

Notice of a Board meeting shall state the time and place of the meeting and reasonable details of the matters to be discussed thereat, pursuant to the agenda.

 

The agenda shall be determined by the chairman of the Board, and shall include such matters so determined by him, as well as any other matter requested from the chairman of the Board to be included, by a Director or the general manager reasonable time prior to the Board meeting.

  

Article 103:

 

The quorum for opening a Board meeting shall be a majority of the Directors Entitled to Receive Notices who are not prohibited from participating and voting in such meeting under any applicable law. The quorum shall be verified at the opening of such meeting.

 

Notwithstanding the above, should the Board convene to resolve termination of the Company’s internal auditor’s service, the quorum shall be the majority of the Board.

 

Article 104:

 

The general meeting of the Company’s Board shall appoint one of the Directors to serve as chairman of the Board. The chairman of the Board shall conduct and administer the Board meetings. Should the chairman of the Board be absent from a Board meeting or should he not wish to conduct and administer such meeting, the Directors present at the meeting shall elect one of them to serve as chairman for such meeting, to conduct and administer it, and to sign the its minutes.

 

19

 

 

Article 105:

 

Board Resolutions shall be adopted by an ordinary majority. Each Director shall have one vote. The chairman of the Board shall not have an additional or casting vote.

 

Article 106:

 

Subject to the presence of a due quorum, the Board may exercise all powers and discretion vested in it at the date of meeting, or usually exercised by it, in accordance with these Articles herein.

 

Article 107:

 

The Board may hold meetings using any means of communication, provided that all the participating Directors are able to hear one another at all times.

 

Article 108:

 

The Board may adopt resolutions without actually convening, provided that all Directors Entitled to Receive Notices and those entitled to participate in the discussion and vote have provided their consent for such non–convening for the matter thereof. Should any such meeting not convene, minutes of the resolutions, including the resolution not to convene, shall be prepared, and signed by the chairman of the Board, or shall be drafted by the chairman of the Board and signed by all of the Directors.

 

For the purpose of this Article 108, a “Director’s signature” may be accompanied by his consent, objection or abstention. Instead of a Director’s signature, the chairman of the Board or the Company’s corporate secretary may attach a transcript signed by either of them, specifying such Director’s vote.

 

Article 108A:

 

A resolution adopted without the Board actually convening and signed by the chairman of the Board, provided that all Directors Entitled to Receive Notices and entitled to participate in the discussion and vote on the matter thereof have provided their consent to the above, or a written resolution signed by all Directors Entitled to Receive Notices and entitled to participate in the discussion and vote on the matter thereof, shall be, subject to the provisions of the Law, valid and legally binding as a resolution of a duly convened meeting of the Board in accordance with these Articles herein.

 

Article 109:

 

Subject to the provisions of any applicable law, all acts performed by the Board or pursuant to a Board resolution or by a Board committee or by any Person serving as Director or as a member of a Board committee, shall be valid even if a later defect in the appointment of the Board, the Board committee, the Director, or the committee member is discovered,  or if any or all of them were disqualified from service in their respective positions, as though they were duly nominated for service and have the required skills to serve as Directors or members of the relevant Board committee.

 

Board Committees

 

Article 110:

 

The Board may establish Board committees. Person who is not a member of the Board shall not serve as member of a Board committee to which the Board has delegated any of its powers. Persons who are not Directors may be appointed to serve on a Board Committee designated solely for the purpose of advising and consulting. Subject to the provision of the Companies Law and these Articles herein, the Board may delegate all or any of its powers to a Board committee. Any Board committee shall consist of not less than two (2) Directors.

 

20

 

 

Article 111:

 

Each Board committee must exercise its powers in compliance with all terms and regulations prescribed by the Board. Board committees’ meetings and actions shall comply with the provisions stipulated in these Articled herein relating Board meeting and actions, to the fullest applicable extent, unless otherwise prescribed by the Board.

 

Article 112:

 

Board committees shall routinely report to the Board regarding their respective resolutions or recommendations, as prescribed by the Board.

 

Article 113:

 

The Board may cancel any resolution adopted by a Board committee appointed by it. Nevertheless, such cancellation shall not invalidate such resolution by which the Company acted in relation to other Person, who was unaware of the cancellation thereof.

 

All acts made in good faith at a Board meeting or by a Board committee or by any Person acting as a Director shall be valid even if a later defect in the appointment of the Director or such Person serving or acting as such, or if any or all of them were disqualified from service in their respective positions, as though they were duly nominated for service and have the required skills to serve as Directors.

 

The General Manager

 

Article 114:

 

The general manager shall be appointed and dismissed by the general meeting of the Company’s shareholders, which may appoint more than one general manager.

 

Article 115:

 

The general manager shall be responsible for the day-to-day management of the Company’s business within the framework of the policy determined by the Board and subject to its guidelines. The general manager shall have all the management and executive powers of not vested in other organ in accordance with the Law or these Articles herein, and shall be subject to the Board’s supervision.

 

Article 116:

 

A) The general manager shall notify the chairman of the Board, without delay, of any extraordinary issues material to the Company, and shall provide the Board with reports on such matters, at such times and of such scope as the Board may determine. Should the Company not have an acting chairman of the Board, or should he be unable to exercise his powers, the general manager shall notify or report the aforesaid matters to all members of the Board.

 

B) The chairman of the Board may, in his own initiative or pursuant to a Board resolution, request the general manager to provide a report on the Company’s businesses.

 

C) Where a notice or report requires an action by the Board, the chairman of the Board shall convene, without delay, a Board meeting to discuss the notice or the resolution to act as required.

 

The Company’s Office Holders

 

Article 117:

 

The general manager may appoint office holders from time to time (except for Directors and a general manager) for either permanent, temporary or special positions, as he  finds appropriate, and he may terminate the appointment of any of the above officer holder from time to time in his sole discretion.

 

21

 

 

Article 118:

 

The general manager may establish the powers and positions of the officer holders so appointed by him, as well as their respective employment terms, all subject to the provisions of the Companies Law.

 

Internal Auditor

 

Article 119:

 

To the extent required by any applicable law, the Board shall appoint an internal auditor in accordance with the recommendation of the audit committee.

 

Article 120:

 

The internal auditor shall examine, among other things, the compliance of the Company’s actions with the provisions of the Law and proper business procedures.

 

Article 121:

 

The internal auditor shall be subject to the chairman of the Board’s supervision.

 

Article 122:

 

The internal auditor shall submit to the Board a proposal for an annual or periodic work program for approval. The Board shall approve such proposal or any modifications it considers necessary.

 

The Accounting Auditor

 

Article 123:

 

One or more accounting auditors shall be appointed by every annual general meeting of the Company’s shareholders, and shall hold office until the end of the following annual general meeting. Notwithstanding the above, accounting auditor may be appointed for a longer period, which shall exceed the end of the third annual general meeting following the annual general meeting in which the auditor was appointed, by an ordinary majority resolution of the general meeting.

 

Article 124:

 

The general meeting of the Company’s shareholders may terminate the accounting auditor’s service, subject to, and in accordance with, the provisions of the Companies Law.

 

Article 125:

 

The accounting auditor’s compensation for performing the audit shall be determined by the Board, which shall report such compensation to the annual general meeting of the Company’s shareholders.

 

Article 126:

 

The accounting auditor’s compensation for additional services which are not related to auditing shall be determined by the Board, which shall report such compensation, including payments and other of the Company’s obligations to the auditor, to every annual general meeting of the Company’s shareholders; the term “auditor” shall include, for the purposes of this Article 126 herein, a partner, an employee related to the accounting auditor and a corporate body under his control.

 

22

 

 

Validity of Acts and Approval of Non-Extraordinary Transactions

 

Article 127:

 

Subject to the provisions of any applicable law, all acts done by the Board or by a Board committee or by any Person acting as a Director or as a member of a Board committee or by the general manager, as the case may be – shall be valid even if later discovered that there was a defect in the appointment of the Board, the Board committee, the Director, the committee member or the general manager, as the case may be, or that any such officer holders does not qualify to serve in his position.

 

Article 128:

 

Should an office holder have a personal interest in any of the Company’s transactions, such office holder shall disclose to the Company, reasonable time prior to the discussion on the approval of such transaction, information regarding the nature of his personal interest, including any relevant fact or document.

 

Article 129:

 

A Company’s transaction with an office holder or a Company’s transaction with another Person in which an office holder has personal interest, which is not an extraordinary transaction, shall be approved by the Board. The Board may approve such transaction either by providing a general approval for a particular type of transactions or by approving a particular transaction.

 

Article 130:

 

The Company’s extraordinary transaction with an office holder, the Company’s engagement with a Director of the Company regarding the terms and conditions of his service and/or employment in other positions, the Company’s extraordinary transaction with one of its controlling shareholders, the Company’s extraordinary transaction with another Person in which one of the Company’s office holders or  controlling shareholders have  personal interest and the Company’s engagement with one of its controlling shareholders or any of his relatives (if he also serves as one of the Company’s office holders  – regarding his terms and conditions of services and if he is an employee of the Company who does not serve as an office holder – regarding his terms and conditions of employment), shall be approved in accordance with any applicable law.

 

Distribution of Dividends

 

Article 131:

 

Subject to the provisions of the Companies Law, the Board may resolve to distribute dividends.

 

Dividends and Bonus Shares

 

Article 132:

 

Subject to any special or limited rights attached to any classes of Shares, dividend or bonus shares shall be distributed relatively to the paid par value of the Shares, without consideration to any premium paid on such Shares.

 

Article 133:

 

The Company may set determining date for determining the right to receive dividends, provided that such date shall be later than the date on which the dividend distribution was approved.

 

Article 134:

 

The Board may delay the distribution of any dividend, bonus, benefit, rights or other amounts to be paid on account of Shares which are subject to the Company’s lien, and to use any such amount or exercise any such bonus, benefit or right and to use the consideration received upon such exercise for payment of any debts owed by the holder of such Shares on which the has lien.

 

Article 135:

 

The transfer of Shares shall not provide the transferee with the right to participate in the distribution of dividends or any other distribution declared after such transfer and prior to the registration of the transfer with the Register. Notwithstanding the above, where the transfer of Shares is subject to the Board’s approval, the date of registration of the transfer with the Register shall be replaced by the date of such approval.

 

23

 

 

Article 136:

 

Dividends unclaimed within seven (7) years from the date of approving their distribution shall be forfeited and shall be reverted to the Company.

 

Article 137:

 

Unless other instructions were provided, any dividend may be paid by check or payment order which shall be sent via mail to the registered address of the Person entitled to receive such dividend, and if there are two or more joint registered owners, to the registered shareholder whose name appears first in the Register. Any such check shall be in favor of the shareholder entitled to receive it, and its payment shall be used as release of any payments paid in connection with such Share.

 

Article 138:

 

The Board may withhold from any dividend or other distribution in connection with a shareholder’s Shares, whether such shareholder is the sole holder of such Shares or holds them jointly with others, any amounts due from the shareholder, on account of payment demand or other similar demands.

 

Article 139:

 

The Board may, in accordance with its discretion, set aside to special funds any amounts from its profits or from the revaluation of its assets, or from the proportional share in the revaluation of its affiliated companies’ assets, and to determine the purpose of such funds.

 

Merger

 

Article 140:

 

A merger shall be approved by an ordinary majority of the general meeting of the Company’s shareholders, unless otherwise stipulated by the Law.

 

Minutes

 

Article 141:

 

The Company shall maintain a register of the minutes of the general meetings of its shareholders, class meetings, Board meetings and Board committees meetings. All minutes shall be archived at the Office or at such other address in Israel, of which the Company has notified the Registrar of Companies, for the period of seven (7) years following the date of any such meetings.

 

Article 142:

 

The abovementioned minutes shall include the following:

 

A) the date and location in which the meeting was held;

 

B) the names of participants, and if they are representatives of an Alternate Directors, the names of their respective appointers, and in meetings of the Company’s shareholders – the number and class of the Shares held by the voters;

 

C) the summary of the discussions held and the resolutions adopted;

 

D) directives and instructions provided by the Board to its committees or general manager; and

 

E) documents, reports, approvals, opinions and other information presented, discussed or attached.

 

24

 

 

Article 143:

 

Minutes of the general meeting of the Company’s shareholders signed by the chairman of the general meeting shall constitute a prima facie evidence of its content. Minutes of the meetings of the Board or Board committees, approved and signed by the Director chairing such meeting shall constitute a prima facie evidence of its content.

 

Register of Shareholders

 

Article 144:

 

The company shall maintain a Register which shall include the following:

 

A) With respect to Shares registered under a Person’s name –

 

1) the name, identity number and address of the each shareholder, as provided to the Company;

 

2) the number of Shares and their respective classes held by each shareholder, their par value and if any consideration was yet to be paid – such unpaid consideration;

 

3) the issuing date of the Shares or the transfer dates to shareholders, as the case may be; and

 

4) where the Shares include serial numbers, the Company shall note next to the name of each shareholder the numbers of such Shares registered under such shareholder’s name.

 

B) With respect to bearer shares –

 

1) note indicating issuance of bearer Shares, their issuance date and the number of bearer Shares issued;

 

2) the numbering of the bearer Share and of the Share certificates;

 

If a share deed was cancelled following the Shareholder’s request, such Shareholder’s name and number of Shares registered under his name shall be registered in the Register.

 

C) With respect to Dormant Shares - also their numbers and the date on which they became dormant, all to the Company’s knowledge.

 

D) With respect to Shares which do not confer any voting rights in accordance with Section 309(b) or 333(b) of the Companies Law - also include their numbers and the date on which they became Shares which do not confer any voting rights, all to the Company’s  knowledge.

 

E) All such other details which required or permitted under the Companies Law or these Articles herein.

 

Article 145:

 

The Company may maintain an additional Register outside of Israel.

 

Article 146:

 

The Register shall be deemed as a prima facie evidence of its contents. In the event of contradiction between the information provided in the Register and the one provided in a Share certificate, the evidentiary weight of the Register shall prevail over that of the Share certificate.

 

Notices

 

Article 147:

 

Notice of a general meeting of the Company’s shareholders shall be provided in accordance with Article 63 above.

 

25

 

 

Article 148:

 

A) Notices which the Company is required to deliver to its registered shareholders in accordance with any applicable law, subject to Article 63 above, shall be delivered to such shareholders by personal delivery shall be delivered to the last addresses they provided the Company. Delivery by mail shall be deemed duly delivered – If delivered to addresses in Israel within seventy two (72) hours from delivery, and to an address outside of Israel, within ten (10) days from delivery.

 

B) The Company may deliver notices to the registered shareholders, whether they hold Shares registered under their names or bearer Shares, by publishing the notice in two Hebrew-language daily newspapers with wide circulation as stipulated in Article 63 above, and the publication date of the 2 newspapers publications shall be deemed as the receipt date of such notice by the shareholders.

 

Sub-section (a) above shall not apply in such cases where the Company shall send notices in accordance with this subsection (b), unless otherwise required by any applicable law.

 

C) Nothing in sub-Sections (a) and (b) above shall impose upon the Company any obligation to provide notices to shareholders who did not provide it with their addresses in Israel.

 

Article 149:

 

The following Shareholders shall be deemed to have not provided the Company with a mail delivery address in Israel:

 

A) Shareholder who failed to confirm the receipt of a registered mail sent to the address he provided the Company with requesting such confirmation or an update of a new address, within thirty (30) days from the date the mail was sent.

 

B) Shareholder whose been sent a registered mail by the Company which was returned to the Company by the postal services or where the postal services sent the Company a notice that such shareholder no longer resides in that address, or any similar notice.

 

Article 150:

 

Where Shares are jointly held, the Company may duly send a notice by sending it to the shareholder whose name is registered first in the Register.

 

Article 151:

 

Any document or notice sent to a shareholder in accordance with the provisions of these Articles herein shall be deemed to have been duly sent despite the departure, bankruptcy or winding up of such shareholder (whether the Company was aware of or not), so long as no other Person was registered as the holder of his Shares, and such delivery shall be deemed for all purposes as adequate with respect to any Person interested in such Shares.

 

Winding Up and Liquidation

 

Article 152:

 

Should the Company be wound up and liquidated, either voluntarily or otherwise, the following shall apply, unless otherwise provided in these Articles herein or in the terms and conditions of any Share issued:

 

A) The liquidator shall first use all of the Company’s assets to discharge its obligations (the Company’s remaining assets following such discharge of all its obligations shall be referred to hereinafter as the “Remaining Assets”).

 

B) Subject to special rights attached to Shares, the liquidator shall distribute all Remaining Assets amongst the shareholders on a pro rata basis to the par value of their respective Shares.

 

C) Pursuant to an ordinary majority resolution of the general meeting of the Company’s shareholders, the liquidator may distribute the Remaining Assets or any part thereof amongst the shareholders in specie or transfer any part of them to a trustee who shall hold them for the benefit of the shareholders, as the liquidator deems appropriate. 

 

26

 

 

Exemption of Liability

 

Article 153:

 

A) The Company may exempt an office holder in advance from all or any of his liabilities for damage resulting from breach of his duty of care to it.

 

B) Notwithstanding the above, the Company may not exempt a Director in advance for his liability for a breach of the duty of care in distribution, as such term is defined in the Companies Law.

 

Insurance

 

Article 154:

 

The Company may enter into an insurance agreement for the insurance of office holders’ liability, in whole or in part, for an obligation imposed upon him in resulting from an act performed in his capacity as an office holder, in any of the following cases:

 

A) a breach of the duty of care to the Company or to another Person;

 

B) a breach of the fiduciary duty to the Company, provided that the office holder acted in good faith and had reasonable basis to believe that the act would benefit the Company;

 

C) a monetary obligation imposed on the office holder in favor of another Person;

 

D) a payment imposed on the office holder in connection with an Administrative Enforcement Procedure, including reasonable litigation expenses and attorney’s fees; or

 

E) any other insurable act in accordance with the provisions of the Companies Law.

 

Indemnity

 

Article 155:

 

Subject to the provisions of the Companies Law, the Company may indemnify an office holder for any of the following liabilities and expenses he incurred resulting from an act performed in his capacity as an office holder:

 

A) a monetary obligation imposed on him in favor of another Person pursuant to a judgment, including a settlement or arbitrator’s award approved by court;

 

B) reasonable litigation expenses, including attorney’s fees, incurred by the office holder pursuant to an investigation or proceeding conducted against him by an competent authority, and which concluded without a criminal indictment being filed against him and without a monetary fine being imposed on him as an alternative to a criminal proceeding, and which does not require proof of criminal thought; in this sub-Article:

 

conclusion of a proceeding without a criminal indictment being filed in a matter in which a criminal investigation has been commenced – shall mean the closing of a file in accordance with Section 62 of the Criminal Procedure Law (Consolidated Version) 5742-1982 (hereinafter in this sub-Article: the “Criminal Procedure Law”), or the stay of proceedings by the Attorney–General in accordance with Section 231 of the Criminal Procedure Law;

 

“Monetary liability as a substitute for legal proceedings” – a monetary liability that has been imposed by any applicable law as a substitute for a legal proceeding, including an administrative fine pursuant to the Administrative Offences Law, 5746-1985, a fine for an offence that has been determined as a finable offence pursuant to the provisions of the Criminal Procedure Law, a financial sanction or penalty;

 

27

 

 

C) reasonable litigation expenses, including attorney’s fees, incurred by the office holder or which he is ordered to pay by a court in proceedings filed against him by the Company or on its behalf or by another Person, or in a criminal indictment of which he is acquitted, or in a criminal indictment in which he is convicted of an offence not requiring proof of criminal thought or in an Administrative Enforcement Procedure conducted against him;

 

D) a payment imposed on the office holder in favor of an injured party in connection with an Administrative Enforcement Procedure;

 

E) any other liability or expense for which it is or shall be permitted to indemnify an office holder in accordance with the Companies Law.

 

Article 156:

 

The Company may indemnify an office holder retroactively, and it may undertake in advance to indemnify an office holder, or to indemnify him retroactively, as stipulated in Article 155(A) above, for a liability or expense imposed on him in resulting from an act performed in his capacity as an office holder, provided that the undertaking shall be limited to events which in the Board’s opinion are to be expected given the Company’s  activities at the time the indemnity undertaking is given, as well as the reasonable amounts or criteria as the Board so determined to be expected given the Company’s activities when the indemnity is given as well as the amount and the criteria that the board of directors determined as reasonable in the circumstances of the case, and it may undertake o indemnify him in advance as stipulated in Article 155 (B)-(E) above.

 

Article 157:

 

In no case shall the total accumulated sum of indemnity to be paid by the Company (in addition to such sums received from the insurance company, if received, for Directors and officer holders’ insurance purchased by the Company) to all office holders, in accordance with all letters of indemnity provided to them by the Company, exceed 25% of the Company’s equity in accordance with the Company’s most recent financial reports as of the indemnity payment date.

 

Signatory Rights

 

Article 158:

 

A) The signature of any Person duly authorized by the Board from time to time, alone or together with others, in general or for a particular matter, accompanied by the Company’s seal or printed name, shall bind the Company.

 

B) The Board may determine separate signatory rights with regards to the Company’s different operations and with regards to sums for which such Persons are authorized to sign.

 

Amendment to these Articles of Association

 

Article 159:

 

The Company may amend these Articles herein by an ordinary majority resolution adopted by the general meeting of the Company’s shareholders (provided that the provisions of Articles 6, 83, 84, 87, 88, 91, 92, 93 and 159 may only be amended by a resolution at the general meeting of the Company’s shareholders, provided however, that such amendment was also approved by a resolution of at least 75% of the members of the Board then in office, at a session of the Board which has taken place prior to the general meeting).

 

 

28

 

Exhibit 10.2

 

COMPENSATION POLICY FOR EXECUTIVES AND DIRECTORS

 

(As amended, July 9, 2020)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Executives and Directors

 

Compensation Policy of Medigus Ltd.

 

(the “Company”)

 

1. Objectives of the Company’s Compensation Policy

 

The purpose of the Company’s compensation policy is to establish sustainable guidelines for the Company’s applicable organs in determining the Company’s compensation to its Office Holders (as such term is defined below) in light of the following objectives of such compensation:

 

A. To establish a correlation between the interests of the Company’s Office Holders and those of the Company and its shareholders.

 

B. To recruit and maintain qualified Office Holders, who may contribute to the Company’s financial and commercial success, given the unique challenges it faces and its business environment.

 

C. To provide incentives for the Company’s Office Holders, in order to ensure high-level operations without encouraging the taking of unreasonable risks.

 

D. To establish an appropriate balance between fixed compensation, compensation which incentivizes short-term results and compensation which reflects the Company’s long-term operation.

 

2. Compensation Policy; Background

 

Objectives

 

Through this document, the Company will determine and publish its policy with regards to the compensation of its Office Holders, including all components of compensation, while establishing principles, considerations, parameters and rules for the determination of Office Holders’ terms of tenure by the Company’s organs during the application period of this compensation policy. The policy is presented to the Company’s general meeting of the shareholders (the “General Meeting”) and subject to their approval, thereby providing an opportunity for shareholders to influence the method used to determine the compensation of Office Holders, and to express their opinion on the matter. The publication of the compensation policy increases and improves the effectiveness of the Company’s disclosure to its investors and to the capital market. In addition to the foregoing, the compensation policy is intended to comply with the obligation set forth in the Israeli Companies Law, 5759-1999 (hereinafter: the “Companies Law”).

 

Application of the Compensation Policy

 

In accordance with the provisions of the Companies Law, the compensation policy will apply with respect to the terms and conditions of the tenure and employment of the Office Holders in the Company. The definition of Office Holders in the Companies Law includes “a general manager, chief business manager, deputy general manager, vice general manager, any person filling any of these positions in a company even if he holds a different title, as well as a director, or a manager directly subordinate to the general manager.” For the purpose of this policy, each Office Holder other than a director shall be referred to as an “Executive”.

 

The compensation policy is not intended to establish personal terms and conditions for specific Office Holders, but rather to set forth objective principles and parameters which will apply to all Company’s Office Holders. This policy sets forth maximum amounts only, and nothing in this policy shall obligate the Company to grant any particular type or amount of compensation to any Office Holder, unless expressly stated otherwise, nor shall it derogate from approval procedures mandated by law.

 

- 2 -

 

 

In accordance with the provisions of the Companies Law, the compensation policy is subject to approval every three years. Therefore, the current compensation policy shall be valid for a period of three years from the date of its approval by the General Meeting or as otherwise required by the Companies Law. The Company may, pursuant to the Companies Law, amend or renew the compensation policy within that period of implementation, subject to an approval at the General Meeting or as otherwise required by the Companies Law.

 

It should be noted that, by law, contractual agreements with Office Holders regarding the terms and conditions of their tenure and employment which were approved prior to the approval of this compensation policy shall continue to apply, and do not require additional approval in accordance with the provisions of this policy.

 

Establishment and Approval of the Compensation Policy

 

In accordance with the Companies Law, the responsibility for approving the compensation policy applies with the board of directors, after the foregoing has considered the recommendation issued by the Company’s compensation committee. The compensation policy is subject to the approval of the General Meeting (including by a majority of those participants who are not controlling shareholders or interested parties, as provided in the Companies Law). In accordance with the provisions of the Companies Law, in the event that the General Meeting does not approve the policy, the board of directors will be entitled to approve the policy based on grounds provided by the board of directors and the compensation committee, according to which the foregoing action is taken in the Company’s best interest.

 

Maintenance of the Compensation Policy

 

The holder of the most senior position in the Company in the field of human resources (as of the adoption of this policy - the Chief Financial Officer) under the supervision of the Company’s compensation committee, is responsible for monitoring any changes in the Company, in its business environment, in the capital market, in the labor markets, and in other relevant factors, which may impact the Company’s considerations regarding the determination of compensation for Office Holders. When applicable, the compensation committee shall convene to discuss the foregoing, and where necessary, present its recommendations for necessary updates to the policy to the Company’s board of directors.

 

3. Characteristics of the Company and of Its Office Holders

 

Business Environment and Its Effect on Office Holders’ Compensation

 

As a public company engaged in the research, development and marketing of medical devices, the Company has two objectives: providing its clients efficient and safe systems, and maximizing its revenues for the benefit of its shareholders. Further information regarding the Company’s business activity may be found in the Company’s filings with the Securities and Exchange Commission (“SEC”).

 

For fulfilling the Company’s objectives, the Company has established, and may be required to establish further operation centers outside of Israel and has appointed, and may be required to appoint Office Holders to serve in such centers. In light of the disparities between acceptable compensation levels and competitive market in Israel and other countries, the quantitative parameters for the determination of executive compensation are separately addressed regarding Israel and other countries.

 

In light of this, the Company’s commercial success depends, to a large extent, both on its ability to recruit skilled Office Holders and employees with unique background and experience in the field of medical devices, and on its ability to provide its Office Holders and employees with incentives designated for the investment of outstanding personal efforts on their behalf and for achievement of goals established by the Company’s board of directors. The need to achieve defined regulation and commercialization milestones emphasizes the necessity in conditioning parts of certain Office Holders’ compensation upon personal achievements.

 

Description of Office Holders’ Positions

 

A description of the positions and responsibilities of the Company’s Office Holders to whom this policy may apply may be found in the Company’s annual reports filed with the SEC.

 

- 3 -

 

 

4. Compensation Components and the Balance between them

 

General

 

An adequate balance between the components of compensation exists when a linkage is maintained between compensation and the creation of value for the Company’s shareholders, while maintaining the Company’s ability to recruit and maintain talented Office Holders and incentivizing them to pursue the Company’s objectives. In particular, an appropriate balance between the fixed component and the variable components avoids excessively emphasizing one component, since excessively emphasizing the fixed component may result lack of initiative, whereas excessively emphasizing the variable component may encourage the taking of uncontrolled, unreasonable risks by Office Holders in a manner which is not for the Company’s benefit or which does not conform with the Company’s objectives.

 

Compensation Components

 

Fixed Compensation

 

Fix compensation is based on a base salary and benefits. The base salary is a fixed amount paid to an Executive on a monthly basis, regardless of the Executive’s performance. This component constitutes the basis for payment of the additional benefits (as further elaborated below). Payment of the base salary enables the implementation of flexible and effective incentive plans, while minimizing risk-taking caused by over-compensation on variable components’ basis. Both the base salary and the additional benefits must also take into account the prevailing conditions in the Company’s market (“benchmarking”); however, the Company does not believe this consideration to be dominant, inter alia in the interest of avoiding a “salary race” between companies in its market. It should be noted that additional benefits are unique and depend upon the prevailing customs in different countries, and that when the Company engages employment agreements with Executives for positions outside of Israel, such Executives may be entitled to receive additional benefits according to the prevailing customs in the countries in which they serve, in order to ensure the competitiveness of the employment terms and conditions offered by the Company relative to its competitors in the relevant country.

Variable Compensation

 

Cash variable compensation is one of the components used for achieving the objectives of this compensation policy herein, and particularly for creating a correlation between the interests of the Company’s Executives and those of the Company and its shareholders. In order to promote the objectives of this policy herein, the conditions for the payment of bonuses shall reflect the Company’s short-term and long-term objectives, insofar as possible, and shall constitute a proportionate part of the total compensation in a manner that constitutes a dominant component in the entire compensation package, and primarily with respect to the fixed salary component, while not constitute an excessively large portion of such compensation package, in order not to create incentives for taking uncontrolled or unreasonable personal and organizational risks. In order to create incentives for Executives to achieve their goals, the variable compensation shall be determined in a manner that links the payment of compensation to short-term and long-term performance objectives. Although it is common practice to pay bonuses upon achievement of financial goals, the Company’s objectives for the payment of bonuses may be dependent upon other measurable achievements, such as achieving regulatory milestones, receiving various authorizations, executing agreements, etc. as well as non-measurable “qualitative” achievements. Dependency of bonuses upon achievement of non-financial achievement is relevant to a large extent given the Company’s transitional stage between being a research and development company and a commercial one.

 

Equity-Based Compensation

 

Equity-based compensation is used to link between the Company’s value for its shareholders (which is reflected by the increase of the Company’s price per share) and the compensation of its Office Holders. This component is implemented by one of, or a mix of, equity compensation such as options, restricted stock units (RSUs), restricted shares and other equity-based compensation. Equity-based compensation constitutes an incentive over time, as well as an incentive to be employed by the Company over long periods of time, by setting vesting dates for the granted equity awards, by their expiration pursuant to the termination of the relevant office holder’s tenure, or by conditioning the grant or vesting of equity awards (or portions thereof) on the achievement of objectives. Furthermore, accelerated vesting mechanisms may create incentives for Office Holders to remain employed by the Company and to achieve its objectives even if an extraordinary event, such as the merger or sale of the Company, change of control, or termination of employment in certain circumstances, is expected. Equity-based compensation is an important component in this compensation policy herein, since it is common practice in comparative companies and is important to the Company’s ability to recruit and retain Office Holders, it is an efficient substitute for cash compensation, and is especially appropriate since some of the operations which are crucial for the Company’s success are long-term ones, and some of the Company’s Office Holders’ efforts may only bear fruit over long periods of time.

 

- 4 -

 

 

Termination-Based Compensation

 

Compensation paid upon the termination of tenure is used both as an incentive to recruit talented Executives by reducing their exposure upon terminations of their service due to various circumstances, as well as an incentive for Executives to serve in the Company for long periods of time, should the compensation be dependent upon seniority.

 

5. Considerations and Parameters for the Determination of Compensation

 

General Considerations for the Determination of Executive’s Compensation

 

When determining the compensation of an Executive, the Company’s board of directors, compensation committee and management shall comply with the guidelines stipulated by this policy herein, including regarding the cap on the compensation components and the quantitative parameters which have been determined in this section below, and will also consider the following factors (in addition to any other relevant factor):

 

(i) The Executive’s personal data, including his education, skills, expertise, and professional experience and achievements, whether in the Company or in other companies, as well as his uniqueness in the market; for this purpose, it should be noted that the medical devices market requires employment of Executives who hold unique experience and expertise, including experience working with regulatory entities such as the FDA, experience in conducting clinical experiments, experience in marketing medical devices to customers such as hospitals, and managing engagements for the purpose of medical reimbursement outside of Israel;

 

(ii) The Executive’s position, characteristics, responsibilities, efforts required for success in the position, the extent to which such Executive is essential for the Company’s success, the possibility to recruit a replacer for his position, the potential damage to the Company in the event the Executive is dismissed or resigns, his seniority and previous compensation arrangements with the Company;

 

(iii) The Executive’s residential address and address of service – if the Executive resides in a country in which the prevailing compensation in the relevant market for his position is higher than its equivalent in Israel or in which the living conditions are more difficult or easy than the ones in Israel, the compensation, including any benefits, shall be adjusted to take into account all such differences;

 

(iv) Prevailing salary levels for similar positions in the market – in order to ensure the Company is competitive and recruits appropriate and high-quality personnel, it must offer a salary at a level which corresponds with the prevailing salary in its market. The foregoing is particularly relevant to the medical devices market, which requires unique experience and skills, available by a limited number of office holders. The Company’s market includes medical device companies, and particularly such companies which received material regulatory approvals and are focusing their efforts in commercializing their respective products worldwide; public companies whose market value, the nature of their operations or their revenue, is similar to those of the Company; and companies which primarily operate in the United States and in Europe, and which employ Executives serving and operating in these areas; and

 

(v) The ratio between Executive’s compensation cost and the Salary Cost of other Company’s employees (including the Company’s Contract Employees1), and particularly the ratio between the compensation cost of the foregoing Executives and the average and the median Salary Costs of employees and the effect such ratios have on the working relations in the Company; the Company acknowledges it has to pay different levels of compensation to its various employees and Executives, inter alia for the purpose of recruiting talented and experienced Executives and employees who constitute key personnel for the achievement of the Company’s objectives. It should be noted that where Executives reside and serve in such countries in which higher compensation than the one available in Israel is paid in accordance with customary market terms, the Company shall consider such higher compensation levels in its evaluation of the above ratios.

 

- 5 -

 

 

Establishment of Fix Compensation

 

The base salary shall be negotiated by the Company and the relevant Executive prior to his or her appointment for office, and upon the Company’s periodic evaluation of his or her base salary during his or her tenure. The base salary shall be based upon the parameters specified above, provided that the base salary shall not deviate from the pre-determined cap for such Executive, as further elaborated below.

 

In addition to the base salary, the Company may include the following benefits, provided that such benefits, including the following will be in accordance with applicable law and common practice in the market from time to time: (i) vacations days (or redemptions thereof); (ii) allocations to pension and/or insurance funds, including loss of working capacity insurance; (iii) education funds (Keren Hishtalmut); (iv) directors’ and officers’ insurance; (v) reimbursement for employment of service related expenses; (vi) company vehicle (type of vehicle will be determined according to the Executive’s position), including reimbursement of all related expenses, and tax payments incurred in connection with the vehicle as shall be in effect from time to time (or, alternatively, reimbursement of expenses in private vehicle, which shall not exceed the cost of company vehicle and all related costs; (vii) internet, laptop computer, cellular telephone for personal use, home phone expenses and daily newspaper; (viii) accommodation during employment or service related travels; (ix) mandatory allocations such as recuperation pay (Dmei Havra’a); and (x) office holders’ indemnification and exemption of liability in accordance with the Companies Law, the Company’s Articles of Association and the Company’s policy from time to time.

 

Executives who serve outside of Israel (including such Executives who serve in the Company’s U.S. subsidiary or in such other subsidiaries which may exist from time to time) may be entitled to benefits in accordance with applicable custom and practice in their country of service and for Executives of similar rank; Accordingly, Executives serving in the United States will be entitled to medical and dental insurance coverage for the Executive and his immediate family, which shall be paid by the Company, as well as employer’s allocations for 401(k) funds, as well as similar or parallel benefits as customary in other global locations.

 

Establishment of Performance-Related Cash Variable Compensation

 

The Company shall establish parameters and conditions for the payment of an annual cash bonus, including maximum bonus amounts and the maximum percentage of the annual fixed compensation such bonuses may include, on an annual, or multi annual, basis and threshold conditions for payment.

 

Eligibility for the annual cash bonus shall be based upon measurable criteria, which may include financial results (such as revenue, profit or fund raising targets) and milestones such as regulatory approvals, agreement executions (such as licenses or distribution or collaboration agreements), performance of medical procedures and other business millstones (such as number of procedures or MD training). Additionally, the Company may determine that, with respect to the chief executive officer (the “CEO”) or an officer who is a director, that a non-material portion of his or her annual cash bonus will be based on the evaluation of the board of directors in an amount that will not exceed, with respect to any calendar year, 25% of the annual fixed compensation, and, with respect to any officer subordinated to the CEO, which does not serve as a director, a portion or all of his or her annual cash bonus will be based on the evaluation of the CEO.

 

1 Contract Employees” shall mean employees of a Manpower Contractor of whom the Company is, in practice, the employer, and employees of a Service Contractor who are hired by the Company for the provision of services; for this purpose, the meaning of “Manpower Contractor” and “Service Contractor” are as defined in the Engagement of Employees by Manpower Contractors Law, 5756-1996. For the purposes of this Section herein, “Salary Cost” shall mean any payment paid for employment including employer contributions, retirement payments, vehicle and related expenses, and any other benefit or payment.

 

- 6 -

 

 

In the event of a new hired Executive or of an Executive who’s engagement ends during the year, his entitlement to an annual cash bonus may be determined on a pro rata basis. The Company may also determine threshold conditions which, unless met, will not result in payment of any bonuses.

 

At the time of approval of the financial statements of each year, the Company shall evaluate the rate of objectives met during the preceding year and during the period until the approval date of the annual financial statements. In the event that an Executive met all of his pre-determined objectives, such Executive shall be entitled to receive 100% of his performance-related compensation component, and in the case of a partial achievement of such objectives, or of some of the objectives, the Company shall pay a proportional part of such maximum component, provided that the applicable threshold conditions for payment were also met.

 

In addition to the annual cash bonus specified above, the compensation committee and the board of directors may, from time to time and to the extent they deem it is required, approve payment of a signing bonus or a special bonus for an office holder either under special circumstances, for special contributions, achievements or assignments or in the event of a change in control of the Company. The Company considers payment of such signing and special bonuses as an important tool for providing incentives for its Executives, especially in light of the inability to foresee all the specific grounds for payment of bonuses pursuant to the principles set forth in this compensation policy herein.

 

The payment of variable compensation shall be subject to the provision of a written undertaking by the Executive receiving such variable compensation to repay any amount of such variable compensation paid to him based on data which has later been found to be incorrect, and which has been restated in the Company’s financial statements within a period of three years following the grant of such performance related compensation. The compensation committee and the board of directors shall be authorized not seek recovery to the extent that (i) to do so would be unreasonable or impracticable or (ii) there is low likelihood of success under governing law versus the cost and effort involved; the aforementioned undertaking shall be in accordance with any general claw-back policy as may be adopted by the Company.

 

Establishment of Equity-Based Compensation

 

Equity-based compensation is an effective tool, designated for the creation of incentives for Office Holders, which correspond with the long-term objectives of the Company and its shareholders. Stock options are currently appropriate key equity based compensation vehicle. In the future, the Company may offer various types of equity based compensation vehicles (e.g. restricted shares, restricted share units, phantom shares, performance shares, performance share units, etc.) as well as a mix between such vehicles. When determining the types of equity- based vehicles and the mix between them, if any, the Company will consider among other things, the types of equity awards then available to the Company and the balance between aligning officer’s and shareholder’s interests and the Company’s risk management policy at the time.

 

To the extent legally available and applicable, the Company will grant options to its Israeli residents Officer Holders in accordance with Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961 and/or means of other equity-based compensation, which may promote the Company’s objectives, as determined by the board of directors. Office holder receiving such equity-based compensation shall bear any applicable tax. Reference to “options” in this compensation policy shall also include other means of equity-based compensation which may be provided in the future.

 

Grant of options shall be in accordance with and subject to the terms of the Company’s current or future applicable equity-based compensation plans, and when granting options to office holders, the Company shall set the following conditions:

 

(i) Maximum Grant Date Value of Options Granted to Each Office Holder – such value will be subject to the cap on equity grants, as further elaborated below.

 

(ii) Maximum Dilution Rate of the Company’s Share Capital – the maximum dilution rate may not exceed 10% of the Company’s share capital on a fully diluted basis.

 

(iii) Vesting / Minimum Holding Period – options granted will vest over periods ranging from once a month to once a year, and will become fully vested over several years (e.g., two (2) to four (4) years) but no less than two (2) years from the date of grant. The company may set accelerated vesting terms and conditional vesting terms for the options granted.

 

(iv) Conditional Vesting / Objective Dependent Exercise – the Company will consider adoption of conditional vesting and/or objective dependent exercise of options, in consideration of the Office Holder’s position. Notwithstanding the aforementioned, the Company is not obligated under this compensation policy to condition the grant or exercise of options granted upon the achievement of personal or Company objectives. Such objectives may be identical to, or different from, the objectives set by the Company for the payment of annual or special cash bonuses and may be adjusted, when applicable, following major acquisitions, divesture, organizational changes or material changes in the Company’s business environment. To the extent that options’ vesting is conditioned upon the achievement of objectives, the Company may determine that such options will become fully vested upon the achievement of the relevant objective, rather than by the lapse of vesting periods.

 

- 7 -

 

 

(v) Exercise Price for stock options – will be set as an incentive to maximize the Company’s value, and will be equal to, or higher than, the price per share in the stock exchange determined by the board of directors on the date of grant, or will be equal to the average price per share during a pre-determined period prior to the grant approval date as determined by the board of directors.

 

The board of directors shall have the discretion to reduce, cancel or suspend payment of any variable compensation components, in cases where such reduction, cancellation or suspension of payment is deemed necessary. In addition, the board of directors may set a maximal exercise value of variable components which are not exercised in cash.

 

Establishment of Relocation Compensation

 

Relocation compensation may be granted to an Executive under relocation circumstances. Such compensation may include reimbursement for out of pocket one time payments and other ongoing expenses, such as travel, housing allowance, car or transportation allowance, home leave visit, healthcare, participation in children tuition fees etc., all as reasonable and customary for the relocated country.

 

6. Compensation Components Caps

 

General

 

The fixed and variable compensation components will be subject to the following:

 

(i) The fixed compensation maximum rates stated in this policy refer to provision of services on a 100% basis and consist of base salary and any benefits available under this compensation policy.

 

(ii) The annual bonus cap stated in this policy refers to the target annual bonus to be granted upon achievement of 100% of the objectives for payment of such annual bonus.

 

(iii) In the case of equity-based compensation, the cap stated in this policy refers to the value of the options granted (or of other means of such compensation) as of the date of grant based on acceptable valuation practices at the time of grant utilizing the straight line approach per year of vesting (taking into account the cost of previous vesting grant for that year).

 

Non-Executive Directors

 

The Company’s non-executive directors may be compensated by means of (i) an annual payment of up to NIS 111,345, and by means of payment for participation in board of directors (or committees) meetings up to an amount of NIS 4,285 per meeting, or (ii) an annual payment of up to NIS 175,620 (or an annual payment of up to NIS 300,000 in the case of the chairman of the board of directors), which will include payment for participation in board of directors (or committees) meetings. Such directors may also be entitled to receive equity-based compensation in accordance with any applicable law, but will not be entitled to receive performance-based compensation, such as bonuses. The Company may repay director’s expenses in accordance with any applicable law. The chairman of the board of directors may also be granted an annual bonus of up to NIS 200,000.

 

The caps on each of the non-executive directors’ compensation components per year are as follows:

 

Variable Equity-based Compensation   Annual Bonus   Signing and Special Bonus
up to 100% of the annual payment described in clause (ii) above   Not Applicable (other than in the case of the chairman of the board of directors as provided above)   Not Applicable

 

- 8 -

 

 

Chief Executive Officer

 

The CEO’s fixed compensation shall range between the following amounts: (i) a CEO whose position is primarily in Israel: up to NIS 170,000, per month, and (ii) a CEO whose position is primarily in the United States or Europe2: up to NIS 250,000, per month.

 

The caps on the CEO’s variable compensation components per year are as follows:

 

Variable Equity-based Compensation   Annual Bonus   Signing and Special Bonus
Up to 100% of the annual fixed compensation   Up to 50% of the annual fixed compensation   Up to 50% of the annual fixed compensation

 

Special and signing bonuses will not be included in the calculation of the maximum annual bonus.

 

2 For the purposes of this compensation policy herein, the NIS-USD and NIS-EUR exchange rates shall be as follows: USD 1 = NIS 3.7; EUR 1= NIS 4.2.

 

Other Executives

 

Other Executive’s fixed compensation shall range between the following amounts: (i) an Executive whose position is primarily in Israel: up to NIS 120,000, per month, and (ii) an Executive whose position is primarily in the United States or Europe: up to NIS 170,000, per month.

 

The caps on other Executive’s variable compensation components per year are as follows:

 

Variable Equity-based Compensation   Annual Bonus   Signing and Special Bonus
Up to 100% of the annual fixed compensation   Up to 50% of the annual fixed compensation   Up to 50% of the annual fixed compensation

 

Special and signing bonuses will not be included in the calculation of the maximum annual bonus.

 

Termination of Services

 

Executives shall be entitled to an advance notice period in accordance with existing agreements, and, in the absence of provisions in the agreements, as determined by the law. In any event, the advance notice period shall not exceed six (6) months. During said notice period, Executives will be required to continue to fulfill their duties, unless the Company decides to release them from this obligation.

 

In addition to any payments required under any applicable law upon termination of service, vesting of outstanding options and payment of an additional severance bonus may be included in office holder’s employment agreement, or may be paid upon Executive’s severance, subject to receipt of all required approvals. The Company will consider payment of a severance bonus in consideration of the objectives of this compensation policy herein, as well as: (i) the service period of the Executive in question; (ii) the Executive’s terms and conditions of service; (iii) the Company’s operations during Executive’s service; (iv) the Executive’s contribution to the achievement of the Company’s objectives and to its profitability; and (v) the circumstances of the severance.

 

The maximum severance bonus that may be paid by the Company is as follows: (i) non-executive directors will not be eligible for severance bonus, (ii) the CEO may be entitled to a severance bonus of up to 50% of the annual fixed compensation, and (iii) other Executives may be entitled to a severance bonus of up to 25% of the annual fixed compensation. An Executive’s severance bonus will be based on his last monthly salary as of the termination date of his service and his or her termination of service must not be in circumstances which, in the Company’s opinion, justify severance pay to be revoked.

 

- 9 -

 

 

7. Directors’ and Officers’ Liability Insurance, Indemnification and Exemption

 

The Company may provide its directors and officers, including those serving in any of its subsidiaries from time or time, with a liability insurance policy (the “Insurance Policy”) provided that the engagement is in the ordinary course of business, in market terms and is not expected to materially influence the Company’s profits, properties and undertakings. The coverage limit of the Insurance Policy shall be of up to US$30 million per occurrence and for the insurance period (additional coverage for legal expenses not included), provided that the annual premium shall not exceed US$500,000 and that the deductible (except for extraordinary matters as prescribed in the Insurance Policy, such as lawsuits against the Company pursuant to securities laws and/or lawsuits to be filed in the US/Canada) shall not exceed US$1,000,000 per occurrence.

 

The Company may extend the Insurance Policy in place to include cover for liability pursuant to a future public offering of securities. The additional premium for such extension of liability coverage shall not exceed 400% of the last paid annual premium. The Insurance Policy, as well as the additional premium shall be approved by the compensation committee (and if required by law, by the board of directors) which shall determine that the sums are reasonable considering the exposures pursuant to such public offering of securities, the scope of cover and the market conditions and that the Insurance Policy reflects the current market conditions, and it does not materially affect the Company’s profitability, assets or liabilities.

 

Upon circumstances to be approved by the compensation committee (and, if required by law, by the board of directors), the Company shall be entitled to enter into a “run off” Insurance Policy of up to seven (7) years, with the same insurer or any other insurance (the “Run Off Coverage”). The limit of liability of the insurer shall not exceed US$30 million per claim and in the aggregate for the term of the policy, the premium for the insurance period shall not exceed 400% of the last paid annual premium and the deductible (except for extraordinary matters as prescribed in the Insurance Policy, such as lawsuits against the Company pursuant to securities laws and/or lawsuits to be filed in the US/Canada) shall not exceed US$1,000,000 per claim. The Run Off Coverage, as well as the limit of liability and the premium for each extension or renewal, shall be approved by the compensation committee which shall determine whether the sums are reasonable considering the Company’s exposures, the scope of coverage and market conditions and if the Run Off Coverage reflects then prevailing market conditions, and, provided, further, that the Run Off Coverage shall not materially affect the Company’s profitability, assets or liabilities. 

 

In addition, the Company may exempt all directors and officers, as may be appointed from time to time in the future, from liability for a breach of their duty of care to the Company and provide them with indemnification to the fullest extent permitted by law and the Company’s articles of association.

 

8. Miscellaneous

 

The Company’s compensation committee and board of directors shall be authorized to approve a deviation of up to 10% from any limits, caps or standards detailed in this policy, and such deviation shall be deemed to be in alignment with this policy.

 

An Immaterial Change in the Terms of Employment of an Executive, which is not a director or the CEO may be approved by the CEO, provided that the amended terms of employment are in accordance with this policy. An “Immaterial Change in the Terms of Employment” means a change in the terms of employment of an officer with an annual total cost to the Company not exceeding an amount equal to 20% of the annual fixed compensation of such Executive.

  

 

- 10 -

 

 

Exhibit 10.4

 

COMMON STOCK PURCHASE AGREEMENT

 

THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of October 8, 2020, by and between Smart Repair Pro, Inc., a private corporation incorporated under the laws of the State of California (“Pro”), Purex Inc., a corporation incorporated under the laws the State of California (“Purex”)(Pro together with Purex, the “Companies”), the stockholders of the Companies detailed in Schedule 1 attached hereto (the “Pro Stockholder”, the “Purex Stockholders” respectively, and together the “Stockholders”) and Vicky Hacmon, ID 033847799 of 112 Rokach Street, Ramat Gan, Israel (the “Manager”) on the one hand, and Medigus Ltd., a public company incorporated under the laws of the State of Israel of 7A Industrial Park, P.O. Box 3030, Omer, 8496500 Israel (the “Purchaser”) on the other hand.

 

The parties hereby agree as follows:

 

1. Purchase and Sale of Common Stock.

 

1.1 Purchase and Issuance of Common Stock.

 

(a) Companies Valuation. The valuation used for the purpose of determining the purchase price for the Pro Common Stock and the Purex Common Stock (as each are defined herein), shall be calculated on a joint basis, and shall be equal to; (A) the Companies consolidated seller discretionary earnings, calculated as the Companies EBITDA (as reflected in the Companies consolidated income statement for the period ended December 31, 2020 or the “Determination Period”), plus general and administrative expenses (including Manager’s compensation expenses) and research and development expenses relating to the development of new products incurred during the Determination Period (the “SDE”); multiplied by (B) 3.5; minus (C) the outstanding Stockholders Loan (as defined herein)(the “Companies Valuation”). The Companies Valuation shall be allocated among the Companies such that Pro’s valuation shall equal 88% of the Companies Valuation (the “Pro Portion” and the “Pro Valuation” respectively) and Purex’s valuation shall be equal to 12% of the Companies Valuation (the “Purex Portion” and the “Purex Valuation” respectively). The Companies target SDE for the annual period ended December 31, 2020 shall be $1,000,000 (the “SDE Target”).

 

(b) Subject to the terms and conditions of this Agreement, the Purchaser agrees to invest $1,100,000 in Pro (the “Pro Investment Amount”) in consideration for the issuance by Pro at the Closing (as defined below) of 5,572 shares of Pro common stock (the “Pro Primary Shares” and “Pro Common Stock” respectively) at a price per share for each Pro Primary Share of $197.4107, reflecting a pre-money valuation on a fully diluted basis equal to the Pro Valuation, calculated based on the SDE Target (the “Pro PPS”).

 

(c) Subject to the terms and conditions of this Agreement, the Purchaser agrees to invest $150,00 in Purex (the “Purex Investment Amount”) in consideration for the issuance by Purex at the Closing (as defined below) of 557 Purex common stock (the “Purex Primary Shares” and the “Purex Common Stock” respectively) at a price per share of Purex Common Stock of $269.1964, reflecting a pre-money valuation on a fully diluted basis equal to the Purex Valuation, calculated based on the SDE Target (the “Purex PPS”). The shares of Pro Primary Shares together with the Purex Primary Shares issued to the Purchaser pursuant to this Agreement shall be referred to in this Agreement as the “Primary Shares.” The Pro Investment Amount together with the Purex Investment Amount shall be referred to in this Agreement as the “Investment Amount”).

 

 

 

 

1.2 Post-Closing Adjustment.

 

(a) Within three days of their approval and in any event as soon as practicable following the end of the Determination Period, the Companies shall provide Purchaser with each of the Companies’s respective financial statements (including statement of income, balance sheet and statement of cash flows) relating to the Determination Period, signed and certified by the Companies’ officers (the “Determination Period Financials”). The Determination Period Financials shall be prepared in accordance with generally accepted accounting principles.

 

(b) In the event that the Companies actual SDE, as reflected in the Determination Period Financials (the “Actual SDE”) is lower than the SDE Target, then the Companies Valuation shall be recalculated based on the formula included in Section ‎1.1(a) (the “Adjusted Companies Valuation”) and the Pro Valuation, Pro PPS, Purex Valuation and Purex PPS shall be adjusted accordingly (the “Adjustment”, the “Adjusted Pro Valuation”, the “Adjusted Pro PPS” the “Adjusted Purex Valuation” and the “Adjusted Purex PPS” respectively). For the avoidance of doubt, the Closing Inventory shall remain unchanged in the event of an Adjustment.

 

(c) Following the Adjustment, each of the Companies shall issue to the Purchaser additional shares of Purex and Pro as follows:

 

(i) Pro shall issue to the Purchaser such number of additional Pro Common Stock equal to (x) the number of Pro Primary Shares that would have been issued to the Purchaser based on Adjusted Pro PPS; less (y) the number of Pro Primary Shares actually issued to Purchaser upon the Closing (the “Pro Adjustment Shares”). The percentage received by dividing the Pro Adjustment Shares by Pro’s issued outstanding share capital on a fully diluted basis shall be referred to herein as the “Pro Adjustment Percentage”.

 

(ii) Purex shall issue to the Purchaser such number of additional Purex Common Stock equal to (x) the number of Purex Primary Shares that would have been issued to the Purchaser based on the Adjusted Purex PPS; less (y) the number of Purex Primary Shares issued to Purchaser upon the Closing (the “Purex Adjustment Shares”). The percentage received by dividing the Purex Adjustment Shares by Purex’s issued outstanding share capital on a fully diluted basis shall be referred to herein as the “Purex Adjustment Percentage”;

 

(d) For the avoidance of doubt, in the event that the Actual SDE is equal to or exceeds the SDE Target, no adjustment shall be affected pursuant to this Section ‎1.2

 

1.3 Secondary Sale of Common Stock.

 

(a) Simultaneously with the Closing, Purchaser or its Affiliate shall purchase from the Pro Stockholder additional Pro Common Stock (the “Pro Secondary Shares”), such that the Pro Secondary Shares and the Pro Primary Shares combined shall constitute 50.01% of Pro’s issued and outstanding share capital on a fully diluted basis immediately after the Closing (the “Pro Post-Closing Holdings”) or such closest attainable percentage. In the event that an Adjustment is affected following receipt by Purchaser of the Determination Period Financials, Pro Stockholder shall have the right to repurchase from Purchaser, for no consideration, such number of Pro Secondary Shares constituting the Pro Adjustment Percentage (the “Pro Repurchase Right” and the “Pro Repurchase Shares” respectively).

 

2

 

 

(b) Simultaneously with the Closing, Purchaser or its Affiliate shall purchase from the Purex Stockholders additional Purex Common Stock (the “Purex Secondary Shares”), such that the Purex Secondary Shares and the Purex Primary Shares combined shall constitute 50.01% of Purex’s issue and outstanding share capital on a fully diluted basis immediately after the closing (the “Purex Post-Closing Holdings”) or such closest attainable percentage. The Purex Secondary Shares shall be purchased in equal amounts from each of the Purex Stockholders. In the event that an Adjustment is affected following receipt by Purchaser of the Determination Period Financials, Purex Stockholders shall have the right to repurchase from Purchaser, for no consideration, such number of Purex Secondary Shares constituting the Purex Adjustment Percentage (the “Purex Repurchase Right” and the “Purex Repurchase Shares” respectively). Each Purex Stockholder shall have an equal Purex Repurchase Right to an equal number of Purex Repurchase Shares. The Pro Secondary Shares and the Purex Secondary Shares shall be referred to in this Agreement as the “Secondary Shares”.

 

(c) In the event that the Purex Repurchase Right and Pro Repurchase Right is exercised, the Parties shall take all such actions required in order to affect the repurchase rights and duly transfer the Purex Repurchase Shares and Pro Repurchase Shares back to the Stockholders in accordance with the terms contained herein.

 

(d) In consideration for the Secondary Shares, Purchaser shall pay the Stockholders as follows:

 

(i) Upon Closing, Purchaser shall pay the Stockholders aggregate cash consideration of $150,000 (the “Cash Consideration”), allocated among the Pro Stockholder and Purex Stockholders in accordance with the Pro Portion and the Purex Portion, with the Purex Portion of the Cash Consideration to be allocated among each Purex Stockholder in accordance with their pro rata portion of the Purex Secondary Shares.

 

(ii) Post-Closing and following the receipt by Purchaser of the Determination Period Financials, the implementation of the Adjustment and exercise of the Purex and Pro Repurchase Right (if applicable), Purchaser shall issue to the Stockholders restricted American Depositary Shares of Purchaser (“ADSs”) as follows:

 

(1) The price per each Pro Secondary Shares shall calculated by dividing $440,000 by the number of Pro Secondary Shares (the “Pro Secondary PPS”). In consideration for the Pro Secondary Shares, Purchaser shall issue to the Pro Stockholder ADSs of US Dollar value equal to (x) the number of Pro Secondary Shares; minus (y) the number of Pro Repurchase shares; together multiplied by the (z) Pro Secondary PPS (the “Pro ADS Consideration”). The price per ADS used in order to calculate the number of ADSs issued as Pro ADS Consideration shall be equal to the higher of (i) $1, or (ii) the 60 day closing average of the ADSs on the Nasdaq Capital Market (the “ADS Valuation”).

 

(2) The price per each Purex Secondary Shares shall be calculated by dividing $60,000 by the number of Purex Secondary Shares (the “Purex Secondary PPS”). In consideration for the Purex Secondary Shares, Purchaser shall issue to the Purex Stockholders ADSs, of US Dollar value equal to (x) the number of Purex Secondary Shares; minus (y) the number of Purex Repurchase Shares; together multiplied by the (z) Purex Secondary PPS (the “Purex ADS Consideration”). The price per ADS used in order to calculate the number of ADSs issued as Purex ADS Consideration shall be based on the ADS valuation.

 

1.4 Milestone Payments. The Stockholders shall be entitled to issuance of additional ADSs subject to achievement of the following milestones, in accordance with the following allocation all in accordance with the term contained herein. As a condition to the issuance of any ADS Portion (as defined herein), Stockholders will, prior to the planned date of issuance of such ADS Portion (the “ADS Portion Issuance Date”), provide Purchaser with an execute addendum to this Agreement, attesting that the Stockholders representations and warranties included in Sections 6.6 (Restricted Securities), 6.7 (Legends), 6.8 (Purchase Entirely for Own Account), 6.9 (Accredited Investor), 6.10 (Foreign Investors) and 6.11 (No General Solicitation) are true and correct in all respects as of the applicable ADS Portion Issuance Date.

 

3

 

 

(a) H1 2021 Milestone:

 

(i) Within three days of their approval and in any event as soon as practicable following the end of the financial period ended June 30, 2021 (“H1 2021 Period”), the Companies shall provide Purchaser with each of the Companies’ respective financial statements (including statement of income, balance sheet and statement of cash flows) relating to the H1 2021 Period, signed and certified by the Companies’ officers (the “H1 2021 Financials”). The H1 2021 Financials shall be prepared in accordance with generally accepted accounting principles.

 

(ii) In the event that the Companies SDE for H1 2021, in accordance with the H1 2021 Financials exceeds $600,000, the Stockholders shall be jointly entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation (the “H1 2021 Milestone” and “H1 2021 Milestone ADSs” respectively). Purchaser shall issue to the Pro Stockholder and the Purex Stockholders (with the Purex Portion divided equally among the Purex Stockholders) their respective portion of the H1 2021 Milestone ADSs in accordance with the Pro Portion and the Purex Portion.

 

(b) 2021 Annual Milestone:

 

(i) Within three days of their approval and in any event as soon as practicable following the end of the financial period ended December 31, 2021 (“2021 Annual Period”), the Companies shall provide Purchaser with each of the Company’s respective financial statements (including statement of income, balance sheet and statement of cash flows) relating to 2021 Annual Period, signed and certified by the Companies’ officers (the “2021 Annual Financials”). The 2021 Annual Financials shall be prepared in accordance with generally accepted accounting principles.

 

(ii) In the event that the Companies SDE for 2021 Annual Period, in accordance with the 2021 Annual Financials exceeds $1,200,000, the Stockholders shall be jointly entitled to the issuance of ADSs of aggregate value equal to $375,000 based on the ADS valuation (the “2021 Annual Milestone” and “2021 Annual Milestone ADSs” respectively). Purchaser shall issue to the Pro Stockholder and the Purex Stockholder their respective portion of the 2021 Annual Milestone ADSs in accordance with the Pro Portion and the Purex Portion (with the Purex Portion to be divided equally among the Purex Stockholders. In the event that the 2021 Annual Milestone is achieved, and the H1 2021 Milestone was not, the Stockholders shall also be entitled to receive the H1 2021 Milestone ADSs in addition to the 2021 Annual Milestone ADSs.

 

(iii) The Pro ADS Consideration, Purex ADS Consideration, H1 2021 Milestone ADSs and 2021 Annual Milestone ADSs shall be referred to herein individually as a “ADS Portion” and collectively be referred to as the “ADS Consideration”.

 

(iv) Set Off. Purchaser shall be entitled to offset from any Portion of the ADS Consideration that becomes due and payable the following amounts: (i) any amount of Losses that are indemnifiable by an Indemnitor under this Agreement; and (ii) the aggregate of all claimed amounts under any issued Claim Notice existing as of the time of such payment.

 

4

 

 

1.5 Restriction on Resale of the ADS Consideration.

 

(a) During the six (6) months following the cessation of any statutory restriction period applicable to the resale of the ADSs constituting each ADS Portion of the ADS Consideration, the Stockholders shall not sell ADSs in excess of 25% of such ADS Portion.

 

(b) During the period commencing six (6) months following the cessation of any statutory restriction applicable to each ADS Portion, such ADS Portion may be freely resold by the Stockholders in accordance with applicable law, provided that no more than 10% of each respective ADS Portion be traded in a single trading day.

 

2. Financing Arrangements.

 

2.1 Stockholder Loans. Purchaser and the Stockholders hereby acknowledge and agree that the Companies ongoing capital requirements shall be financed by the Stockholders and Purchaser by way of stockholder loans, upon terms mutually agreed between the Parties. Within fourteen (14) days following the Closing, Purchaser and the Stockholders shall each extend a loan of principle amount equal to $250,000 in accordance with the terms of the loan agreement provided by Purchaser (the “Stockholder Financing” and the “Loan Agreement” respectively). If the Companies require additional financing, the Companies shall submit notice to Purchaser and the Stockholders, detailing the required amount and use of proceeds. Purchaser and the Stockholders shall extend a stockholder loan covering the requested amount, up to an aggregate cap of $1,000,000, on a 60/40 basis respectively.

 

2.2 Additional Financing. Purchaser may, upon its sole discretion, provide the Companies with additional financing of up to a principle amount of $1 million, in order to finance the acquisition of additional online Amazon stores (the “Acquisition Financing”) provided that such Acquisition Financing shall constitute 80% of the applicable acquisition cost, with the remaining 20% to be financed by the Stockholders. The Acquisition Financing shall bear interest and shall be secured by a first degree fixed charge upon the Companies online stores, a first degree fixed charge upon the Common Stock held by the Stockholders and a floating charge over the Companies’ available cash and cash equivalents and shall be extended subject to the execution of financing and pledge agreements in the form and substance acceptable to Purchaser . If Acquisition Financing is extended, such Acquisition Financing and any interest accrued thereon shall be repaid prior in preference to any dividend distribution and any other indebtedness of the Companies.

 

3. Manager Arrangements.

 

3.1 Employment. The Manager shall enter into an employment agreement with Pro in accordance with the Offer Letter provided by Purchaser, pursuant to which Manager will invest his full efforts and time to Pro’s activities and operations (the “Employment Agreement”). The Employment Agreement shall provide for certain equity incentives to be determined in accordance with Purchaser’s share incentive plan.

 

3.2 Non-Compete & Non-Solicitation Undertaking. The Manager shall sign a non compete and non solicitation undertaking in a form acceptable to Purchaser (the “Manager Undertaking”), which shall include an acknowledgment that he is a beneficiary of the ADS Consideration and that execution by the Manager of the Manager Undertaking and fulfillment of his obligations thereunder is a material inducement to the Purchaser’s obligations under this Agreement.

 

5

 

 

4. Closing; Delivery.

 

4.1 The purchase and sale of the Primary Shares and the Secondary Shares shall take place remotely via the exchange of documents and signatures, at such time and place as the Companies and the Purchaser mutually agree upon, orally or in writing (which time and place are designated as the “Closing”). The Closing shall be subject to the condition included in Sections 8 and 9 below, which conditions shall be deemed to take place simultaneously and no transaction contemplated therein shall be deemed to have been completed or document deemed to have been delivered until all of the transactions have been completed and all of the documents have been delivered.

 

4.2 At the Closing, the Companies and the Stockholders shall deliver to the Purchaser a certificate representing the Primary Shares and Secondary Shares being purchased by the Purchaser at the Closing against payment of the Investment Amount therefor, by wire transfer to a bank account designated by the Companies. For the avoidance of doubt, the Portions of the ADS Consideration shall be transferred post-Closing all in accordance with the terms contained herein.

 

4.3  Use of Proceeds. The Companies will use the proceeds from the sale of the Primary Shares for the repayment of outstanding loans extended by Stockholders of an aggregate amount of $1,256,697 (the “Stockholder Loan”). Notwithstanding the above, the Companies shall retain $100,000 of the Investment Amount for a period of twelve (12) months following the Closing for the purpose of covering any undisclosed liabilities of the Companies.

 

4.4 Defined Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below.

 

(a) “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one (1) or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person.

 

(b) “Code” means the Internal Revenue Code of 1986, as amended.

 

(c) “Companies’ Intellectual Property” means all patents, patent applications, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information and proprietary rights and processes, software, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and in any and all such cases that are owned or used by the Companies in the conduct of the Companies’ business as now conducted and as presently proposed to be conducted.

 

(d) “Indemnification Agreement” means an agreement between the Companies and the directors designated by the Purchaser to serve as members of the board of directors of each of the Companies, to be elected pursuant to the Voting Agreements, dated as of the date of the Closing, in the form acceptable to Purchaser.

 

(e) “Investors’ Rights Agreements” means the agreements among the Companies, the Stockholders and the Purchaser dated as of the date of the Closing, in the form agreed upon between the Parties.

 

(f) “Key Employee” means the Manager and any employee or consultant who either alone or in concert with others develops, invents, programs or designs any Company Intellectual Property.

 

6

 

 

(g) “Knowledge” including the phrase “to the Companies’ knowledge” shall mean the actual knowledge after reasonable investigation and assuming such knowledge as the individual would have as a result of the reasonable performance of his or her duties in the ordinary course of the Manager.

 

(h) “Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, prospects or results of operations of the Company.

 

(i) “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

(j) “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(k) “Transaction Agreements” means this Agreement, the Investors’ Rights Agreements, the Voting Agreement, the Employment Agreement, the Manager Undertaking, the Indemnification Agreements and the Loan Agreement.

 

(l) “Voting Agreements” means the agreements among the Companies, the Purchaser and the Stockholders, dated as of the date of the Closing, in the forms agreed upon between the Parties.

 

5. Representations and Warranties of the Companies. The Companies hereby represent and warrant to the Purchaser that, except as set forth on the Disclosure Schedule attached as Exhibit A to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true and complete as of the date of the Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections contained in this Section ‎5, and the disclosures in any section of the Disclosure Schedule shall qualify other sections in this Section ‎5 only to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and a specific reference to such other section.

 

5.1 Organization, Good Standing, Corporate Power and Qualification. The Companies are corporations duly organized, validly existing and in good standing under the laws of the State of California and have all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. The Companies are duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

 

5.2 Capitalization.

 

(a) The authorized capital of the Companies consists, immediately prior to the Closing, of:

 

(i) With respect to Pro, 10,000 shares of common stock, 10,000 shares of which are issued and outstanding immediately prior to the Closing (the “Pro Common Stock”), and with respect to Purex, 1,000 shares of common stock (“Purex Common Stock”), 1,000 shares of which are issued and outstanding immediately prior to the Closing (Purex Common Stock together with Pro Common Stock, the “Common Stock”). All of the outstanding shares of Common Stock have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws.

 

7

 

 

(ii) The Companies hold no Preferred Stock in its treasury.

 

(b) Reserved.

 

(c) Section ‎(c) of the Disclosure Schedule sets forth the capitalization of the Companies immediately following the Closing. There are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Companies any shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock.

 

(d) The Companies have obtained valid waivers of any rights by other parties to purchase any of the Primary Shares or Secondary Shares covered by this Agreement.

 

5.3 Subsidiaries. The Companies do not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. Except as described in Section ‎5.3 of the Disclosure Schedule, the Companies are not participants, jointly or severally, in any joint venture, partnership or similar arrangement.

 

5.4 Authorization. All corporate action required to be taken by the Companies’ respective board of directors, Stockholders and Manager in order to authorize the Companies to enter into the Transaction Agreements, to issue the Primary Shares and transfer the Secondary Shares at the Closing has been taken prior to the Closing. All action on the part of the officers of the Companies necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Companies under the Transaction Agreements to be performed as of the Closing, and the issuance and delivery of the Primary Shares and transfer of the Secondary Shares has been taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Companies, the Stockholders and the Manager, shall constitute valid and legally binding obligations of the Companies, Stockholders and Manager, enforceable against such in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the Indemnification Agreement may be limited by applicable federal or state securities laws.

 

5.5 Valid Issuance of Shares. The Primary Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements and applicable state and federal securities laws. Assuming the accuracy of the representations of the Purchasers in Section ‎6 of this Agreement and subject to the filings described in the Voting Agreement, the Primary Shares will be issued in compliance with all applicable federal and state securities laws.

 

5.6 Governmental Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section ‎6 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for the filing of the Restated Certificates, which will have been filed as of the Closing.

 

8

 

 

5.7 Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or to the Companies Knowledge, investigation pending or currently threatened (i) against the Companies or any officer, director or Key Employee of the Companies; or (ii) to that questions the validity of the Transaction Agreements or the right of the Companies to enter into them, or to consummate the transactions contemplated by the Transaction Agreements; or (iii) to the Companies’ knowledge, that would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither the Companies nor, to the Companies’ knowledge, any of its officers, directors or Key Employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or Key Employees, such as would affect the Companies). There is no action, suit, proceeding or investigation by the Companies pending or which the Companies intend to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Companies) involving the prior employment of any of the Companies’ employees, their services provided in connection with the Companies’ business, any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.

 

5.8 Intellectual Property.

 

(a) The Companies own or possess or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others, including prior employees or consultants. The Companies have not received any communications alleging that the Companies have violated, or by conducting their business, would violate any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person.

 

(b) No product or service marketed or sold (or proposed to be marketed or sold) by the Companies violates or will violate any license or infringes or will infringe any intellectual property rights of any other party.

 

(c) Other than with respect to commercially available software products under standard end-user object code license agreements, and except as described in Section ‎5.8‎(c) of the Disclosure Schedule, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Companies Intellectual Property, nor are the Companies bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, software, licenses, information, proprietary rights and processes of any other Person.

 

(d) The Companies have obtained and possess valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Companies’ business.

 

(e) Each employee and consultant has assigned to the Companies all intellectual property rights he or she owns that are related to the Companies’ business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship with the Companies that (i) relate, at the time of conception, reduction to practice, development, or making of such intellectual property right, to the Companies’ business as then conducted or as then proposed to be conducted, (ii) were developed on any amount of the Companies’ time or with the use of any of the Company’s equipment, supplies, facilities or information or (iii) resulted from the performance of services for the Companies. It will not be necessary to use any inventions of any of its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Companies, including prior employees or consultants.

 

9

 

 

(f) Section ‎5.8(f) of the Disclosure Schedule lists all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, tradenames, copyrights, and licenses to and under any of the foregoing, in each case owned by the Companies.

 

(g) The Companies have not embedded, used or distributed any open source, copyleft or community source code (including but not limited to any libraries or code, software, technologies or other materials that are licensed or distributed under any General Public License, Lesser General Public License or similar license arrangement or other distribution model described by the Open Source Initiative at www.opensource.org, collectively “Open Source Software”) in connection with any of its products or services that are generally available or in development in any manner that would materially restrict the ability of the Company to protect its proprietary interests in any such product or service or in any manner that requires, or purports to require (i) any of the Companies Intellectual Property (other than the Open Source Software itself) be disclosed or distributed in source code form or be licensed for the purpose of making derivative works; (ii) any restriction on the consideration to be charged for the distribution of any Companies Intellectual Property; (iii) the creation of any obligation for the Companies with respect to Companies Intellectual Property owned by the Companies, or the grant to any third party of any rights or immunities under Companies Intellectual Property owned by the Companies; or (iv) any other limitation, restriction or condition on the right of the Companies with respect to its use or distribution of any Companies Intellectual Property.

 

(h) No government funding, facilities of a university, college, other educational institution or research center, or funding from third parties was used in the development of any Companies Intellectual Property. No Person who was involved in, or who contributed to, the creation or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational institution or research center in a manner that would affect Companies’ rights in the Companies Intellectual Property.

 

5.9 Compliance with Other Instruments. The Companies are not in violation or default (i) of any provisions of their Restated Certificates or Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule, or (v) of any provision of federal or state statute, rule or regulation applicable to the Companies, the violation of which would have a Material Adverse Effect. The execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Companies’ or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Companies’.

 

5.10 Agreements; Actions.

 

(a) Except for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(a) of the Disclosure Schedule there are no agreements, understandings, instruments, contracts or proposed transactions to which the Companies are a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments to, the Companies in excess of $50,000, (ii) the license of any patent, copyright, trademark, trade secret, software or other proprietary right to or from the Companies, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit the Companies’ exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Companies with respect to infringements of proprietary rights.

 

10

 

 

(b) Except for the Transaction Agreements, and except as disclosed in Section ‎5.10‎(b), the Companies have not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $100,000 in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for business expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than in the ordinary course of business. For the purposes of ‎(a) and ‎(b) of this Section ‎5.10, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such section.

 

(c) The Companies are not guarantors or indemnitors of any indebtedness of any other Person.

 

5.11 Certain Transactions.

 

(a) Other than (i) standard employee benefits generally made available to all employees, standard employee offer letters and Confidential Information Agreements (as defined below), (ii) standard director and officer indemnification agreements approved by the board of directors of the Companies, (iii) the purchase of shares of the Companies’ capital stock, in each instance, approved in the written minutes of the board of directors (previously provided to the Purchasers or their respective counsel), and (iv) the Transaction Documents, there are no agreements, understandings or proposed transactions between the Companies and any of its officers, directors, consultants or Key Employees, or any Affiliate thereof.

 

(b) Other than as disclosed is Section ‎5.11(b) of the Disclosure Schedule, the Companies are not indebted, directly or indirectly, to any of its directors, officers or employees or to their respective spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available to all employees. None of the Companies’ directors, officers or employees, or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Companies or, have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of the Companies’ customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct or indirect ownership interest in any firm or corporation with which the Companies are affiliated or with which the Companies have a business relationship, or any firm or corporation which competes with the Companies.

 

5.12 Rights of Registration and Voting Rights. The Companies are not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. Except as contemplated in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Companies.

 

5.13 Property. The property and assets that the Companies own are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair the Companies’ ownership or use of such property or assets. With respect to the property and assets it leases, the Companies are in compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property or assets. The Companies do not own any real property.

 

11

 

 

5.14 Financial Statements. The Companies have delivered to the Purchaser their unaudited financial statements for the fiscal year ended December 31, 2019 and its unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of June 30, 2020 (the “Balance Sheet Date”) and for the six-month period ended on the Balance Sheet Date (collectively, the “Financial Statements”). The Financial Statements have been prepared in accordance with international financial reporting standards (“IFRS”) applied on a consistent basis throughout the periods indicated. The Financial Statements fairly present in all material respects the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject in the case of the unaudited Financial Statements to normal year-end audit adjustments. Except for the Stockholders Loan, and except as disclosed in Section ‎5.14 of the Disclosure Schedule, the Companies have no liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to the Balance Sheet Date; (ii) obligations under contracts and commitments incurred in the ordinary course of business; and (iii) liabilities and obligations of a type or nature not required under IFRS to be reflected in the Financial Statements, which, in all such cases, individually and in the aggregate would not exceed $100,000. The Companies maintain and will continue to maintain a standard system of accounting established and administered in accordance with IFRS.

 

5.15 Changes. Since the Balance Sheet Date there have been no events or circumstances of any kind that have or could reasonably be expected to result in a Material Adverse Effect.

 

5.16 Employee Matters.

 

(a) To the Companies’ knowledge, none of its employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the Companies or that would conflict with the Companies’ business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the Companies’ business by the employees of the Companies, nor the conduct of the Companies’ business as now conducted and as presently proposed to be conducted, will, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now obligated.

 

(b) The Companies are not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors. The Companies have complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification and collective bargaining. The Companies have withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Companies and are not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing.

 

(c) To the Companies’ knowledge, no Key Employee intends to terminate employment with the Company or is otherwise likely to become unavailable to continue as a Key Employee. The Companies do not have a present intention to terminate the employment of any of the foregoing. The employment of each employee of the Companies is terminable at the will of the Companies. Except as required by law, upon termination of the employment of any such employees, no severance or other payments will become due. The Companies have no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination of employment services.

 

12

 

 

(d) The Companies have not made any representations regarding equity incentives to any officer, employee, director or consultant of the Companies.

 

(e) Section ‎5.16‎(e) of the Disclosure Schedule includes a list of all current and former employees of the Companies.

 

(f) To the Companies’ knowledge, none of the Key Employees or directors of the Companies have been (i) subject to voluntary or involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his or her business or property; (ii) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (iii) subject to any order, judgment or decree (not subsequently reversed, suspended, or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him or her from engaging, or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory, banking, insurance, or other type of business or acting as an officer or director of a public company; or (iv) found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated.

 

5.17 Tax Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the Companies which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Companies which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable federal, state, local or foreign governmental agency. The Companies have duly and timely filed all federal, state, county, local and foreign tax returns or other tax filings required to have been filed by it and there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year.

 

5.18 Insurance. The Companies have in full force and effect insurance policies concerning such casualties as would be reasonable and customary for companies like the Companies sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed.

 

5.19 Employee Agreements. Each current and former employee, consultant and officer of the Companies has executed an agreement with the Companies regarding confidentiality and proprietary information (the “Confidential Information Agreements”).

 

5.20 Permits. The Companies have all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Companies are not in default in any material respect under any of such franchises, permits, licenses or other similar authority.

 

5.21 Amazon Seller Code of Conduct and Policies. The Companies adhere to and comply with all Amazon policies, agreements, guidelines, and codes of conduct applicable to the conduct of the Companies’ business (the “Amazon Policies”). The Companies have not previously violated the Amazon Policies and have not received notice of any such violation.

 

5.22 Corporate Documents. The Certificate of Incorporation and Bylaws of the Companies as of the date of this Agreement are in the form provided to the Purchasers.

 

13

 

 

5.23 Foreign Corrupt Practices Act. Neither the Companies nor any of its directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Companies or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Companies nor any of their directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. Neither the Company nor any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law (collectively, “Enforcement Action”).

 

5.24 Data Privacy. In connection with its collection, storage, use and/or disclosure of any information that constitutes “personal information,” “personal data” or “personally identifiable information” as defined in applicable laws (collectively “Personal Information”) by or on behalf of the Companies, the Companies are and have been in compliance with (i) all applicable laws (including, without limitation, laws relating to privacy, data security, telephone and text message communications, and marketing by email or other channels) in all relevant jurisdictions, (ii) the Companies’ privacy policies and public written statements regarding the Company’s privacy or data security practices, and (iii) the requirements of any contract codes of conduct or industry standards, by which the Company is bound. The Companies maintain and have maintained reasonable physical, technical, and administrative security measures and policies designed to protect all Personal Information owned, stored, used, maintained or controlled by or on behalf of the Companies from and against unlawful, accidental or unauthorized access, destruction, loss, use, modification and/or disclosure. The Companies are and have been, to the Companies knowledge, in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations.

 

5.25 Export Control Laws. The Companies have conducted all export transactions in accordance with applicable provisions of United States export control laws and regulations, including the Export Administration Regulations, the International Traffic in Arms Regulations, the regulations administered by the Office of Foreign Assets Control of the U.S. Treasury Department, and the export control laws and regulations of any other applicable jurisdiction. Without limiting the foregoing: (a) the Companies have obtained all export licenses and other approvals, timely filed all required filings and has assigned the appropriate export classifications to all products, in each case as required for its exports of products, software and technologies from the United States and any other applicable jurisdiction; (b) the Companies are in compliance with the terms of all applicable export licenses, classifications, filing requirements or other approvals; (c) there are no pending or to the knowledge of the Companies, threatened claims against the Companies with respect to such exports, classifications, required filings or other approvals; (d) there are no pending investigations related to the Companies’ exports; and (e) there are no actions, conditions, or circumstances pertaining to the Company’s export transactions that would reasonably be expected to give rise to any material future claims.

 

5.26 Regulatory Approvals. The Companies possess all permits, licenses, registrations, certificates, authorizations, orders and approvals from the appropriate federal, state or foreign regulatory authorities necessary to conduct their business, including all such permits, licenses, registrations, certificates, authorizations, orders and approvals required by the FDA, EPA or any other federal, state or foreign agencies or bodies engaged in the regulation of drugs, pharmaceuticals, medical devices, sanitation or biohazardous materials. The Companies have not received any notice of proceedings relating to the suspension, modification, revocation or cancellation of any such permit, license, registration, certificate, authorization, order or approval.

 

14

 

 

5.27 Regulations. The Companies are and have been in compliance with all applicable laws administered or issued by the FDA, EPA or any similar governmental entity, including the Federal Food, Drug, and Cosmetic Act and all other laws regarding developing, testing, manufacturing, marketing, distributing or promoting the products of the Companies, or complaint handling or adverse event reporting.

 

5.28 Disclosure. The Companies have made available to the Purchaser all the information reasonably available to the Companies that the Purchaser has requested for deciding whether to acquire the Primary Shares and Secondary Shares, including certain of the Company’s projections describing its proposed business plan (the “Business Plan”). No representation or warranty of the Companies contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchaser at the Closing contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. The Business Plan was prepared in good faith; however, the Companies do not warrant that it will achieve any results projected in the Business Plan. It is understood that this representation is qualified by the fact that the Companies have not delivered to the Purchaser, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of securities.

 

6. Representation and Warranties of the Stockholders. Each of the Stockholders herby represents and warrants to the Purchaser, severally and not jointly, acknowledging that Purchaser is entering the Agreement in reliance thereon, that:

 

6.1 Ownership. The Stockholders own, beneficially and of record, and have good, valid marketable title to, all the Secondary Shares and no other person owns, beneficially or of record the Secondary Shares. The Secondary Shares are free and clear of any liens, rights of first refusal, co-sale rights, sale limitation or pre-emptive rights, except as a result of the transactions contemplated hereunder. No other person or entity has any power or right, whether shared with any other person or entity, to dispose of the or direct the disposition, or to vote or direct the voting of the Secondary Shares.

 

6.2 Authority. The Stockholders have all requisite power and full legal right to execute and deliver this Agreement, and to perform all of their obligations hereunder. This Agreement and the transactions contemplated hereby have been duly executed and delivered on the part of the Stockholders, and constitute legal, valid and binding obligations, enforceable against each Stockholder in accordance with their terms.

 

6.3 No Conflict. The execution, delivery and performance by the Stockholders of this Agreement and in accordance with its terms, and the consummation by the Stockholders of the transactions contemplated hereby, will not result (with or without the giving of notice or the lapse of time or both) in any conflict, violation, breach or default, or the creation of any lien, or the termination, acceleration, vesting or modification of any right or obligation under or with respect to (a) any judgement, decree, order, statute, rule or regulation binding on or applicable to the Stockholders; (b) any agreement or instrument to which the Stockholders are party or by which their assets are bound.

 

6.4 Litigation. The Stockholders are not aware of any claim, action or proceeding that is pending in any court or before any arbitrator against the Stockholders with respect to the Secondary Shares or any other Common Stock of the Companies’ held by them.

 

15

 

 

6.5 Upon full receipt of the ADS Consideration (or such applicable ADSs as the Stockholders shall be entitled to upon achievement of the H1 2021 Milestone 2021 Annual Milestone), the Stockholders shall have no further rights in or to the Secondary Shares sold thereby.

 

6.6 Restricted Securities. The Stockholders understands that the ADS Consideration has not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Stockholders’ representations as expressed herein. The Stockholders understands that the ADS Consideration is “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Stockholders must hold the ADS Consideration indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Stockholders acknowledge that the Purchaser has no obligation to register or qualify the ADS Consideration for resale. The Stockholders further acknowledge that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the ADS Consideration, and on requirements relating to the Purchaser which are outside of the Stockholders control, and which the Purchasers are under no obligation and may not be able to satisfy. The Stockholders understand that this offering is not intended to be part of the public offering, and that the Stockholders will not be able to rely on the protection of Section 11 of the Securities Act.

 

6.7 Legends. The Stockholders understand that the ADSs constituting the ADS Consideration may be notated with one or all of the following legends:

 

“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(a) Any legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate, instrument, or book entry so legended.

 

6.8 Purchase Entirely for Own Account. This Agreement is made with the Stockholders in reliance upon the Stockholders’ representation to the Purchaser, which by the Stockholders’ execution of this Agreement, the Stockholders hereby confirm, that the ADS Consideration to be acquired by the Stockholders will be acquired for investment for the Stockholders’ own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Stockholders have no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Stockholders further represents that the Stockholders do not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the ADS Consideration.

 

16

 

 

6.9 Accredited Investor; Non U.S. Person; Investment Experience. The Stockholders acknowledge that they are able to fend for themselves, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating and understanding the merits and risks of the investment in the Purchaser. The Stockholders are either (i) an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under Regulation S promulgated under the Securities Act. To the extent that the Stockholders are non U.S. Persons, Stockholders (x) are not acquiring the ADS Consideration on account or benefit of any U.S. Person, (y) are not, at the time of execution of the Agreement, and will not be at the time of the issuance of the ADS Consideration, in the United States and (z) are not a “distributor” (as defined in Regulation S promulgated under the Securities Act).

 

6.10 Foreign Investors. If the Stockholders are not a United States person (as defined by Section 7701(a)(30) of the Code), the Stockholders hereby represent that they have satisfied themselves as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the ADS Consideration or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the ADS Consideration, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the ADS Consideration. The Stockholders subscription and payment for and continued beneficial ownership of the ADS Consideration will not violate any applicable securities or other laws of the Stockholders jurisdiction.

 

6.11 No General Solicitation. The Stockholders have neither directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the ADS Consideration.

 

7. Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company that:

 

7.1 Authorization. The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable against such Purchaser in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investors’ Rights Agreement may be limited by applicable federal or state securities laws.

 

7.2 Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Companies, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Primary Shares and Secondary Shares to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Primary Shares or the Secondary Shares.

 

7.3 Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Primary Shares with the Companies’ management. The foregoing, however, does not limit or modify the representations and warranties of the Companies in Section ‎5 of this Agreement or the right of the Purchaser to rely thereon.

 

17

 

 

7.4 Restricted Securities. The Purchaser understands that the Primary Shares and the Secondary Shares have not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Primary Shares and Secondary Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Primary Shares and Secondary Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Companies have no obligation to register or qualify the Primary Shares, or the Secondary Shares for resale. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Primary Shares and Secondary Shares, and on requirements relating to the Companies which are outside of the Purchaser’s control, and which the Companies are under no obligation and may not be able to satisfy. The Purchaser understands that this offering is not intended to be part of the public offering, and that the Purchaser will not be able to rely on the protection of Section 11 of the Securities Act.

 

7.5 No Public Market. The Purchaser understands that no public market now exists for the Primary Shares and Secondary Shares, and that the Companies have made no assurances that a public market will ever exist for the Primary Shares and Secondary Shares.

 

7.6 Legends. The Purchaser understands that the Primary Shares and Secondary Shares may be notated with one or all of the following legends:

 

“THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”

 

(a) Any legend set forth in, or required by, the other Transaction Agreements.

 

(b) Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate, instrument, or book entry so legended.

 

7.7 Accredited Investor; Non U.S. Person; Investment Experience. The Purchaser acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating and understanding the merits and risks of the investment in the Companies. The Purchaser is either (i) an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act, or (ii) a Non U.S. Person as defined under Regulation S promulgated under the Securities Act. To the extent that the Purchaser is a non U.S. Person, Purchaser (x) is not acquiring the Primary Shares or Secondary Shares on account or benefit of any U.S. Person, (y) is not, at the time of execution of the Agreement, and will not be at the time of the issuance of the Primary Shares, in the United States and (z) is not a “distributor” (as defined in Regulation S promulgated under the Securities Act).

 

18

 

 

7.8 Foreign Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Primary Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Primary Shares and Secondary Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Primary Shares or the Secondary Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the Primary Shares and the purchase of the Secondary Shares will not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

 

7.9 No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Primary Shares and Secondary Shares.

 

7.10 Residence. Purchaser’s office or offices or principal place of business is as identified in the preamble to this agreement.

 

8. Conditions to the Purchasers’ Obligations at Closing. The obligations of Purchaser to purchase Primary Shares and the Secondary Shares at the Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived:

 

8.1 Representations and Warranties. The representations and warranties of the Companies and the Stockholders contained in Section ‎5 and Section ‎6 shall be true and correct in all respects as of such Closing.

 

8.2 Performance. The Companies, Stockholders and Manager shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Companies, Stockholders and the Manager on or before such Closing.

 

8.3 Compliance Certificate. The chief executive officer of the Companies’ shall deliver to the Purchaser at such Closing a certificate certifying that the conditions specified in Sections ‎8.1 and ‎8.2 have been fulfilled.

 

8.4 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares pursuant to this Agreement shall be obtained and effective as of such Closing.

 

8.5 Opinion of Company Counsel. The Purchasers shall have received from counsel for the Companies, an opinion, dated as of the Closing, in the form acceptable to the Purchaser.

 

8.6 Board of Directors. As of the Closing, the authorized size of the Pro board of directors (the “Pro Board”) shall be three (3), and the Pro Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Pro Stockholder. As of the Closing, the authorized size of the Purex board of directors (the “Purex Board”) shall be three (3), and the Purex Board shall be comprised of Mr. Eli Yoresh, Mr. Liron Carmel and a director designated by the Purex Stockholders.

 

19

 

 

8.7 Indemnification Agreement. The Companies shall have executed and delivered the Indemnification Agreements for each of the members of the Pro Board and Purex Board respectively.

 

8.8 Investors’ Rights Agreement. The Companies and the Stockholders of the Companies shall have executed and delivered the the Investors’ Rights Agreement for each of Pro and Purex.

 

8.9 Voting Agreement. The Companies and the Stockholders shall have executed and delivered their respective Voting Agreement.

 

8.10 Restated Certificate. The Companies shall have each adopted and filed their respective restated certificates with the Secretary of State of California, in the form acceptable to the Purchaser (the “Restated Certificates”) on or prior to the Closing, which shall continue to be in full force and effect as of the Closing.

 

8.11 Restated Bylaws. The Companies’ shall have each amended their respective Bylaws on or prior to the Closing, in accordance with a form acceptable to Purchaser (the “Restated Bylaws”).

 

8.12 Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate certifying (i) the Certificate of Incorporation and Bylaws of the Companies as in effect at the Closing, (ii) resolutions of Pro Board and Purex Board approving the Transaction Agreements and the transactions contemplated under the Transaction Agreements, and (iii) resolutions of the Stockholders of the Companies approving the Restated Certificates and Restated Bylaws.

 

8.13 Employment Agreement. The Manager shall have executed and entered the Employment Agreement with Pro on or prior to the Closing with such Employment Agreement to be in effect as of the Closing.

 

8.14 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to Purchaser, and Purchaser (or its counsel) shall have received all such counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates.

 

9. Conditions of the Companies’ and Stockholder Obligations at Closing. The obligations of the Companies’ and the Stockholder to sell the Primary Shares and Secondary Shares to the Purchaser at the Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived:

 

9.1 Representations and Warranties. The representations and warranties of the Purchaser contained in Section ‎6 shall be true and correct in all respects as of such Closing.

 

9.2 Performance. The Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by Purchaser on or before such Closing.

 

9.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Primary Shares and sale of the Secondary Shares pursuant to this Agreement shall be obtained and effective as of the Closing.

 

20

 

 

9.4 Investors’ Rights Agreement. Purchaser shall have executed and delivered the Investors’ Rights Agreement for each of the Companies.

 

9.5 Voting Agreement. Purchaser shall have executed and delivered the Voting Agreement for each of the Companies.

 

10. Indemnification.

 

10.1 Effectiveness; Survival.

 

(a) Purchaser has the right to fully rely upon all representations, warranties and covenants of the Companies and Stockholders (as applicable, severally and not jointly, the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules attached hereto. Unless otherwise set forth in this Agreement, the representations and warranties of the Companies and Stockholders contained in or made pursuant to this Agreement shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of Purchaser.

 

(b) The representations and warranties of the Companies and the Stockholders contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing until the earlier of:

 

(c) immediately prior to the consummation of a Deemed Liquidation Event (as such terms are defined under the Restated Certificates), or

 

(d) (1) in case of Section 4.8 (Intellectual Property), until the 36th months anniversary of the Closing; (2) in case of Sections ‎5.1 (Organization), ‎5.2 (Capitalization), ‎5.4 (Authorization), ‎5.5 (Valid Issuance of Shares), ‎5.6 (Consents) and ‎5.9 (Compliance with Other Instruments) (the representations and warranties referred to in this clause ‎(d), collectively, the “Fundamental Representations”), until the expiration of the applicable statute of limitation period; and (3) other than as set forth in clause (1) and (2) above, the 24th months anniversary of the Closing Date; in each case, with respect to any theretofore un-asserted claims as set forth in clause (c) below;

 

provided, however, that no limitation shall apply to breach of any representation or warranty which constitutes fraud or willful misrepresentation by the Companies (as the case may be) (“Fraud”). The applicable survival period shall be referred to, as applicable, as the “Claims Period”.

 

(e) Except for Fraud, the Companies and Stockholders shall not have any liability with respect to any breach of representation and warranty, unless a claim is made hereunder prior to the expiration of the Claims Period for such representation and warranty, in which case such representation and warranty shall survive as to that claim until the claim has been finally resolved.

 

(f) It is the intention of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations and warranties, and this Section ‎(f) constitutes a separate written legally binding agreement among the parties hereto.

 

10.2 Indemnification.

 

(a) Indemnifiable Losses. The Indemnitor shall indemnify Purchaser (including its shareholders, limited and general partners directors and officers) (each, an “Indemnitee”) against, and hold each Indemnitee harmless from all claims, actions, suits, settlements, damages, expenses (including, reasonable legal costs and expenses), losses, diminution of value, or costs sustained or incurred by such Indemnitees (collectively, “Losses”) resulting from, or arising out of, a breach or misrepresentations of any of the Indemnitor’s representations, warranties or covenants made in this Agreement, subject to the limitations in this Section ‎10.2. For the avoidance of doubt, Indemnitors shall indemnify Indemnitee for losses on a joint and not several basis.

 

21

 

 

(b) Limitations. The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations, notwithstanding anything to the contrary in this Agreement, but in addition to any other limitation or condition contained herein; provided, however, that no such limitation shall apply to Fraud:

 

(c) Other than in respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate of Losses equal or exceeds US$50,000, in which case indemnification shall be made from the first dollar amount.

 

(d) Except for Fraud, the Indemnitor’s liability shall be limited to the aggregate amount of the Investment Amount under the Agreement at the Closing and the ADS Consideration payable by Purchaser to the Indemnitors, and each Indemnitee shall be entitled to receive the indemnifiable Loss up to the sum of the Investment Amount as of the Closing and the ADS Consideration actually payable thereafter.

 

(e) Claims Notice; Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder it shall give the Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable detail the facts and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor informed, in all material respects, with respect thereto. In the event that such Claims Notice results from a third party claim against the Indemnitee, such Indemnitee shall promptly upon becoming aware of the commencement of proceedings by such third party provide the Indemnitor with the Claims Notice and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s expense) with counsel mutually satisfactory to the parties; provided, however, that the Indemnitees shall have the right to retain their own counsel, at the reasonable expense of the Indemnitor, and within the indemnification limitations herein, if representation of all parties by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the parties in such proceeding. Failure of the Indemnitees to give prompt notice or to keep it informed, as provided herein, shall not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is actually and materially prejudiced by such failure. The Indemnitor shall not be liable nor shall it be required to indemnify or hold harmless the Indemnitee in connection with any settlement effected without its consent in writing, which shall not be unreasonably withheld or delayed.

 

(f) Sole Remedy. The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall be the exclusive remedy available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision does not limit the right to seek specific performance, a restraining order or injunctive relief with respect to any provision of this Agreement.

 

11. Miscellaneous.

 

11.1 Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and each Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers or the Company.

 

22

 

 

11.2 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

11.3 Governing Law. This Agreement shall be governed by the internal law of the State of Israel, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Israel.

 

11.4 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

11.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

11.6 Notices.

 

(a) General. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or in the preamble to this Agreement, or to such e-mail address or address as subsequently modified by written notice given in accordance with this Section ‎11.6.

 

11.7 No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. The Companies agrees to indemnify and hold harmless Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Companies or any of its officers, employees or representatives is responsible.

 

11.8 Fees and Expenses. Each party to this Agreement shall bear the cost of their own respective legal fees and expenses.

 

11.9 Attorneys’ Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

 

11.10 Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Companies, Stockholders and Purchaser. Any amendment or waiver effected in accordance with this Section ‎11.10 shall be binding upon the Purchaser and each transferee of the Primary Shares or Secondary Shares, each future holder of all such securities, the Stockholders and the Companies.

 

23

 

 

11.11 Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

11.12 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

11.13 Entire Agreement. This Agreement (including the Exhibits hereto), the Restated Certificates, Restated Bylaws and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.

 

11.14 Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.

 

11.15 Termination of Closing Obligations. Purchaser shall have the right to terminate its obligations to complete the Closing if prior to the occurrence thereof, any of the following occurs:

 

(a) the either of the Companies consummates a Deemed Liquidation Event (as defined in the Restated Certificate);

 

(b) the closing of an initial public offering of either of the Companies, in which case the Purchaser may terminate their obligations hereunder immediately prior to, or contingent upon, such closing; or

 

(c) either of the Companies (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (v) becomes subject to any involuntary proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, when proceeding is not dismissed within thirty (30) days of filing, or have an order for relief entered against it in any proceedings under the United States Bankruptcy Code.

 

11.16 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the competent courts of the State of Israel and to the jurisdiction of Tel-Aviv courts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Tel-Aviv, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

[Signature Page Follows]

 

24

 

 

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

  SMART REPAIR PRO, INC.:
   
  By: /s/ Julia Gerasimova
  Name:   Julia Gerasimova
  Title: Owner
     
  PUREX, INC.:
   
  By: /s/ Galit Mccord
  Name: Galit Mccord
  Title: Owner

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

  PURCHASER:
   
  MEDIGUS LTD.
   
  By: /s/ Eli Yoresh
  Name:   Eli Yoresh
  Title: Chairman

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

  STOCKLHOLDERS:
   
  JULIA GERASIMOVA
   
  /s/ Julia Gerasimova
   
  GALIT MCCORD
   
  /s/ Galit Mccord
   
  SOLY HACMON
   
  /s/ Soly Hacmon
   
  MANAGER:
   
  VICKY HACMON
   
  /s/ Vicky Hacmon

 

 

 

 

EXHIBITS AND SCHEDULES

 

Schedule 1 SCHEDULE OF STOCKHOLDERS
Exhibit A DISCLOSURE SCHEDULE

 

 

 

 

SCHEDULE 1

 

Schedule of Stockholders

 

[***]

 

 

 

 

EXHIBIT A

 

Disclosure Schedule

 

[***]

 

 

 

 

 

Exhibit 10.5

 

SHARE PURCHASE AGREEMENT

 

THIS SHARE PURCHASE AGREEMENT is made as of October 14, 2020, by and between Eventer Technologies Ltd., an Israeli company (the “Company”) and Medigus Ltd. (the “Investor”).

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company to raise capital by means of issuance of the Company’s Ordinary Shares, nominal value NIS 0.1 per share (the “Ordinary Shares”) to the Investor, at a purchase price of US$2.305777 per each Ordinary Share (the “Ordinary Share PPS”); and

 

WHEREAS, the Investor desires to purchase and the Company desires to issue and sell to the Investor the Ordinary Shares pursuant to the terms and conditions more fully set forth in this Agreement.

 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1. PURCHASE AND SALE OF PURCHASED SHARES.

 

1.1 Sale and Issuance of Shares. Subject to the satisfaction of the closing conditions set forth in Section ‎5 hereof, at the Closing (as defined below), the Company shall issue and sell to the Investor, and the Investor shall purchase, from the Company, according to the allocation set forth in Exhibit A attached hereto, for an aggregate purchase price of US$750,000 (the “Purchase Price”), an aggregate of 325,270 Ordinary Shares (the “Purchased Shares”) at the Ordinary Share PPS, representing 50.01% of the Company’s share capital on a Fully Diluted Basis (the “Investor Closing Holdings”) reflecting a pre-money valuation on a Fully-Diluted Basis (as defined below) of US$749,600.

 

The capitalization table of the Company, reflecting the issued and outstanding share capital of the Company on a Fully Diluted Basis, immediately prior to Closing and immediately following the Closing, assuming the investment of the Purchase Price, is attached hereto as Exhibit B (the “Capitalization Table”).

 

In this Agreement, “Fully-Diluted Basis” shall mean all issued and outstanding shares of the Company, including but not limited to (i) all Ordinary Shares; (ii) all securities convertible or exercisable into shares (being deemed so converted); (iii) all convertible investments, financings or loans (being deemed so converted); (iv) all options, warrants and other rights to acquire shares or other securities exercisable for shares (being deemed allocated and so exercised) (excluding the Allocated Option and Anti-Dilution Protection Shares); and (v) any adjustments of the number of issued shares triggered by or in connection with the transaction contemplated by this Agreement (if any), including anti-dilution adjustment.

 

Notwithstanding the aforesaid, with respect to the (a) reservation of 74,100 options to purchase Ordinary Shares for options and other equity awards promised to such persons and entities listed in Schedule 1.1 (the “Allocated Options”), and (b) an additional reservation of 8,410 Ordinary Shares which may be issued upon issuance of certain of the Allocated Options, all as described in Schedule 1.1 (the “Anti-Dilution Protection Shares”), if any shares shall be issued following the exercise of any Allocated Options and if any Anti-Dilution Protection Shares shall be issued, then the Company shall issue to the Investor, for no additional consideration and with no other action required on the part of the Company or the Investor, such number of Ordinary Shares that would result in no dilution of the Investor’s proportionate holding in the Company due to any such issuances (i.e. the Investor’s holding shall not fall below the Investor Closing Holdings, except to the extent such dilution results from further issuances approved in accordance with the Restated Articles) (the “Adjustment Shares”) and the Company shall deliver to the Investor a share certificate representing such Adjustment Shares, register the Adjustment Shares in the Company’s Shareholders Register and file all required notices with the Israeli Registrar of Companies. The Adjustment Shares shall be deemed, for all purposes, as “Purchased Shares” that have been issued as of the Closing.

 

 

 

  

1.2 Closing. The consummation of the transactions contemplated hereby, including the purchase and sale of the Purchased Shares (the “Closing”) shall take place remotely via the exchange of documents and signatures, at such time and place as the Company and Investor mutually agree upon (such designated time and place, the “Closing Date”). The Closing shall be subject to the conditions of Section ‎5 below, which conditions shall be deemed to take place simultaneously and no transaction described in such sections shall be deemed to have been completed or any document delivered until all such transactions have been completed and all such required documents delivered.

 

1.3 Restated Articles. The Company shall adopt on or before the Closing the Amended and Restated Articles of Association in the form attached hereto as Exhibit C (the “Restated Articles”). The Purchased Shares shall have and confer upon the holders thereof the rights, preferences, privileges and restrictions set forth in the Restated Articles, as may be amended from time to time in accordance with their terms.

 

1.4 Second Tranche Closing.

 

(a) If following the Closing, the Company shall determine that the EBIDTA set forth in Schedule 1.4 has been achieved, in whole or in part (in which case, the rate of achievement shall be stated) (the “Milestone Conditions”), the Company shall deliver a written notice (a “Second Tranche Notification”) to the Investor that a closing of the purchase and sale of 1 additional Ordinary Share (the “Second Tranche Closing Share”) (the “Second Tranche Closing”) is to take place pursuant to this Subsection 1.4. The Second Tranche Notification shall include the proposed date for the Second Tranche Closing, which date shall be no earlier than fourteen (14) days after the date of the Second Tranche Notification. Subject to the terms and conditions of this Agreement and at the Second Tranche Closing, the Company shall sell and issue to the Investor and the Investor shall purchase at the Second Tranche Closing the Second Tranche Closing Share against payment of US$250,000 or a proportionate portion thereof, in accordance with the level of achievement of the Milestone Conditions (the “Second Tranche Amount”), by wire transfer to a bank account designated by the Company. Notwithstanding the foregoing, in lieu of the issuance of the Second Tranche Closing, the Parties may mutually agree to apply an additional premium on account of the Purchased Shares. In case of issuance of the Second Tranche Closing Share, all shares held by the Investor shall be deemed to have effective price per share equal to the total amount of the Purchase Price and the Second Tranche Amount divided by the total number of shares purchased by the Investor.

 

The initial consideration and determination whether or not the Milestone Conditions shall have been achieved shall be made by the directors of the Company excluding the Medigus Directors (as defined in the Restated Articles). Upon receipt of the Second Tranche Notification, the Investor may ask for any information and clarifications it deems necessary to determine whether the Milestone Conditions have been met, and it may also respond with an objection to the Second Tranche Notification based on its position that the Milestone Conditions have not been achieved. In such case of disagreement, the parties may refer the matter to an arbitrator to be mutually agreed upon, and in case of disagreement, the matter would be dealt with pursuant to the provisions of Section 8.5 of this Agreement. The Investor shall not be required to pay any portion of the Second Tranche Amount until a non-appealable decision has been made. In all such actions, the Medigus Directors shall not be involved in their capacities as directors, in any actions taken by the Company with respect to the Second Tranche Closing.

 

(b) The Investor’s obligation to transfer the Second Tranche Amount and purchase the Second Tranche Closing Share at the Second Tranche Closing may be satisfied by any person or entity that is a Permited Transferee of the Investor (as such term is defined in the Restated Articles) (the “Additional Investor”), subject to compliance with the provisions of Section 20.1.1 of the Restated Articles, applied as if this is a Transfer; provided, that the Investor alone shall remain the party to this Agreement, such as for purposes of the Share Exchange Option Agreement, the Information Rights Agreement, etc.; provided however that the Additional Investor shall provide a letter of confirmation regarding the provisions of Section 3 of this Agreement.

 

2

 

  

(c) For any and all purposes under this Agreement and any other Transaction Documents, the date of issuance of the Second Tranche Closing Share shall be deemed to be the date of Closing, specifically for purposes of the provisions of Section 7 of this Agreement.

 

(d) Notwithstanding the foregoing, the obligations of the Investor under this Subsection 1.4 shall terminate and be of no further force or effect upon the earlier of (i) December 31, 2023, or (ii) immediately prior to the consummation of a Deemed Liquidation (as defined in the Restated Articles).

 

1.5 Closing Deliverables.

 

(a) At the Closing, the Company shall deliver to the Investor:

 

(i) True and correct copies of written resolutions, or minutes of a meeting, of the Board, approving and adopting in all respects the execution, delivery and performance by the Company of this Agreement and the transactions contemplated hereby, including, among others, (i) authorizing the issuance and sale of the Purchased Shares against payment of the purchase price therefor; (ii) the approval of the execution, delivery and performance by the Company of all agreements contemplated herein to which the Company is party and any agreements, instruments or documents ancillary thereto; (iii) reservation of 74,100 Ordinary Shares for issuance to directors, officers, consultants and employees of the Company or its subsidiaries; (iv) reservation of 8,410 Ordinary Shares for issuance pursuant to the provisions of Schedule 1.1; and (iv) the adoption of new signatory rights; all in the form attached hereto as Schedule 1.5(a)(i);

 

(ii) True and correct copies of written resolutions, or minutes of meeting, of the Company’s shareholders approving and adopting in all respects the execution, delivery and performance by the Company of this Agreement and the transactions contemplated hereby, including, among others, (i) the adoption of the Restated Articles as an amendment and restatement of the existing Articles of Association of the Company as in effect prior to the Closing; and (ii) the approval of the execution, delivery and performance by the Company of all agreements contemplated herein to which the Company is party and any agreements, instruments or documents ancillary thereto; all in the form attached hereto as Schedule 1.5(a)(ii);

 

(iii) A copy of the Restated Articles;

 

(iv) The Share Exchange Option Agreement, in the form attached hereto as Exhibit D (the “Share Exchange Option Agreement”), duly executed by the Company and certain of its shareholders;

 

(v) A duly executed share certificate representing the Purchased Shares issued to the Investor at the Closing in the name of the Investor, in the form attached hereto as Schedule 1.5(a)(v);

 

(vi) A copy of the register of shareholders of the Company (the “Shareholders Register”), certified by an executive officer of the Company and prepared in accordance with Section 130 of the Companies Law, 5759–1999, as amended (the “Companies Law”), in which the Purchased Shares issued at the Closing are registered in the name of the Investor, in the form attached hereto as Schedule 1.5(a)(vi);

 

3

 

 

(vii) Duly completed notices to the Israeli Registrar of Companies, in the forms attached hereto as Schedule 1.5(vii), ready for immediate filing, as are required for all matters arising from this Agreement and the transactions contemplated hereby (including, of the issuance of the Purchased Shares at the Closing, the adoption of the Restated Articles and the changes to the composition of the Board);

 

(viii) True and correct copies of all waivers of preemptive rights (if the period for exercise of such right has not lapsed in accordance with its terms) by all holders of such rights, with respect to this Agreement and the transactions contemplated hereby;

 

(ix) Deleted

 

(x) Director indemnification agreements with the members of the Board, including the director(s) appointed by the Investor (the “Indemnification Agreement”), duly approved by the Board and shareholders and executed by the Company, in the form attached hereto as Schedule 1.5(a)(x);

 

(xi) Information Rights Agreement, dated as of the Closing, duly executed by the Company, in the form attached hereto as Schedule 1.5(a)(xi);

 

(xii) a certificate duly executed by an executive officer of the Company as of the Closing stating that the conditions specified in Section 5 have been satisfied, in the form attached hereto as Schedule 1.5(a)(xii); and

 

(xiii) an executed copy of the Revolving Promissory Note, in the form attached hereto as Schedule 1.5(a)(xiii) (the “Revolving Promissory Note”).

 

(b) At the Closing, the Investor shall deliver to the Company:

 

(i) The Share Exchange Option Agreement;

 

(ii) Any identification documents required for the purpose of making the filings required under Section 1.5(a)(vii);

 

(iii) The Indemnification Agreement, duly executed by the director appointed by the Investor; and

 

(iv) The Revolving Promissory Note, duly executed by the Investor.

 

1.6 Purchase Price. At the Closing, the Investor shall transfer to the Company the Purchase Price to be invested at the Closing by wire transfer of immediately available funds according to the Company’s wire instructions (details of which will be provided by the Company in writing prior to the Closing).

 

1.7 Adjustment of Shenhav-Eventer LP’s Holdings. Immediately prior to the Closing, Shenhav-Eventer LP shall be issued 14,500 additional Ordinary Shares of the Company, as compensation for their dilution by the purchase of shares by the Investor.

 

2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company hereby represents and warrants to the Investor that, except as set forth on the Disclosure Schedule delivered to the Company on the date hereof (the “Disclosure Schedule”), which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true, correct and complete as of the date hereof and as of the Closing (as if made on the Closing Date); except, in each case, as to such representations and warranties that address matters as of a particular date, which are true, correct and complete only as of such date. The Disclosure Schedule is arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in this Section ‎2, and the information set forth in any one in any section or subsection of the Disclosure Schedule applies to and qualifies (a) the representation and warranty set forth in this Agreement to which it corresponds, and (b) whether or not an explicit reference or cross-reference is made, each other representation and warranty set forth in this Agreement for which it is reasonably apparent on its face that such information is relevant to such other section.

 

4

 

  

Material Adverse Effect” means a material and adverse affect on the assets, properties, conditions (financial or otherwise), operating results or business of the Company, as currently conducted and as currently proposed to be conducted.

 

2.1 Organization. The Company is a company duly organized and validly existing under the laws of the State of Israel, is not a “breaching company” (within the meaning of Section 362.A of the Israeli Companies Law) and has all requisite corporate power and authority to carry on its business as currently conducted and as currently proposed to be conducted.

 

2.2 Capitalization.

 

(a) The authorized share capital of the Company is or will be on or immediately prior to the Closing (but following the adoption of the Restated Articles), as set forth in the Restated Articles, and such number of shares of each class as set forth in the Capitalization Table are or shall be (as of the Closing) issued and outstanding.

 

(b) The outstanding securities of the Company, on a Fully-Diluted Basis, are owned by and registered in the names of such security holders, and in such numbers as specified in the Capitalization Table and in Section 2.2(b) of the Disclosure Schedule.

 

(c) The Board has reserved 74,100 Ordinary Shares prior to the Closing for issuance of, and grant of options or other equity awards exercisable into, Ordinary Shares of the Company to directors, officers, employees, consultants and service providers of the Company or its subsidiaries under the Company’s 2017 Employee Share Option Plan or under other grant agreements and schemes (the “Plan” and the “ESOP Pool”, respectively), all of which have been allocated and/or promised. The Company has furnished to the Investor complete and accurate copies of the Plan and forms of agreements adopted thereunder. Section 2.2(c) of the Disclosure Schedule sets forth for each outstanding or promised option or equity award: (i) the name of the holder thereof; (ii) the exercise price, (iii) the vesting commencement date and vesting schedule (and any acceleration terms, if any); (iii) whether each such option or award was granted and is subject to tax pursuant to Section 3(i) or Section 102 of the Israeli Income Tax Ordinance [New Version], 1961 (and specifying the subsection of Section 102) or tax regimes of other jurisdictions.

 

(d) The issued and outstanding shares of the Company were duly and validly authorized and issued, fully paid and non-assessable, and offered and issued in compliance with the provisions of the Company’s Articles of Association as in effect at the time of each such issuance and in compliance with all applicable corporate and securities laws. None of the issued and outstanding shares of the Company was offered or sold in such a manner as to make the offer, issuance or sale of such shares not exempted from registration requirements under applicable securities law.

 

(e) Except for the preemptive rights and bring-along provisions under applicable law or in the Restated Articles, there are no outstanding share capital, options, warrants, rights (including conversion, preemptive rights, rights of first refusal or similar rights) or agreements for the purchase from the Company of any of its share capital, or any securities convertible into or exchangeable for shares of the Company (whether now or hereinafter authorized or issued), other than as set forth in the Capitalization Table, or that could require the Company or a shareholder of the Company to issue, sell, transfer or otherwise cause to be outstanding any of the Company’s share capital or securities convertible or exercisable into shares thereof.

 

5

 

  

(f) No option, security or other equity award convertible or exercisable into shares of the Company contains a provision for acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such option, security or other equity award upon the occurrence of any event or combination of events, including without limitation in the case where the Plan is not assumed in an acquisition. No share, option, security or other equity award convertible or exercisable into shares of the Company is subject to repurchase or redemption (contingent or otherwise) by the Company, its subsidiaries or its shareholders, and neither the Company nor any subsidiary or shareholder have repurchased or redeemed any of the Company’s shares, options, security or other equity awards. The Company has never adjusted or amended the exercise price or any other terms of any options previously awarded, whether through amendment, cancellation, replacement grant, repricing, or any other means.

 

(g) The Company has not granted or agreed to grant registration rights and is not under any contractual obligation to register under the U.S. Securities Act of 1933 (together with the rules and regulations promulgated thereunder, all as amended, the “Securities Act”), any of its currently outstanding securities, securities that may hereafter be issued upon conversion thereof, or shares or other securities it may hereafter issue or grant.

 

(h) The Company has not declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its share capital.

 

2.3 Authorization. All corporate action on the part of the Company, its directors and shareholders, necessary for the authorization, execution and delivery of this Agreement, and the other agreements, instruments or documents entered into in connection with this Agreement and to which the Company is a party (collectively, the “Transaction Documents”) and for the performance of all obligations of the Company under the Transaction Documents in accordance with their terms has been taken or will be taken prior to the Closing. The Transaction Documents, when executed and delivered by the Company, and assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

2.4 Valid Issuance of Shares. The Purchased Shares that may be issued to the Investor hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, shall be duly and validly issued, fully paid, and non-assessable, issued in compliance with all applicable state securities laws, and free and clear of liens, pledges, charges, encumbrances or other restrictions on transfer of any kind (including, without limitation, preemptive rights), other than restrictions on transfer under this Agreement, the Company’s Articles of Association (or, upon Closing, the Restated Articles) and under applicable securities laws and other than liens or encumbrances created by or imposed on each Investor as to itself. The offer, sale and issuance of the Purchased Shares to be issued pursuant to this Agreement constitute transactions exempted from the registration requirements of Section 15 of the Securities Act and the Israeli Securities Law, 1968, as amended. The rights, privileges and preferences of the Purchased Shares are as stated in the Restated Articles, as may be amended from time to time in accordance with its terms.

 

6

 

 

2.5 No Conflict; Consents. The execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated by the Transaction Documents do not and will not (a) result in any conflict with, or a breach or violation, with or without the passage of time and giving of notice, of any of the terms, conditions or provisions of, or give rise to rights to others (including rights of termination, cancellation or acceleration) under: (i) the Company’s Articles of Association, as in affect prior to the Closing; (ii) any judgment, injunction, order, writ, decree or ruling of any court or governmental authority, domestic or foreign, to which the Company is subject; (iii) any material contract or agreement, lease, license or commitment to which the Company is a party or by which it is bound; or (iv) any applicable law; (b) result in the creation of any lien, charge or encumbrance upon any asset of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company; or (c) require the consent, approval or authorization of, registration, qualification or filing with, or notice to any person or any federal, state, local or foreign governmental authority or regulatory authority or agency, on the part of the Company, which has not heretofore been obtained or made or will be obtained or made prior to Closing, except the filing of the Restated Articles and the other required notices specified in Sections ‎1.4 with the Israeli Registrar of Companies, each of which shall be made as soon as practicable following the Closing.

 

2.6 Directors; Officers. The directors, observers and officers of the Company are listed on Section ‎2.6 of the Disclosure Schedule. The Company has no agreement, obligation or commitment with respect to the election of any individual to its Board or to the right to nominate an observer to the Board, and, to the Company’s knowledge, there is no such agreement among the Company’s shareholders, except as stated in the Restated Articles. All agreements, commitments and understandings of the Company, whether written or oral, with respect to any compensation to be provided to any of the Company’s directors, observers or officers have been fully disclosed in writing to the Investor prior to the Closing.

 

2.7 Subsidiaries. The Company does not own or control, directly or indirectly, any interest or any other right in any other corporation, association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement.

 

2.8 Compliance with Laws and Other Instruments. The Company is, and has been, in compliance, in all material respects, with all applicable laws (including export, import and other trade compliance laws). The Company has not received any written notice of or been charged with the violation of any law and, to Company’s knowledge, there is no threatened action or proceeding against the Company under any of such laws. The Company is not in violation of or default under (i) any provisions of its Articles of Association as in affect prior to the Closing, (ii) any order, writ, injunction, decree or judgment of any court or any governmental department, commission or agency, domestic or foreign, to which it is subject or by which it is bound. The Company has obtained all franchises, permits, licenses, consents and any similar authorizations that are material to its business as currently conducted and as currently proposed to be conducted under applicable law, and is in compliance, in all material respects, with such franchises, permits, licenses, consents and similar authorizations. None of the Company’s products, intellectual property or operations is subject to any restriction or limitation or requires a license or registration under applicable laws relating to marketing, export or import controls. Without limiting the generality of the foregoing, the Company has not and is not using or developing, or otherwise engaged in, encryption technology or other technology whose development, commercialization or export is restricted, and the conduct of the business as currently conducted and as currently proposed to be conducted does not require obtaining a license from the Israeli Ministry of Defense or an authorized body thereof pursuant to Section 2(a) of the Control of Products and Services Declaration (Engagement in Encryption), 1974, or from the Israeli Ministry of Economy pursuant to the Law of Regulation of Security Exports, 2007.

 

7

 

 

2.9 Financial Statements; No Undisclosed Liabilities.

  

(a) The Company has made available to each Investor its audited financial statements for the fiscal year ended December 31, 2019, and its unaudited financial statements (including balance sheet, profit and loss and income statement and statement of cash flows, excluding notes thereto) as of June 30, 2020 (collectively, the “Financial Statements”). The Financial Statements have been prepared in accordance with the Israeli generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods indicated, except that the unaudited Financial Statements may not contain all footnotes required by GAAP. The Financial Statements fairly present in all material respects the financial condition and operating results of the Company (if applicable, on a consolidated basis), as of the dates, and for the periods, indicated therein, subject in the case of the unaudited Financial Statements to normal year-end audit adjustments that individually and in the aggregate are not material.

 

(b) The Company has no liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to December 31, 2019, which, individually and in the aggregate, do not exceed US$10,000; (ii) obligations under contracts and commitments incurred in the ordinary course of business; and (iii) liabilities and obligations listed in Section 2.9 of the Disclosure Schedule.

 

(c) The Company is not a guarantor or indemnitor of any debt or obligation of another, nor has the Company given any loan, security or otherwise agreed to become liable for any obligation of any person. No person has given any guarantee of, or security for, any obligation of the Company. The Company did not extend any loans or advances to any person, other than advances for expenses to its employees in the ordinary course of business.

 

(d) The Company maintains a standard system of accounting established and administered in accordance with GAAP.

 

2.10 Absence of Certain Changes. Since December 31, 2019, except as set out in Section 2.9 and except as set out in Section 2.10 of the Disclosure Schedule, there has not been:

 

(a) any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial Statements, except for changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect;

 

(b) any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 

(c) any waiver or compromise by the Company of a valuable right or of a debt owed to it that, in each case, is material to the assets, properties, conditions (financial or otherwise), operating results or business of the Company, as currently conducted and as currently proposed to be conducted;

 

(d) any satisfaction or discharge of any lien, claim or encumbrance, or payment of any obligation by the Company, in each case except in the ordinary course of business and the satisfaction, discharge or payment of which would not be material to the assets, properties, conditions (financial or otherwise), operating results or business of the Company, as currently conducted and as currently proposed to be conducted;

 

(e) any resignation or termination of employment of any officer or key employee of the Company;

 

(f) any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets;

 

(g) any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

 

8

 

  

(h) any declaration, setting aside, payment or other distribution in respect of any of the Company’s share capital, or any direct or indirect redemption, purchase or other acquisition of any of such share capital by the Company;

 

(i) any sale, assignment, lease of or transfer of any of the Company’s assets (whether tangible or intangible), except in the ordinary course of business;

 

(j) receipt of any notice that there has been a loss of, or material order cancellation by, any major customer of the Company;

 

(k) to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or

 

(l) any arrangement or commitment by the Company to do any of the things described in this Section 2.10.

 

2.11 Assets and Properties. The Company has good and marketable title to all of the tangible or personal properties and assets owned by the Company, which are material to the business of the Company as currently conducted and as currently proposed to be conducted, and such properties and assets are free and clear of all mortgages, deeds of trust, liens, pledges, charges, security interests, conditional sale agreement, loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the tangible property and assets it leases, the Company is in compliance in all material respects with such leases and, to its knowledge, holds a valid leasehold or license interest free of any liens, pledges, charges, security interest, claims or encumbrances, other than those of the lessors of such property or assets. The Company does not own any real property.

 

2.13 Intellectual Property. Terms used but not otherwise defined in this Section ‎2.12 shall have the meaning set forth in Section ‎(h) below.

 

(a) The Company owns or has the right to use, or can acquire on commercially reasonable terms, sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others, including without limitation the past and present employees and consultants and employers of the past and present employees and consultants of the Company, free and clear of all liens, charges, claims and restrictions. To the Company’s knowledge, no product or service marketed, sold or rendered (or proposed to be marketed, sold or rendered) by the Company violates or will violate any license or infringes or will infringe any intellectual property rights of any other person. Other than with respect to commercially available software products under standard end-user object code license agreements or agreements providing for confidentiality of information entered into in the ordinary course of business, the Company is not bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any other person. Other than non-exclusive license agreements in the Company’s standard form of license agreement, which form was provided to the Investor, and other than with respect to commercially available software products under standard end-user object code license agreements or agreements providing for confidentiality of information entered into in the ordinary course of business, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual Property. The Company is not obligated or under any liability whatsoever (contingent or otherwise) to make any payments by way of royalties, fees or otherwise to any owner or licensee of, or other claimant to, any patent, trademark, service mark, trade name, copyright or other intangible asset, with respect to the use thereof or in connection with the conduct of its business as currently conducted and as currently proposed to be conducted. The Company has not received and is not aware of any communications alleging that the Company has violated or, by conducting Company’s business, would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, mask works or other proprietary rights or processes of any other person. To the Company’s knowledge, no person has violated or is violating the Company Intellectual Property owned by the Company. The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Company’s business.

 

9

 

  

(b) Section 2.13 of the Disclosure Schedule is a complete list of all (i) patents, trademarks, service marks, trade names, copyrights, domain name, registration with respect to any of the Company Intellectual Property and any applications for and under any of the foregoing; and (ii) unregistered trademark.

 

(c) All of the Company’s employees and consultants, past and present, who were or are engaged in the development, invention, discovery, programming or design of any Company Intellectual Property, have entered into written agreements with the Company assigning to the Company all rights, title and interests in Company Intellectual Property developed, invented, programmed, designed, conceived or reduced to practice (either alone or jointly with others) in the course of their employment or engagement, as the case may be, or that relate to the Company’s business as currently conducted and as currently proposed to be conducted, and explicitly waiving all non-assignable rights (including moral rights) and rights to receive royalties or compensation in connection therewith (including, without limitation, under Section 134 of the Israeli Patent Law, 1967). Any and all Company Intellectual Property which has been, is currently being or will be developed by any employee or consultant of the Company is and shall be the sole property of the Company. The Company has taken all required security measures to protect the secrecy, confidentiality and value of all the Company Intellectual Property, which measures are reasonable and customary in the industry in which the Company operates and, to the Company’s knowledge, there has been no breach of security of the Company’s systems involving any such information. To the Company’s knowledge, it will not be necessary to use any of the developments, ideas, inventions, trade secrets, proprietary information or other intellectual property of any of its employees or consultants made prior to their employment or engagement by the Company.

 

(d) No funding or grants from, or facilities of, a governmental body or institution, university, college or other academic or educational institution or research center, or organization whose primary purpose is to create or foster the creation of Open Source Software (as defined below) (or any affiliate of any of the foregoing), was used by the Company or on its behalf, or by any of its founders prior to the incorporation of the Company, in the development of the Company Intellectual Property. Other than as set forth in Section 2.13(d) of the Disclosure Schedule, to the knowledge of the Company, no current or former employee, consultant or independent contractor of the Company, who is or was involved in, or who is contributing or contributed to the creation or development of any Company Intellectual Property is or has performed services for or otherwise is or was under restrictions resulting from his or her relations with any government, university, college or other academic or educational institution or research center, or organization whose primary purpose is to create or foster the creation of Open Source during the time such employee, consultant or independent contractor is or was so involved in, or contributing to the creation or development of any Company Intellectual Property.

 

10

 

 

(e) All of the rights, title and interests in the Company Intellectual Property that was developed, invented, programmed, designed, conceived or reduced to practice by Julien Azoulay (the “Founder”) (either alone or jointly with others) prior to, upon or with a view of the incorporation of the Company, if any (“Founder IP”) was duly, fully and irrevocably assigned by the Founder to the Company upon or in connection with the incorporation of the Company, free and clear of any liens, charges, claims and restrictions, and, to the extent already required, all declarations and documents required by the various patent offices in the countries in which the Company Intellectual Property was registered in order to register such assignments have been duly executed, submitted, approved and registered. The Founder is the sole inventor and developer of the Founder IP (including the inventions, methods and devices described and claimed in the patents which are part of such Founders IP, if any) without any contribution, assistance, participation or alleged rights of any third party. Neither the Founder nor, to the Company’s knowledge, any other person has any further interest in or rights to any of the Founder IP. During the period in which the Founder was developing the Founder IP, the Founder was not employed or engaged by any third party. The Founder is not and was never employed by, engaged with or a staff member of any governmental body or institution, university, college or other academic or educational institution or research center, or organization whose primary purpose is to create or foster the creation of Open Source Software.

 

(f) All use and distribution of the Company’s products and services and any Open Source Software by or on behalf of the Company is in compliance, in all material respects, with Open Source Software licenses applicable thereto, including without limitation all copyright notice and attribution requirements. The Company has not embedded, incorporated, bundled, linked to, used or distributed any Open Source Software in connection with any of its products or services that are available to any third party or otherwise in development in any manner that would restrict the ability of the Company to protect its proprietary interests in any such product or service or in any manner that requires, or purports to require (i) any Company’s products, services or any portion thereof, or any other Company Intellectual Property (other than the Open Source Software itself) to be disclosed or distributed in source code form or to be licensed for the purpose of making derivative works; (ii) any restriction on the consideration to be charged for the distribution of any Company’s products, services or any portion thereof, or any other Company Intellectual Property; (3) the creation of any obligation for the Company with respect to Company’s products, services or any portion thereof, or any other Company Intellectual Property, or the grant to any third party of any rights or immunities under Company Intellectual Property owned by the Company; or (4) any other limitation, restriction or condition on the right of the Company with respect to its use, distribution or rendering of any Company’s products, services or any portion thereof, or any other Company Intellectual Property.

 

(g) No source code of any of the Company’s proprietary software has been licensed (as such) or otherwise provided or disclosed to another person or entity, and the Company does not have any duty or obligation (whether present, contingent, or otherwise) to license (as such) or otherwise provide the source code for any of the Company’s proprietary software to any person.

 

(h) Definitions. The following terms used in this Agreement shall have the meanings set forth below:

 

Company Intellectual Property” means all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, trade names, copyrights, trade secrets, know-how, inventions, designs, works of authorship, computer programs and technical data, domain names, mask works, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses and rights in, to and under any of the foregoing, in any and all such cases that are owned or used by and, to the Company’s knowledge, as are necessary for the Company in the conduct of the Company’s business as currently conducted and as currently proposed to be conducted.

 

knowledge”, including the phrase “to the Company’s knowledge” (or similar phrases), when used in this Section ‎2.13 (Intellectual Property) shall mean the actual knowledge of the Company, without conducting any patent search, freedom to operate, infringement, or any similar search.

 

Open Source Software” shall mean all software or other material that is distributed as “free software”, “open source software” or under a similar licensing or distribution terms (including but not limited to the GNU General Public License (GPL), Affero GPL, GNU Lesser General Public License (LGPL), Library General Public License, Lesser General Public License, Mozilla Public License (MPL), Eclipse Public License (EPL), Common Development and Distribution License, BSD licenses, the Artistic License and the Apache License), Berkeley Software Distribution license, Open Source Initiative license, MIT, and/or Public Domain licenses, freeware type licenses or other distribution model described by the Open Source Initiative at www.opensource.org).

 

11

 

  

2.15 Data Privacy. In connection with its collection, storage, transfer (including, any transfer across national borders) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other third parties (including, information that alone or in combination with other information can be used to specifically identify a person or any financial services data collected or used by the Company) (collectively “Personal Information”), in any manner (including, through internet websites or (if applicable) mobile applications owned, maintained or operated by the Company (“Company Sites”), through any products or services provided to customers of the Company, or maintained by third parties having authorized access to such information), the Company has not yet taken any specific actions and following the Closing will conduct a thorough review of all actions required in order to ensure compliance, in all material respects, with all applicable laws in all relevant jurisdictions. No action, claim, proceeding, compliant, inquiry, audit or investigation is pending or, to the Company’s knowledge, threatened against the Company, the Founder or any of its officers, directors, or employees (in their capacity as such) by any private party or any governmental authority, foreign or domestic, with respect to Personal Information. There has been no loss, unauthorized access to or other misuse by or on behalf of the Company of such Personal Information, and, to the knowledge of the Company, no third party misused any Personal Information collected by the Company.

 

2.16 Material Agreements.

 

(a) Section 2.16(a) of the Disclosure Schedule contains a true and complete list of all material contracts, agreements, instruments, transactions, judgments, orders, writs or decrees to which the Company is a party or by which it is bound, including the following (each, a “Material Agreement”), true and correct copies of which have been made available to the Investor:

 

(i) any obligations (contingent or otherwise) of, or payments to, the Company in excess of US$ 10,000 individually or in the aggregate;

 

(ii) any license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company (other than non-exclusive licenses from the Company entered into in the ordinary course of business, or commercially available software products under standard end-user object code license agreements licensed to the Company);

 

(iii) any grant of rights to manufacture, produce or assemble the Company’s products to any other person;

 

(iv) any agreement granting any other person the right to market, distribute or resell (including as an OEM or value-added reseller) any of the Company’s technology, products or services;

 

(v) any covenants, restrictions or limitations on the Company’s right to do business (including, the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell its products or services) or compete in any area, field or geography with any person (including any exclusivity with respect to any geographic territory, any customer, or any product or service), or any agreement providing any person a right of first notification, right of first offer, right of first refusal or exclusivity in case of a sale (or offer to sell) the Company or any of its shares or assets or with respect to the provision of services or products to the Company;

 

(vi) any indemnification by the Company with respect to infringements of proprietary rights (other than non-exclusive licenses from the Company entered into in the ordinary course of business);

 

12

 

  

(vii) any joint development agreement, joint venture agreement, collaboration agreement, strategic alliance agreement or agreement involving the sharing of profits, losses, costs or liabilities with any other person;

 

(viii) any lien, charge, pledge or other encumbrance on the Company’s assets, properties or rights;

 

(ix) any agreement for the sale, exchange or other disposition of any of the assets or rights of the Company to any person, or of any person by the Company, other than the sale of inventory in the ordinary course of business;

 

(x) any agreement which is otherwise material to the Company; or

 

(xi) any proposed offer, arrangement or commitment by the Company to enter into or effect any of the foregoing agreements in this Section 2.15(a).

 

(b) The Material Agreements are valid, binding and in full force and effect, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, or (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. Neither the Company nor, to the Company’s knowledge, any other party thereto, is in breach of any Material Agreement. No party to any Material Agreement has made a written claim to the Company to the effect that the Company has failed to perform any material obligation thereunder, nor has any such party notified the Company of an intention to terminate, or not to renew, any such contract or agreement.

 

2.17 Labor Matters.

 

(a) True, correct and complete copies of all employment or consulting contracts, deferred compensation agreements, bonus, incentive, profit-sharing, deferred compensation, pension or severance plans, and other like benefits (whether on retirement, death or termination or during periods of sickness or disability), currently in force and effect for the benefit of any current or former officer, director, employee or consultant of the Company (or for the benefit of the dependents of any such person), as well as a description of any policy, practice, or custom currently in force and effect, have been made available to the Investor. The Company does not currently operate any share or equity incentive plan for the benefit of any of its officers, directors, employees or contractors, other than the Plan. Other than as required by applicable law, the Company has no agreement, policy, custom, practice, plan or program for the payment of any form of severance or other payments in connection with the termination of employment services.

 

(b) Each officer and key employee of the Company (other than directors, who are not employees of the Company) is currently devoting one hundred percent (100%) of his or her business time to the conduct of the business of the Company, and the Company is not aware of any other officer or key employee of the Company planning to work less than full-time at the Company in the near future.

 

(c) The Company has no employment agreement or engagement with any officer, employee or consultant, which is not terminable by it at will without liability, upon up to 30 days prior notice. No key employee of the Company has been dismissed or has given notice of termination of his/her employment in the last 12 months period preceding the date of this Agreement, nor to the Company’s best knowledge, do any of the officer or key employees of the Company have at present any intention to terminate his or her employment agreement.

 

13

 

 

(d) The Company has complied, in all material respects, with all applicable employment laws, policies, procedures and agreements relating to employment, and terms and conditions of employment. The Company has paid in full to all of its respective employees and consultants all wages, salaries, commissions, bonuses, benefits and other compensation due and payable to such employees or consultants on or prior to the date of this Agreement. The Company has complied in all material respects with the applicable laws relating to the proper withholding and remittance to the proper tax and other authorities of all sums required to be withheld from employees or persons deemed to be employees under applicable laws. To the Company’s knowledge, all persons classified by the Company as consultants or contractors thereof are correctly classified as such and not as employees for any purpose. All Company’s employees are subject to Section 14 Arrangement under the Israeli Severance Pay Law, 1963 from the commencement date of their employment and on the basis of their entire salary. The Company’s liability for any obligations to pay any amount of severance payment, pension, accrued vacation, and other social benefits and contributions, under applicable law or contract, or any other payment of substantially the same nature, is fully funded by deposit of funds in severance funds, pension funds, managers insurance policies or provident funds (and if not required to be so funded) adequate provisions have been made in the Company’s Financial Statements;

 

(e) To the Company’s knowledge, no employee of the Company nor any consultant with whom the Company has contracted, is in violation of any material term of any employment or engagement contract, assignment agreement, non competition agreement, restrictive covenant or any other contract or agreement, or is subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s or consultant’s ability to promote the interest of the Company or to comply with its obligations to the Company (including the obligation to assign intellectual property rights) or that would conflict with the Company’s business, and the continued employment or engagement of such employee or consultant by the Company will not result in any such material violation. The Company has not received any notice alleging that any such violation has occurred.

 

(f) The Company is not a party to, bound by or subject to, and no employee of the Company benefits from, any collective bargaining agreement, collective labor agreement, extension orders (tzavei harchava) (other than extension orders that apply to all employees in Israel generally), or other contract or arrangement with a labor union, trade union or other organization or body, to provide benefits or working conditions beyond the minimum benefits and working conditions required by applicable law. No labor union has requested or has sought to represent any of the employees, representatives or agents of the Company, nor is the Company aware of any labor organization activity involving its employees. There is no strike or other labor dispute involving the Company pending or, to the Company’s knowledge, threatened.

 

2.18 Taxes. Subject to the provisions of Section 2.18 of the Disclosure Schedule,

 

(a) The Company has duly and timely filed all tax returns and reports (including information returns and reports) as required by applicable law. Each such return or report was true and complete in all material respects when filed. None of such returns or reports has been audited by any taxing authority and the Company has not been advised that any of such returns or reports will be audited. There is no pending (or threatened by written notice delivered to the Company prior to the date hereof) dispute, examination, audit, claim or other action concerning any tax or tax return of the Company claimed or raised by any tax authority. Any and all taxes and other charges due by the Company to any local or foreign tax authorities (including, without limitation, those due in respect of the properties, income, franchises, licenses, sales or payrolls) have been timely paid. The Company has never had any tax deficiency proposed or assessed against it and has not executed any waiver of any statute of limitations on the assessment or collection of any tax or governmental charge. The Company has not incurred any taxes, assessments or governmental charges other than in the ordinary course of business. The Company has made adequate provisions on the Financial Statements and its books of account for all taxes, assessments and governmental charges with respect to its business, properties and operations for the applicable period thereof. The Company is not and have never been subject to tax in any country other than its jurisdiction of incorporation by virtue of being treated as a resident of or having a permanent establishment or other place of business in that country, and no claim has ever been made by a tax authority in a jurisdiction where the Company does not file tax returns that it is or may be subject to taxation by that jurisdiction.

 

14

 

  

(b) The Company has not made any elections pursuant to the Israeli Income Tax Ordinance [New Version], 1961 (together with the regulations promulgated thereunder, as amended, the “ITO”). The Company is not subject to any tax ruling nor has it ever applied to receive any tax determination or ruling.

 

(c) All related party transactions or agreements to which the Company is a party (including, intercompany agreements) comply with transfer pricing rules and regulations under applicable law (including, Section 85A of the ITO).

 

(d) The Plan has received a favorable determination or approval letter from, or is otherwise approved by, the Israeli Tax Authority in accordance with Section 102(b)(2) of the ITO. All options purported to be granted and shares purported to be issued under Section 102(b)(2) of the ITO were and are in compliance with the applicable requirements of Section 102(b)(2) of the ITO (and any written requirements, regulations and rules promulgated thereunder).

 

2.19 Governmental Grants. The Company has not applied, obtained or received any grant, loan, incentives, benefits (including tax benefits), subsidies or other assistance from any governmental or regulatory authority or any agency, or any international or bilateral fund, institute or organization or public entities or authorities, including, from the Investment Center of the Ministry of Economy and Industry of the State of Israel or the National Authority for Technological Innovation (previously known as the Office of the Chief Scientist of Israel’s Ministry of Economy), nor is the Company an “approved enterprise”, “benefited enterprise” or “preferred enterprise” within the meaning of the Israeli Encouragement of Capital Investments Law, 1959.

 

2.20 Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or, to the Company’s knowledge, investigation pending, or, to the Company’s knowledge, currently threatened against the Company, any of its properties, or any Founder, officer, director or employee of the Company, including, without limitation, arising out of their employment or board relationship with the Company or in their capacity as such, or that questions the validity of the Transaction Documents or the right of the Company to enter into them, or to consummate the transactions contemplated by the Transaction Documents. Neither the Company nor, to the Company’s knowledge, any of its officers, directors, consultants or employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or employees, such as would affect the Company). There is no action, suit, proceeding or investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or, to the Company’s knowledge, threatened (or any basis therefor known to the Company) involving the prior engagement of any of the Company’s employees or the Founders, their services provided in connection with the Company’s business, any information or technologies allegedly proprietary to any of their former employers or their obligations under any agreements with former employers.

 

2.21 Related-Party Transactions. Except as listed in Section 2.21 of the Disclosure Schedule, No Founder, employee, shareholder, officer, or director of the Company, nor members of their immediate family or affiliates of any of the foregoing: (i) is indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them (other than advances for employees’ expense reimbursement in the ordinary course of business); (ii) to the Company’s knowledge, has any direct or indirect interest in any contract, arrangement or proposed transaction with the Company or its affiliates which is material to the Company or its business (other than employment relations disclosed to Investor hereunder); or (iii) to the Company’s knowledge, has any direct or indirect ownership interest in any contract with the Company, or in any firm, corporation or business with which the Company is affiliated or with which the Company has a business relationship, or that competes with the Company, except for passive ownership of less than one percent (1%) of the issued and outstanding share capital of any such publicly traded company.

 

15

 

  

2.22 Corporate Books. The Articles of Association of the Company as in effect immediately prior to the Closing are in the form provided to Investor. The Company has provided to the Investor accurate and complete copies of the minutes of all meetings, or written consents in lieu thereof, of directors (and any committee thereof) and shareholders since its incorporation, reflecting, in all material respects, resolutions passed, enacted, consented to or adopted thereby. The corporate records of the Company have been maintained, in all material respects, in accordance with all applicable statutory requirements and are complete and accurate in all material respects.

 

2.23 Insurance. The Company has no insurance policies, and intends to obtain required insurance policies which are reasonably sufficient in amount (subject to reasonable deductions) following the Closing to allow it to replace any of its properties that might be damaged or destroyed and to insure the risks associated with its business and affairs.

 

2.24 No Corrupt Practices. Neither the Company nor any officer, director, employee or agent purporting to act on its behalf has, directly or indirectly: (i) made, offered to make, provided or paid any unlawful contributions, gifts, entertainment or other unlawful expenses to any local or foreign official, political party or official thereof or candidate for political office, or failed to disclose fully any such contributions in violation of any applicable laws; (ii) made, or offered to make, any payment to any local, state, federal or any other type of governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments required or allowed by applicable laws (including, without limitation, the United States Foreign Corrupt Practices Act of 1977, as amended); (iii) made, or offered to make, any payment to any agent, employee, officer or director of any entity with which the Company does business for the purpose of influencing such agent, employee, officer or director to do business with the Company; (iv) engaged in any transactions, maintained any bank account or used any corporate funds, except for transactions, bank accounts and funds which have been and are reflected in the normally maintained books and records of the Company; or (v) made, or offered to make, any payment in the nature of criminal bribery or any other payment in violation of any applicable law. Neither the Company, nor, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to any anti-corruption laws.

 

2.25 Brokers and Finders. The Company has no contract, arrangement or understanding with any broker, finder or similar agent with respect to the transactions contemplated by this Agreement. No commission or compensation in the nature of a finders’ fee shall be payable by the Company or any of its officers, employees or representatives, in their capacities as such, in connection with the transactions contemplated by this Agreement.

 

2.26 Disclosure. No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Investor at the Closing contains any untrue statement of a material fact or, to the Company’s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made.

 

16

 

 

3. REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.

 

The Investor hereby represents and warrants, with respect to itself only, that the following representations are true, correct and complete as of the date hereof and as of the Closing (as if made on the Closing Date); except, in each case, as to such representations and warranties that address matters as of a particular date, which are given only as of such date:

   

3.1 Authorization; Organization. The Investor is duly organized, validly existing and, if applicable, in good standing under the laws of the jurisdiction in which it has been incorporated and has full power and authority to enter into the Transaction Documents. The Transaction Documents to which the Investor is a party, when executed and delivered by the Investor, and assuming the due authorization, execution and delivery by the other parties hereto and thereto, constitute valid and binding obligations of the Investor, enforceable against the Investor in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

 

3.2 No Conflict; Consents. The execution, delivery and performance by the Investor of the Transaction Documents to which it is a party and the consummation of the transactions contemplated by such Transaction Documents do not and will not (a) result in any conflict with, or a breach or violation, with or without the passage of time and giving of notice, of any of the terms, conditions or provisions of, or give rise to rights to others (including rights of termination, cancellation or acceleration) under: (i) the governing documents of the Investor; (ii) any judgment, injunction, order, writ, decree or ruling of any court or governmental authority, domestic or foreign, to which the Investor is subject; (iii) any material contract or agreement, lease, license or commitment to which the Investor is a party or by which it is bound; (iv) any applicable law; or (b) require the consent, approval or authorization of, registration, qualification or filing with, or notice to any person or any federal, state, local or foreign governmental authority or regulatory authority or agency, on the part of the Investor, which has not heretofore been obtained or made or will be obtained or made prior to Closing.

 

3.3 Purchase Entirely for Own Account. The Purchased Shares will be acquired for investment for the Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor does not presently have any contract, undertaking, agreement or arrangement to sell, transfer or grant participation rights to any person with respect to any of the Purchased Shares. The Investor has not been formed for the specific purpose of acquiring the Purchased Shares.

 

3.4 Disclosure of Information. The Investor has had an opportunity to discuss the Company’s business, operations, properties, prospects, technology, plans, management, financial affairs and the terms and conditions of the offering of the Purchased Shares with the Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however, does not limit, modify or qualify the representations and warranties of the Company in Section ‎2 of this Agreement or the right of the Investor to rely thereon. The Investor acknowledges that any projections provided (if any) by the Company are uncertain in nature, and that some or all of the assumptions underlying such projections may not materialize or will vary significantly from actual results.

 

3.5 Investment Experience; Accredited Investor; Non-U.S. Person. The Investor is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating and understanding the merits and risks of the investment in the Purchased Shares.

 

3.6 Restricted Securities. The Purchased Shares have not been and will not be registered under the Securities Act or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available. Investor is aware that the Company is under no obligation to effect any such registration or to file for or comply with any exemption from registration. The sale and issuance of the Purchased Shares have not been registered under the Securities Act by reason of a specific exemption from registration which depends upon, among other things, the accuracy of the Investor’s representations as expressed herein.

 

17

 

  

4. CONDITIONS OF INVESTOR’S OBLIGATIONS AT CLOSING.

 

The obligations of the Investor to purchase the Purchased Shares at the Closing are subject to the fulfillment on or before the Closing of each of the following conditions, unless otherwise waived in writing by the Investor:

 

4.1 Representations and Warranties. The representations and warranties of the contained in Section ‎2 shall have been true in all respects on and as if made as of the Closing.

 

4.2 Performance. The Company shall have performed and complied, in all respects, with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing.

 

4.3 Delivery of Documents. All of the documents to be delivered by the Company pursuant to Section ‎1.6, shall have been in a form as attached to this Agreement, or, if not attached, in a form and substance satisfactory to the Investor and shall have been delivered to the Investor.

 

4.4 Receipt of Consents. The Company shall have been obtained at or prior to the Closing Date all consents required to consummate the transactions herein.

 

4.5 Absence of Adverse Changes. There shall not have occurred any event, change, effect, condition or circumstance that, when taken individually or together with any other events, changes, effects, conditions or circumstances, is or is reasonably likely to be adverse to the business, assets, properties, operations, results of operations or financial condition of the Company.

 

4.6 Restated Articles. The Restated Articles shall have been duly adopted.

 

4.7 Option Pool. The ESOP Pool shall have been duly reserved prior to the Closing.

 

5. CONDITIONS OF THE COMPANY’S OBLIGATIONS AT CLOSING.

 

The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, unless otherwise waived in writing by the Company:

 

5.1 Representations and Warranties. The representations and warranties contained in Section ‎4 shall have been true in all respects on and as if made as of the Closing.

 

5.2 Payment of Purchase Price. The Investor shall have delivered to the Company the Investor’s respective portion of the Purchase Price for the Purchased Shares issued to the Investor at the Closing.

 

6. AFFIRMATIVE COVENANTS BY THE COMPANY.

 

6.1 Use of Proceeds. The Company will use the Purchase Price for general working capital purposes substantially in accordance with the Budget, attached hereto as Exhibit E, as may be amended from time to time by the Board.

 

6.2 Directors and Officers Insurance. Within thirty (30) days from the Closing, the Company shall purchase a directors and officers liability insurance policy in an amount of at least US$2,500,000 and upon other terms acceptable to the Investor.

 

18

 

 

6.3 Additional Engagements. Within thirty (30) days from the Closing, the Company shall conclude and enter into the following agreements:

   

(a) The Company and a company held by Eli Uzan and others (the “Management Company”) shall enter into a management services agreement, pursuant to which the Management Company will provide management services in consideration for a monthly fee of NIS 50,000 plus VAT (the “Consideration”) (the “Services Agreement”). In the event that the Company will terminate the Services Agreement at any time prior to the end of 3 (three) years from Closing (the “Minimum Term”), then, (i) if at that time the Company shall have met its Budgetary Objective (as defined below) for such moment in time, then, it will pay to the Management Company an amount of money equal to the Consideration due during a period of 3 years, and (ii) if at that time the Company shall not have met its Budgetary Objective for such moment in time, then, it will pay to the Management Company an amount of money equal to the Consideration due during a period of 1 (one) year. The “Budgetary Objective” shall be a 10% or more increase in the EBITDA compared to the former year, starting on 2021.

 

(b) The Company and Screenz Cross Media Ltd. Shall enter into a commercial agreement, based on the principles set out in Schedule 6.3(b).

 

6.4 Filing with the Israeli Registrar of Companies. As soon as possible following the Closing, and in any event no later than 14 days following the Closing, the Company shall file all required notices set forth in Section ‎1.6(a)(vii) with the Israeli Registrar of Companies, including, to the extent required, a translation of the Restated Articles into Hebrew certificated by an officer of the Company as required by the Companies Law and any regulations promulgated thereunder.

 

6.5 Accounting. The accountants and auditors of the Company shall be any firm selected by the Investor, in its sole discretion. The Company will maintain at its main office a system of accounting established and administered in accordance with GAAP consistently applied, which true records and books of account will be made of all dealings or transactions relating to the affairs of the Company. To the extent that as a result of the requirements under this Section 6.5, the Company incurs expenses that are greater than US$ 30,000 (the “Additional Expenses”), at the end of each fiscal year, and subject to the provision by the Company of credible evidence and calculations, the Investor shall reimburse the Company for such Additional Expenses.

 

7. INDEMNIFICATION.

 

7.1 Effectiveness; Survival.

 

(a) The Investor has the right to fully rely upon all representations, warranties and covenants of the Company (as applicable, severally and not jointly, the “Indemnitor”) contained in or made pursuant to this Agreement and in the schedules attached hereto. Unless otherwise set forth in this Agreement, the representations and warranties of the Company contained in or made pursuant to this Agreement shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Investor.

 

(b) The representations and warranties of the Company contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing until the earlier of: (1) in case of Section 2.13 (Intellectual Property), until the 36th months anniversary of the Closing Date; (2) in case of Sections 2.1 (Organization), ‎‎2.2 (Capitalization), 2.3 (Authorization), 2.4 (Valid Issuance of Shares) and 2.5 (No Conflict; Consents) (the representations and warranties referred to in this clause (2), collectively, the “Fundamental Representations”), until the expiration of the applicable statute of limitation period; and (3) other than as set forth in clause (1) and (2) above, the 24th months anniversary of the Closing Date; in each case, with respect to any theretofore un-asserted claims as set forth in clause (c) below;

 

provided, however, that no limitation shall apply to breach of any representation or warranty which constitutes fraud or willful misrepresentation by the Company (“Fraud”). The applicable survival period shall be referred to, as applicable, as the “Claims Period”.

 

19

 

  

(c) Except for Fraud, the Company shall not have any liability with respect to any breach of representation and warranty, unless a claim is made hereunder prior to the expiration of the Claims Period for such representation and warranty, in which case such representation and warranty shall survive as to that claim until the claim has been finally resolved.

 

(d) It is the intention of the parties hereto that the Claims Periods supersede any statute of limitations applicable to the representations and warranties, and this Section 7.1 constitutes a separate written legally binding agreement among the parties hereto in accordance with the provisions of Section 19 of the Israeli Limitation Law, 1958.

 

7.2 Indemnification.

 

(a) Indemnifiable Losses. The Indemnitor shall indemnify the Investor (including its directors and officers) (each, an “Indemnitee”) against, and hold each Indemnitee harmless from all claims, actions, suits, settlements, damages, expenses (including, reasonable legal costs and expenses), losses, or costs sustained or incurred by such Indemnitees (collectively, “Losses”) resulting from, or arising out of, a breach or misrepresentations of any the Indemnitor’s representations, warranties or covenants made in this Agreement, subject to the limitations in this Section 7.

 

(b) Limitations. The Indemnitee’s right for indemnification hereunder is subject to the following conditions and limitations, notwithstanding anything to the contrary in this Agreement, but in to any other limitation or condition contained herein; provided, however, no limitation shall apply to Fraud:

 

(i) The Indemnitor’s liability shall be limited to direct damages only of the Indemnitees.

 

(ii) Other than in respect of the Fundamental Representations, no Indemnitor shall be liable for any Loss, unless and until the aggregate of Losses equal or exceeds US$20,000, in which case indemnification shall be made from the first dollar amount.

 

(iii) The Indemnitor’s liability shall be limited with respect to the Investor to the sum of the Purchase Price.

 

(c) Claims Notice; Third Party Claims. In the event that an Indemnitee wishes to assert a claim for indemnification hereunder it shall give the Indemnitor a prompt written notice thereof (a “Claims Notice”), which shall describe in reasonable detail the facts and circumstances upon which the asserted claim for indemnification is based and thereafter keep the Indemnitor informed, in all material respects, with respect thereto. In the event that such Claims Notice results from a third party claim against the Indemnitee, such Indemnitee shall promptly upon becoming aware of the commencement of proceedings by such third party provide the Indemnitor with the Claims Notice and the Indemnitor shall have the right to assume the defense thereof (at Indemnitor’s expense) with counsel mutually satisfactory to the parties; provided, however, that the Indemnitees shall have the right to retain their own counsel, at the reasonable expense of the Indemnitor, and within the indemnification limitations herein, if representation of all parties by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the parties in such proceeding. Failure of the Indemnitees to give prompt notice or to keep it informed, as provided herein, shall not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is actually and materially prejudiced by such failure. The Indemnitor shall not be liable nor shall it be required to indemnify or hold harmless the Indemnitee in connection with any settlement effected without its consent in writing, which shall not be unreasonably withheld or delayed.

 

20

 

  

(d) Notwithstanding the forgoing, in the event that as a result of a breach by the Company of any of the representations and warranties set forth in Sections 2.2 or 2.4 above, in a manner that the percentage holdings of the Investors in the Company as of immediately after the Closing shall be lower than the percentage they would have been entitled to pursuant to this Agreement had such breach not occurred (i.e. to the extent that as a result of a breach of the representations and warranties set forth in Sections 2.2 or 2.4 the Company is obligated to issue additional shares or convertible securities) (a “Dilution”), then, in lieu of the indemnification pursuant to Section 7, the Investors shall be issued by the Company additional Ordinary Shares for no additional consideration, in such amount that following the issuance thereof, each Investor’s percentage ownership in the Company, on a Fully Diluted Basis, shall be equal to its percentage ownership immediately prior to such Dilution.

 

(e) Notwithstanding the forgoing, the Investor may elect, in its sole discretion, in lieu of the indemnification pursuant to Section 7, to receive such additional number of Ordinary Shares, for no additional consideration, as is determined by dividing the amount of Losses by the Fair Market Value (as defined and to be determined as set forth below).

 

The “Fair Market Value” of one Ordinary Share at the time of payment shall be determined by Investor and the Company (by decision of the directors of the Company excluding the Medigus Directors); provided, however, that if the Investor and the Company cannot agree on the fair market value of the Ordinary Shares, the fair market value shall be determined by calculating the average ratio of the market cap to EBIDTA (as published on the then most-recent annual audited financial statements) of two public companies in the industry of the Company (which, unless otherwise mutually agreed by Investor and the Company, shall be Live Nation Worldwide, Inc. and CTS Eventim AG) and multiplying such ration by the Company’s EBIDTA (as published on the then most-recent annual audited financial statements of the Company).

 

(f) Sole Remedy. The indemnification provided by the Indemnitor hereunder and the enforcement of such indemnification shall be the exclusive remedy available to the Indemnitees under this Agreement, other than for Fraud; provided that this provision does not limit the right to seek specific performance, a restraining order or injunctive relief with respect to any provision of this Agreement.

 

8. MISCELLANEOUS.

 

8.1 Further Assurances. Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.

 

8.2 Entire Agreement. This Agreement (including the exhibits and schedules hereto), the Restated Articles and the other Transaction Documents constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and supersede all prior agreements and understandings, both written and oral, among any of the parties hereto, with respect to the subject matter hereof (with no concession being made as to the existence of any such prior agreements or understandings).

 

8.3 Amendment; Waiver. Except as explicitly set forth herein, any term of this Agreement may be amended only with the written consent of the Company, and the Investor. The observance of any term hereof may be waived (either prospectively or retroactively and either generally or in a particular instance) only by the prior written consent of the party against which enforcement of such waiver shall be sought. Any amendment or waiver effected in accordance with this Section 8.3 shall be binding upon the Investor and the Company.

 

21

 

 

8.4 Assignment; Successors and Assigns. None of the rights, privileges or obligations set forth in, arising under, or created by this Agreement may be assigned or transferred by the Investor, without the prior written consent of the Company; except that no such consent shall be required after the Closing in case of an assignment of this Agreement along with the transfer of Purchased Shares from the Investor to the Investor’s Permitted Transferee (as is defined in the Restated Articles) and the assumption in writing by such Permitted Transferee of the representations, warranties, covenants and obligations arising under this Agreement, as the Investor hereunder. In such case, the Investor and the Permitted Transferee shall deliver to the Company a notice, in a form reasonably acceptable to the Company, notifying and representing to the Company the foregoing. The Company shall be permitted to assign this Agreement or any and all of its rights, privileges or obligations set forth in, arising under, or created by this Agreement to its successors and assigns (including to a purchaser, successor or assignor of all or substantially all of its assets) after the Closing, subject to the assumption by such successors and assigns of this Agreement or any and all of its rights, privileges or obligations hereunder. Subject to the foregoing, the terms and conditions of this Agreement shall inure to the benefit of, and be binding upon, the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.5 Governing Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with to the laws of the State of Israel, disregarding its conflict of laws rules. Any dispute arising under or in relation to this Agreement shall be resolved exclusively in the competent court located in Tel Aviv-Jaffa, Israel and each of the parties hereby irrevocably submits to the exclusive jurisdiction of such court. Each of the parties hereto (i) consents to submit itself to the exclusive jurisdiction of the abovementioned courts in the event any dispute arises out of this Agreement or the transactions contemplated by this Agreement, (ii) agrees that it shall not attempt to deny or defeat such jurisdiction by motion or other request for leave from the abovementioned court, (iii) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated by this Agreement in any court other than the abovementioned court, and (iv) irrevocably consents to service of process in the manner provided by Section 8.6 or as otherwise provided by applicable law.

 

8.6 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt, or (i) when delivered, if sent by personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail or facsimile (with electronic conformation of delivery) on a business day and during normal business hours of the recipient, and otherwise on the first business day in the place of recipient, (iii) five (5) business days after having been sent, if sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) business day after deposit with an internationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written confirmation of receipt. All communications shall be sent to the respective parties at their address or contact details as set forth below, or to such address or contact details as subsequently modified by written notice given in accordance with this Section 8.6, or, in the case of the Investor, as used for purposes of sending shareholders’ notices by the Company.

 

If to the Company: Eventer Technologies Ltd.
  Attention: Eli Uzan, Director
  Telephone: 054-314-4558
  E-mail: eli@scrnz.com
   
If to the Investor: as set forth on Exhibit A

 

8.7 Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and not alternative.

 

22

 

  

8.8 Interpretation. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. Unless the context requires otherwise, the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety, and not to any particular provision hereof, and all references herein to Sections shall be construed to refer to Sections to this Agreement. Reference to “governmental authorities” (or similar terms) shall include any: (a) nation, principality, state, commonwealth, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign or other government, (c) governmental, quasi-governmental or regulatory body of any nature, including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, organization, unit, or body, or (d) court, public or private arbitrator or other public tribunal. Reference to a “person” shall mean any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, estate, unincorporated organization, governmental authority or other entity, including, any party to this Agreement. Any reference to a “day” or a number of days (without explicit reference to “business days”) shall be interpreted as a reference to a calendar day or number of calendar days, and if any action is to be taken or given on or by a particular calendar day, and such calendar day is not a business day, then such action may be deferred until the first business day thereafter (where “business day” shall mean any day on which banking institutions in Tel-Aviv-Jaffa, Israel are generally open to the public for conducting business and are not required by law to close). For the purposes of this Agreement, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same person, or such person and its affiliates (including persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts indicated herein.

 

8.9 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be enforceable in accordance with its terms and interpreted so as to give effect, to the fullest extent consistent with and permitted by applicable law, to the meaning and intention of the excluded provision.

 

8.10 Counterparts. This Agreement and any Transaction Document may be executed in one or more counterparts, all of which together shall constitute one and the same instrument, binding and enforceable against the parties so executing the same; it being understood that all parties need not sign the same counterpart. Counterparts may also be delivered by facsimile or email transmission (in pdf format or the like, or signed with docusign, e-sign or any similar form of signature by electronic means) and any counterpart so delivered shall be sufficient to bind the parties to this Agreement or any other Transaction Document, as an original.

 

- Signature Pages Follow -

 

23

 

 

IN WITNESS WHEREOF, the parties have executed this SHARE PURCHASE AGREEMENT to be executed as of the date first written above.

  

COMPANY:

 

  Eventer Technologies Ltd.
     
  By: /s/ Eli Uzan
  Name: Eli Uzan
  Title: Chairman

  

  By: /s/ Julien Azoulay
  Name: Julien Azoulay
  Title: Chief Executive Officer

    

 

 

  

IN WITNESS WHEREOF, the parties have executed this SHARE PURCHASE AGREEMENT as of the date first written above.

 

INVESTOR:

 

  Medigus Ltd.
   
  By: /s/ Eli Yoresh
  Name: Eli Yoresh
  Title: Chairman

 

  By: /s/ Liron Carmel
  Name: Liron Carmel
  Title: Chief Executive Officer

   

 

 

  

Exhibit A

 

Investor and Purchased Shares at the Closing

 

Name of Investor   Contact Details   Investment Amount     Purchased Shares  
Medigus Ltd.  

Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel

Attention: Liron Carmel

Telephone: +972-72-260-2200

Email: liron.carmel@medigus.com

 

With a mandatory copy (which shall not

constitute notice) to:

Meitar Law Offices

Attention: Dr. Shachar Hadar, Adv.

Telephone: 03-610-3961

Facsimile: 03-610-3111

Email: shacharh@meitar.com

  US$ 750,000       325,270  

 

 

 

  

Exhibit B

 

Capitalization Table

 

[***]

 

 

 

  

Exhibit C

 

Restated Articles

 

[***]

 

 

 

  

Exhibit D

 

Share Exchange Option Agreement

 

[***]

 

 

 

  

Schedule 1.1

 

Adjustment

 

[***]

 

 

 

 

Schedule 1.4

 

Milestone Conditions

 

[***]

 

 

 

 

Schedule 1.5(a)(i)

 

Board Action

 

[***]

 

 

 

 

Schedule1.5(a)(ii)

 

Shareholders Action

 

[***]

 

 

 

 

Schedule 1.5(a)(v)

 

Share Certificate Form

 

[***]

 

 

 

 

Schedule 1.5(a)(vi)

 

Shareholders Register

 

[***]

 

 

 

 

Schedule 1.5(a)(vii)

 

Registrar of Companies Notices

 

[***]

 

 

 

 

Schedule 1.5(a)(xi)

 

Indemnification Agreement

 

[***]

 

 

 

 

Schedule 1.5(a)(xi)

 

Information Rights Agreement

 

[***]

 

 

 

 

Schedule 1.5(a)(xii)

 

Officer’s Certificate

 

[***]

 

 

 

 

Schedule 1.5(a)(xiii)

 

Revolving Promissory Note

 

[***]

 

 

 

  

Schedule 6.3(b)

 

Principles of Engagement with Screenz Cross Media

 

[***]

 

 

 

 

Exhibit 10.6

 

REVOLVING LOAN AGREEMENT

 

THIS REVOLVING LOAN AGREEMENT (this “Agreement”) is made as of October 14, 2020 (the “Effective Date”), by and between Medigus Ltd. an entity organized and existing under the laws of Israel (“Creditor”), and Eventer Technologies Ltd., an entity organized and existing under the laws of Israel (“Debtor”).

 

1. THE LOAN.

 

1.1 THE ADVANCES.

 

(a) COMMITMENT. From time to time, subject to the conditions in subparagraph 1.1(b) and 1.1(d) hereof, Creditor agrees to lend to Debtor hereunder, in one or more borrowings (an “Advance” or “Advances”), such sums not to exceed at any one time outstanding One Million and Two Hundred and Fifty Thousand USD ($1,250,000.00) (“Commitment”). Subject to the provisions of this Agreement, each Advance may be repaid and reborrowed in part or in full at any time and from time to time hereunder. Creditor may, in its sole discretion, decline to make any Advance only if there is been, or with the passage of time or notice, or both, there would be, an Event of Default (as defined in Section 4 hereof) which is then continuing.

 

(b) NOTICE PERIOD. The disbursement of each Advance shall be made upon written notice received by Creditor (in the form or information similar to the attached as Exhibit 1) (each, an “Advance Notice”), not later than seven Business Days prior to the date of an Advance specifying the date of disbursement (which date shall be a Business Day) and the amount of the Advance. The Creditor may decide, in its sole discretion, if to make the Advance in USD or NIS. “Business Day” means any day other than a Saturday or other day on which pertinent commercial banks are authorized or required by law to close in Israel. Notwithstanding the foregoing, on the Effective Date, and without the Advance Notice Requirement (but subject to subparagraph 1.1(d)), the Creditor shall disburse to the Debtor an amount equal to Two Hundred and Fifty Thousand USD ($250,000) (the “Initial Advance”).

 

(c) NOTICE CONFIRMATION. Notwithstanding anything to the contrary in this Agreement, all notices to be given by Debtor hereunder shall be in writing pursuant to Section 4.1 hereof or by telephone. Each telephonic notice shall be confirmed immediately in writing by Debtor. If there is any discrepancy between the telephonic notice accepted by Creditor and the written confirmation, the terms of the written notice shall be conclusive and binding.

 

(d) PURPOSE. The Debtor will use the Initial Advances for research and development, growth and expansion purposes, and all other Advances for ongoing operations and activities, as also detailed a plan approved by the Creditor, upon signing of this Agreement (the “Business Plan”). Creditor’s approval shall be required for each Advance. Such Business Plan may be amended and updated from time to time by the Board of Directors of the Debtor (including the Medgius Directors (as defined in the Company’s Amended and Restated Articles of Association).

 

 

 

 

1.2 MATURITY. The repayment of each Advance shall be as follows: (a) with respect to each Advance (except for the Initial Advance), immediately (and in no event more than 30 days) following the completion of the project for which purpose the Advance was made (it being clarified that if the Advance was made in connection with a certain performance or event, then the date of such performance or event shall be deemed the completion date), and (b) with respect to the Initial, commencing on the 1st anniversary of the payment date of such Advance, the Creditor shall repay the applicable Advance (and all accrued interest) in twenty four (24) equal monthly installments. The date by which all repayments with respect to a certain Advance shall be made, shall be referred to as the “Maturity Date”.

 

1.3 INTEREST ON ADVANCES. Outstanding principal balances on the Advances shall bear interest at a rate equal to the higher of: (i) of 4% (for percent) per annum, or (ii) the interest rate determined by the Israeli Income Tax Ordinance [New Version] 5721-1961, and the rules and regulations promulgated thereunder. Interest shall accrue on each Advance from the date such Advance is made until such Advance and all accrued and unpaid interest relating to such Advance is repaid. Interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed.

 

1.4 PAYMENT OF INTEREST. Interest shall be payable monthly in accordance with the above Section 1.2. All payments with respect to the Advances received on the interest due date shall be applied first to the payment of interest and all charges or expenses payable by Debtor to Creditor hereunder (in such order as Creditor may determine) and the balance, if any, to principal. All full or partial repayments of Advances, not including the interest payments referred to in this Section 1.4, shall be governed by the terms of Section 1.6 hereof. Taxes shall be withheld from any payment of interest under this Agreement to the extent required under any applicable law (including any applicable tax treaty) and in such case interest payment shall be reduced by such taxes.

 

1.5 DEFAULT INTEREST. During the continuation of an Event of Default, upon notice by the Creditor to the Debtor, the interest rate shall be 2% per annum plus the rate set forth in Section 1.3 hereof.

 

1.6 VOLUNTARY REPAYMENT. Debtor may repay any Advance from time to time, without premium or penalty. Creditor in its sole discretion shall determine how and in what proportions to apply amounts prepaid against the principal and/or accrued interest of each Advance.

 

1.7 FORM OF PAYMENT. All payments of principal and interest payable to Creditor shall be made in the currency of the Commitment (as set forth in Section 1.1.1 hereof) in immediately available funds, without setoff or counterclaim.

 

1.8 LEGALITY. Creditor shall not be required to make any Advance unless the making of such Advance shall not subject Creditor to any penalty or special tax, shall not be prohibited by any law or governmental order or regulation applicable to Creditor or to Debtor or its subsidiaries, and all necessary consents, approvals and authorizations of any person for any such Advance shall have been obtained. Creditor and Debtor agree to use reasonable efforts to obtain such consents, approvals and authorizations, if available.

 

2

 

 

2. FUNDING AND TERMINATION.

 

2.1 CLOSING DELIVERABLES. Upon signing of this Agreement the following shall have been met:

 

(a) EXECUTED COUNTERPARTS. The parties hereto shall have exchanged executed counterparts of this Agreement.

 

(b) CORPORATE AUTHORIZATION. The execution, delivery and performance by the parties of this Agreement have been duly authorized by all required corporate or other action.

 

(c) BUSINESS PLAN. The receipt of a Business Plan satisfactory to the Creditor.

 

2.2 TERMINATION.

 

This Agreement shall terminate on the third anniversary of the Effective Date; provided, however, that any Advances then outstanding shall remain outstanding and subject to the provisions of this Agreement until the end of their respective Maturity Dates. Notwithstanding the aforesaid, this Agreement may continue in full force and effect either at the sole discretion of Creditor, or if requested by Debtor, with consent by Creditor.

 

3. NO RIGHT OF SET-OFF. Except as otherwise agreed between Creditor and Debtor, Creditor is not authorized to and shall not set off or apply any amounts at any time held by Creditor and owing to Debtor, or any other indebtedness at any time owing by Creditor to Debtor, against any Advance or any of Debtor's other obligations hereunder.

 

4. EVENTS OF DEFAULT. The occurrence of any of the following events (“Events of Default”) shall terminate any obligation on the part of Creditor to make any Advance or to continue any Advance and, at the option of Creditor, shall make all sums of interest and principal remaining on any Advance immediately due and payable, without notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor, or other notices or demands of any kind or character.

 

4.1 OVERDUE PRINCIPAL. Debtor shall fail to pay any principal amount of any Advance when due in accordance with the terms hereof and not rectify such failure within 30 days from Creditor's written demand.

 

4.2 OVERDUE INSTALLMENTS OF INTEREST. Debtor shall fail to pay within 10 Business Days when due any installment of interest in accordance with the terms hereof, and not rectify such failure within 30 days from Creditor's written demand.

 

4.3 INSOLVENCY. (a) Debtor becomes insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due or files a petition to take advantage of any applicable bankruptcy, insolvency or reorganization statute or similar law of any jurisdiction now or hereafter in effect; (b) Debtor makes a general assignment for the benefit of creditors or applies for or consents to the appointment of a trustee, interim trustee, custodian, administrator, conservator, receiver or liquidator in any bankruptcy, reorganization, arrangement, insolvency, readjustment of debt, marshalling of assets and liabilities or similar proceedings of or relating to Debtor, as the case may be, or of or relating to a substantial portion of the property of, Debtor or for the winding up, dissolution or liquidation of Debtor; (c) such a receiver, trustee, interim trustee, custodian, administrator, conservator, receiver or liquidator otherwise shall be appointed and shall not be discharged within 45 days after such appointment; or (d) if any order for relief under any applicable bankruptcy law shall be entered in any proceeding by or against Debtor.

 

4.4 DILUTION OF CREDITOR'S HOLDINGS. Creditor ceases to hold over 25% of the voting rights of the Debtor.

 

3

 

 

5. CREDITOR RIGHTS. Upon the occurrence of an Event of Default, Creditor may avail itself of any legal or equitable rights that Creditor may have at law or in equity or under this Agreement. The remedies of Creditor as provided herein shall be distinct and cumulative, and may be pursued singly, successively or together, at the sole discretion of Creditor, and may be exercised as often as occasion therefor shall arise. Failure to exercise any of the foregoing options upon the occurrence of an Event of Default shall not constitute a waiver of the right to exercise the same or any other option at any subsequent time in respect to the same or any other Event of Default, and no single or partial exercise of any right or remedy shall preclude other or further exercise of the same or any other right or remedy.

 

6. SECURITY. This Agreement is secured by a Floating Charge Agreement (as amended from time to time, the “Floating Charge Agreement”) between Creditor and Debtor, of even date herewith.

 

7. DEFAULT PAYMENT. With respect to each Advance, the Debtor may, at its sole discretion, on the Maturity Date of such Advance, convert any unpaid portion of the Advance to Ordinary Shares of the Company, calculated in accordance with the formula set forth in Section 7.2(e) of that Share Purchase Agreement by and between the Creditor and the Debtor dated as of an even-date.

 

8. MISCELLANEOUS

 

8.1 CONFIDENTIALITY. Save as required for under applicable law, each Party hereby undertakes to the other Party to maintain the existence of this Agreement and its content in confidence, and not disclose or convey its content or existence to any person and/or entity whatsoever, other than as is reasonably required for the purpose of carrying out its obligations hereunder, without the prior written consent of the other Party.

 

8.2 NOTICES. Any communications between the parties hereto or notices provided herein to be given may be given by personal delivery or mailing the same, postage prepaid, to Creditor at Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel and to Debtor at Bezalel 4, Ramat Gan; or to such other address as either party may in writing hereafter indicate. Notices shall be deemed effective on the date received.

 

8.3 INFORMATION RIGHTS.

 

(a) Initial Documentation. Debtor has provided to Creditor written documentation and information regarding Debtor's financial position, specifically including all information pursuant to that certain Share Purchase Agreement dated as of October 14, 2020, entered into by and between Debtor and Creditor, and Creditor is aware of and familiar with Debtor's current state of affairs and financial position.

 

(b) Ongoing Rights. Creditor may from time to time reasonably request information regarding the business, financial or corporate affairs of Debtor. In the event of such a request, Debtor shall deliver to Creditor promptly any such information requested.

 

8.4 ASSIGNMENT. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and assigns. Creditor may assign its rights under this Agreement (but not its obligations) without the consent of Debtor. Debtor shall not assign this Agreement or any of the rights, duties or obligations of Debtor hereunder without the prior written consent of Creditor.

 

4

 

 

8.5 WAIVERS. No delay or omission to exercise any right, power or remedy accruing to Creditor upon any breach or default of Debtor under this Agreement shall impair any such right, power or remedy of Creditor, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.

 

8.6 SEVERABILITY. The illegality or unenforceability of any provision of this Agreement shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement.

 

8.7 GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Israel, disregarding its conflict of laws rules.

 

8.8 SEPARATE COUNTERPART; AMENDMENTS. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may be amended only by an instrument in writing duly signed by all parties hereto.

 

8.9 ENTIRE AGREEMENT. This agreement supersedes any previous agreement between the parties in relation to the matters dealt with herein and represents the entire understanding between the parties with respect to such matters.

 

[The remainder of this page is intentionally left blank]

 

5

 

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

  MEDIGUS LTD.
   
  By: /s/ Eli Yoresh
  Name:   Eli Yoresh
  Title: Chairman
   
  By: /s/ Liron Carmel
  Name: Liron Carmel
  Title: Chief Executive Officer
   
  EVENTER TECHNOLOGIES LTD.
   
  By: /s/ Eli Uzan
  Name: Eli Uzan
  Title: Chairman
   
  By: /s/ Julien Azoulay
  Name: Julien Azoulay
  Title: Chief Executive Officer

 

6

 

 

Exhibit 1

 

NOTICE OF ADVANCE

 

Under the terms of the Revolving Loan Agreement effective as of [ ] , Debtor hereby requests the following Advance:

 

Sum requested: ___________

 

Date of request: __________

 

Sums previously advanced and outstanding : __________

 

Accrued interest to date of request: _____________

 

Total loan facility utilized after this request: ___________

 

Debtor hereby confirms that none of the events specified in section 4 of the Revolving Loan Agreement (“Events Of Default”) have occurred.

 

  EVENTOR TECHNOLOGIES LTD.
   
  By:  
  Name:                       
  Title:  

 

 

7

 

 

Exhibit 10.7

 

SHARE EXCHANGE AGREEMENT

 

THIS SHARE EXCHANGE AGREEMENT (this “Agreement”) is made as of October 14, 2020 (the “Effective Date”), by and among Medigus Ltd. an entity organized and existing under the laws of Israel (“Medigus”) the shareholders of Eventer Technologies Ltd., an entity organized and existing under the laws of Israel (the “Company”), listed on Exhibit A hereto (each, a “Shareholder” and collectively, the “Shareholders”), and Eli Uzan solely in its capacity as the representative of the Shareholders (the “Representative”).

 

RECITALS

 

WHEREAS, Medigus has entered into that certain Share Purchase Agreement by and between Medigus and the Company, pursuant to which Medigus acquired Ordinary Shares (the “SPA”) (terms not defined herein shall have the meaning given to them in the SPA);

 

WHEREAS, Medigus, the Company and the Shareholders agreed that, during the Exercise Period, each Shareholder shall have an option to transfer the Eventer Shares held by such Shareholder to Medigus in exchange for the issuance by Medigus of Medigus Shares, all in accordance with the terms herein (the “Share Exchange”);

 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1. DEFINITIONS.

 

1.1 Exchange Date” means that date on which the Eventer Shares are exchanged for the benefit of the Medigus Shares

 

1.2 Exercise Period” means the period commencing on the 2nd anniversary of the Effective Date and ending on the date that is 54 months following the Effective Date (i.e. 4 and a half years).

 

1.3 Eventer FMV” means the fair market value of one Eventer Share at the time of Share Exchange, as shall be mutually determined by Medigus and the Shareholder exercising the Option; provided, however, that if Medigus and the Shareholder cannot agree on the fair market value of the Eventer Share, the fair market value shall be determined by calculating the average ratio of the market cap to EBIDTA (as published on the then most-recent annual audited financial statements) of two public companies in the industry of the Company (which, unless otherwise mutually agreed by Medigus and the Representative, shall be Live Nation Worldwide, Inc. and CTS Eventim AG) and multiplying such ration by the Company’s EBIDTA (as published on the then most-recent annual audited financial statements of the Company).

 

1.4 Eventer Share Value” means the product obtained from multiplying the number of Eventer Shares held by a certain Shareholder by the Eventer FMV.

 

1.5 Eventer Shares” means the Ordinary Shares of the Company, par value NIS 0.10, as may be adjusted from time to time following splits, issuance of bonus shares, etc.

 

1.6 ITA” means the Israeli Tax Authority.

 

1.7 ITO” means the Israeli Tax Ordinance (New Version), 1961, as amended, and all rules and regulations promulgated thereunder.

 

1.8 Medigus Share Price” means the average closing price of one Medigus Share on the Tel Aviv Stock Exchange Ltd. (“TASE”) (or if Medigus Shares are not traded on TASE, on the principal market where such shares or ADSs representing such shares are traded) for a period of 60 consecutive trading days ending on (and including) the third trading day immediately prior to the Exchange Date.

 

 

 

 

1.9 Medigus Shares” means Ordinary Shares of Medigus, NIS 1.00 par value.

 

1.10 Revolving Loan Agreement” means that certain Revolving Loan Agreement by and between Medigus and the Company dated as of an even-date hereof.

 

1.11 Securities Act” means the U.S. Securities Act of 1933, as amended.

 

1.12 Valid Certificate” means a certificate, ruling, approval or any other written instructions issued by the ITA applicable to the Medgius Shares to be received by the applicable Shareholder indicating that no withholding (or reduced withholding or any other instructions regarding withholding) of Israeli tax is required with respect to the holder of such certificate, ruling or approval in form and substance satisfactory to Medgius.

 

2. THE EXCHANGE.

 

2.1 THE OPTION. During the Exercise Period, and subject to Section ‎2.2, Section 2.3 and Section 3, the Representative, on behalf of all Shareholders, shall have an option to exchange all (but not less than all) of the Ordinary Shares held by the Shareholders in exchange for such number of Medigus Shares (the “Option”). The number of Medigus Shares into which a Shareholder’s Ordinary Shares shall be converted shall be determined by dividing: (a) such Shareholder’s Eventer Share Value, by (b) the Medigus Share Price, and rounding the resulting number down to the nearest whole number of shares of Medigus Shares.

 

2.2 LIMITATIONS. Notwithstanding Section 2.1, Medigus shall not be obligated to effect the Share Exchange on the Record Date (as such term is defined under the TASE rules and regulations) of: (i) a distribution of bonus shares; (ii) a rights offer; (iii) any distribution of dividends; (iv) a consolidation of the share capital of Medigus; (v) a share split; or (vi) a reduction of the share capital of Medigus (each of the aforementioned events shall be called: “Corporate Event”). In addition, if the Ex-Date (as such term is defined under the TASE rules and regulations) of a Corporate Event occurs before the Record Date of a Corporate Event, then the Option shall not be exercised on the Ex-Date. Medigus shall also not be required to effect the Share Exchange if Medigus’ Board of Directors determines, in its good faith judgement, that it would be materially detrimental to the Company and its shareholders to effect the Share Exchange on the requested date, then Medigus shall have the right to defer taking action for a period of not more than sixty (60) days after the request to effect the Share Exchange. Any delay to the Share Exchange caused as a result of this Section 2.2 shall extend the Exercise Period by the amount of days in which the Share Exchange was delayed.

 

2.3 NO EXCHANGE. Notwithstanding Section 2.1, the Shareholders shall not be entitled to effectuate the Share Exchange if: (i) the outstanding Advances (as defined in the Revolving Loan Agreement) are equal to, or greater than, US$ 600,000, unless approved by Medigus, at its discretion, or (ii) an Event of Default (as defined in the Revolving Loan Agreement) has occurred.

 

2.4 SPECIAL RIGHTS. Notwithstanding Section 2.1, if at any time prior to the Exercise Period, Medigus exercises any of its rights under 6.3 in the Restated Articles of Association, while the Representative has not affirmatively approved Medigus’s action (the date such actions shall be taken will be deemed the “Decision Date”), then in such case the Representative may, within sixty days from the Decision Date, request that Medigus either (i) effect the Share Exchange under the terms of this Agreement, or (ii) purchase all of the Eventer Shares held by the Shareholders for an amount per share equal to the Eventer Share Value. Medigus may, in its sole discretion, determine, whether it wishes to effect the Share Exchange or purchase the Eventer Shares.

 

2

 

 

3. TAX MATTERS; WITHOLDING.

 

3.1 Notwithstanding any other provision of this Agreement to the contrary, Medgius shall be entitled to deduct and withhold from any consideration actually payable or otherwise deliverable to any Seller hereunder, including such portions of the Medigus Shares, actually payable or otherwise deliverable to the Shareholders such amounts as Medigus may be required to deduct or withhold therefrom under the ITO, or any legal requirement with respect to tax which is applicable to the making of such payment. To the extent that such amounts are so withheld by the Medigus, (i) such withheld amounts shall be treated for all purposes as having been paid to the Shareholder to whom or to which such amounts would otherwise have been paid; and (ii) such withheld amounts shall be remitted by Medigus to the applicable governmental entity.

 

3.2 Without limiting the generality of the foregoing, the parties hereto agree that, no withholding or a reduced amount of withholding under the ITO will be made from any consideration payable or otherwise deliverable hereunder to any Shareholder if such Shareholder provides Medgius with a Valid Certificate, at least five (5) business days prior to the time such payment of consideration is to be made.

 

3.3 For the avoidance of doubt, Medigus shall not be required to issue any Medigus Shares to any Shareholder, unless a Valid Certificate providing for a full exemption is delivered to Medigus by such Shareholder or that the applicable amounts required to be withheld are paid by such Shareholder. For the avoidance of doubt, Medigus shall have, in its sole discretion, the authority but not the obligation to withhold any taxes at the applicable rate, and consequently issue to each Shareholder its respective amount of Medgius Shares less such numbers of shares that represent the amount that was withheld at the source.

 

4. REPRESENTATIONS.

 

4.1 Each Shareholder represents and warrants (severally and not jointly, with respect to itself only) to Medigus that the following representations and warranties are true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the applicable Exchange Date:

 

(a) Authorization; Validity. Such Shareholder has the requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly executed and delivered and constitutes the lawful, valid and legally binding obligation of such Shareholder, enforceable in accordance with its terms and conditions except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium laws, and other laws of general application affecting the enforcement of creditors’ rights and remedies generally and general principles of equity.

 

3

 

 

(b) Compliance with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby by such Shareholder will not result in any violation or default reasonably expected to render the transactions contemplated hereby null, void and of no force and effect under: (a) any instrument, judgment, order, writ or decree which binds such Shareholder; (b) any note, indenture or mortgage applicable to such Shareholder; (c) any agreement or other instrument to which such Shareholder is a party or by which it is bound; or (d) any provision of any law, rule or regulation applicable to such Shareholder. Neither the execution and delivery of this Agreement and any other agreements contemplated hereby or ancillary hereto, nor the compliance, by such Shareholder with the terms and provisions hereof or thereof, will result in the creation or imposition of any liens, claims, encumbrances or third party rights of any kind in respect of the Eventer Shares exchanged and transferred by such Shareholder pursuant hereto.

 

(c) Consents. Such Shareholder is not required to obtain any consent, approval, permit, declaration, registration, or authorization by, or filing with, any person, including any applicable court, governmental or regulatory authority, commission, administrative agency, or non-governmental third party, in connection with the execution and performance of this Agreement or the consummation of the transactions contemplated hereunder.

 

(d) The Eventer Shares. Such Shareholder is the sole owner of the Eventer Shares set forth opposite its name in the Capitalization Table, beneficially and of record. At the applicable Exchange Date, the Eventer Shares exchanged by such Shareholder at such Exchange Date will be free and clear of any pledge, lien, hypothecation, encumbrance, charge, claim, or other security interest of any kind, or any other right of any third party (“Security Interest”), and upon transfer thereof to the Shareholder, Medigus will have good and valid title to such Eventer Shares, beneficially and of record, free and clear of any Security Interest, with the rights attached thereto under the Restated Articles.

 

(e) Litigation. There is no action, suit, investigation or proceeding pending or, to such Shareholder’s knowledge, threatened against such Shareholder before any court, arbitrator or any governmental authority which, if determined or resolved in a manner adverse to such Shareholder, would reasonably be expected to challenge or seek to prevent, enjoin, alter or delay the transactions contemplated hereby.

 

(f) Exchange for Own Account. The Shareholder is exchanging its Eventer Shares for its own account.

 

(g) Sophisticated Shareholder. Such Shareholder acknowledges that following the applicable Exchange Date, such Shareholder will have no future participation in any Company gains, losses, profits or distributions with respect to the Eventer Shares exchanged by such Shareholder at such Exchange Date. If such Eventer Shares increase in value by any means, or if the Company’s equity becomes freely tradable and increases in value, such Shareholder acknowledges that it is voluntarily forfeiting any opportunity to share in any resulting increase in value from such Eventer Shares. Such Shareholder further acknowledges and represents that (a) it has not relied on any representation or statement of Medigus or the Company, nor of any of their respective officers, directors, employees or agents, regarding the present or future value of such Eventer Shares, or the advisability of the decision to exchange such Eventer Shares for the Medigus Shares, and (b) neither Medigus or the Company, nor any of their respective officers, directors, employees or agents, is acting as a fiduciary or financial or investment adviser to such Shareholder, or has given such Shareholder any investment advice, opinion or other information on whether the exchange of such Eventer Shares is prudent.

 

4

 

 

Such Shareholder further acknowledges that (i) Medigus currently may have, and/or later may come into possession of, information with respect to the Company that is not known to such Shareholder and that may be material to a decision to exchange the Eventer Shares at the applicable Exchange Date (“Shareholder Excluded Information”), (ii) it has elected to exchange such Eventer Shares notwithstanding its lack of knowledge of the Shareholder Excluded Information, and (iii) neither Medigus, the Company nor any of their officers, directors, employees, or agents shall have liability to such Shareholder, and such Shareholder waives and releases, any claims that it might have against any of the foregoing, whether under applicable securities laws or otherwise, with respect to the nondisclosure of the Shareholder Excluded Information.

 

(h) Tax Matters. Such Shareholder has had an opportunity to review with its tax advisers the federal, state, local, and/or foreign tax consequences of the transactions contemplated hereby, and such Shareholder is relying solely on such advisers and not on any statements or representations of Medigus, the Company, or any of their respective agents. Such Shareholder understands and acknowledges that the Shareholder (and not Medigus) shall be responsible for, and shall solely bear, all of the Shareholder’s tax liability (including withheld tax liabilities) and any and all related interest and penalties that may arise, or imposed by any taxing authority, domestic or foreign, as a result of or in connection with the transactions contemplated hereby.

 

(i) No Bankruptcy. Such Shareholder is not insolvent, and there has been no request for, nor has there been issued, any bankruptcy decree against such Shareholder, whether temporary or permanent, nor has any legal, administrative or other proceeding concerning the bankruptcy of such Shareholder been commenced.

 

(j) Each certificate, instrument, or book entry representing (i) the Medigus Shares, and (ii) any other securities issued in respect of the Medigus Shares, upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall be notated with a legend. The Medigus Shares will not be registered under the Securities Act or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available (such as in accordance with Section 144 of the Securities Act). The Shareholders are aware that Medigus is under no obligation to effect any such registration or to file for or comply with any exemption from registration. The sale and issuance of such securities have not and will not be registered under the Securities Act by reason of a specific exemption from registration which depends upon, among other things, the accuracy of the Shareholders’s representations as expressed herein.

 

4.2 Medigus represents and warrants to the Shareholders that the following representations and warranties are true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the applicable Exchange Date:

 

(a) Authorization; Validity. Medigus is a duly incorporated or formed and validly existing under the laws of its respective jurisdiction of incorporation. Medigus has the requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly executed and delivered and, assuming due execution and delivery by the Shareholders, constitutes the valid and binding obligation of Medigus, enforceable in accordance with its terms and conditions except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium laws, and other laws of general application affecting the enforcement of creditors’ rights and remedies generally.

 

5

 

 

(b) Consents. Medigus has obtained each consent, approval, permit, declaration, registration, and authorization of, and made each filing with, any person, including any applicable court, governmental or regulatory authority, commission, administrative agency, and non-governmental third party, if any, necessary to consummate the transactions contemplated hereunder.

 

(c) Non Contravention. Neither the execution, delivery or performance by Medigus of this Agreement or any of the transaction documents to which it is a party, nor the consummation of the transactions contemplated hereunder and thereunder, will (with or without notice or lapse of time): (a) contravene, conflict with or result in a violation of (i) any provision of the organizational documents of Medigus, (ii) any applicable law, or (iii) any provision of any contract or agreement to which Medigus is party; or (b) otherwise give any person the right to (i) declare a default or exercise any remedy under any such contract or agreement, (ii) accelerate the maturity or performance of any such contract or agreement, or (iii) cancel, terminate or modify any such contract or agreement, in each case, except as would not have and would not reasonably be expected to have or result in an adverse effect on the ability of Medigus to consummate the transactions contemplated hereunder pursuant to the terms hereof or under the transaction documents.

 

(d) Medigus Shares. All Medigus Shares to be issued to the Shareholders in connection with the Share Exchange will be, when issued, in accordance with the terms thereof, duly authorized, validly issued, fully paid an non-assessable.

 

5. APPOINTMENT OF REPRESENTATIVE. Each Shareholder approves the designation of and designates the Representative as the representative of the Shareholder and as the attorney-in-fact and agent for and on behalf of each Shareholders for all purposes in connection with this Agreement, including with respect to the taking by the Representative of any and all actions in connection on deciding whether or not to effect the Share Exchange, and including but not limited, the exercise of the power to: (i) give and receive notices and communications to or Medigus relating to this Agreement, (ii) determine the Eventer FMV or authorize the identity and the appointment of an Appraiser, and (iii) agree to, object to, negotiate, resolve, enter into settlements and compromises in respect with this Agreement. The Shareholders shall be bound by all actions and decisions taken and consents and instructions given by the Representative in connection with this Agreement, and Medigus shall be entitled to rely on, and shall be relieved from any liability to any Shareholder for any acts done by them in accordance with, any such action, decision, consent or instruction of the Representative. After the Closing, notices or communications to or from the Representative shall constitute notice to or from each of the Shareholders.

 

6. MISCELLANEOUS.

 

6.1 Expenses. Each Party shall bear its own expenses in connection with this Agreement. Without limiting the generality of the foregoing, any fees relating to the obtainment of a Valid Tax Certificate (including a ruling under Section 104H of the ITO) shall be borne by the Company. Notwithstanding the foregoing, the fees and expenses of the Appraiser shall be borne and paid for by the Company.

 

6

 

 

6.2 Confidentiality. Save as required for under applicable law, each Party hereby undertakes to the other Party to maintain the existence of this Agreement and its content in confidence, and not disclose or convey its content or existence to any person and/or entity whatsoever, other than as is reasonably required for the purpose of carrying out its obligations hereunder, without the prior written consent of the other Party.

 

6.3 Notices. Any communications between the parties hereto or notices provided herein to be given may be given by personal delivery or mailing the same, postage prepaid, to Medigus at Omer Industrial Park, No. 7A, P.O Box 3030, Omer 8496500, Israel and to Representative at Bezalel 4, Ramat Gan, Israel; or to such other address as either party may in writing hereafter indicate. Notices shall be deemed effective on the date received.

 

6.4 Assignment. Neither party shall assign this Agreement without the prior written consent of Medgius and the Representative. It is hereby clarified that to the extent a Shareholder transfers any of the Eventer Shares held by such Shareholder to any third party, such third Party shall not have any rights under this Agreement, including the right to exchange such Eventer Shares into Medigus Shares.

 

6.5 Severability. The illegality or unenforceability of any provision of this Agreement shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement.

 

6.6 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Israel, disregarding its conflict of laws rules.

 

6.7 Separate Counterpart; Amendments. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may be amended only by an instrument in writing duly signed by all Medigus and the Representative.

 

6.8 Entire Agreement. This agreement supersedes any previous agreement between the parties in relation to the matters dealt with herein and represents the entire understanding between the parties with respect to such matters.

 

[The remainder of this page is intentionally left blank]

 

7

 

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

  MEDIGUS LTD.
   
  By: /s/ Eli Yoresh
  Name:   Eli Yoresh
  Title: Chairman
   
  By: /s/ Liron Carmel
  Name: Liron Carmel
  Title: Chief Executive Officer
   
  EVENTER TECHNOLOGIES LTD.
   
  By: /s/ Eli Uzan
  Name: Eli Uzan
  Title: Chairman
   
  By: /s/ Julien Azoulay
  Name: Julien Azoulay
  Title: Chief Executive Officer
   
  /s/ Eli Uzan
  ELI UZAN, in his capacity as a Representative

 

8

 

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement effective as of the Effective Date.

 

  /s/ Eli Uzan
  ELI UZAN
   
  /s/ Shenhav-Eventer L.P. Limited Partnership
  SHENHAV-EVENTER L.P. LIMITED
  PARTNERSHIP
   
  /s/ Roee Grinblat
  ROEE GRINBLAT
   
  /s/Joeri Kreisberg
  JOERI KREISBERG
   
  /s/ Shalom Eshel
  SHALOM ESHEL
   
  /s/Menachem Finkelstein
  MENACHEM FINKELSTEIN
   
  /s/ Julien Azulay
  ALTSHULER SHACHAM, in trust for Assaf Greenfield and Pola Umnitzin, by proxy granted to Julien Azulay
   
  /s/ Assaf Greenfeld
  ASSAF GREENFELD

 

 

9

 

 

 

Exhibit 10.8

 

ADDENDUM NO. 1 TO AMENDED AND RESTATED ASSET TRANSFER AGREEMENT

 

This Addendum (“Addendum”) is entered into on this 27 day of July 2020, by and between Medigus Ltd., a company incorporated under the laws of the state of Israel, Registration Number 51-286697-1 (“Medigus”) and ScoutCam Ltd., a company incorporated under the laws of the state of Israel, Registration Number 51-595040-0 (“ScoutCam”). Medigus and ScoutCam are sometimes referred to herein as a “Party” and together as the “Parties”.

 

Capitalized terms used but not defined herein shall have the meaning ascribed to them under the Agreement (as defined below)

 

WHEREAS, the Parties have previously entered into an Asset Transfer Agreement, dated as of March 1, 2019 (the “Prior Agreement”);

 

WHEREAS, the Parties have replaced the Prior Agreement with the Amended and Restated Asset Transfer Agreement, dated as of December 1, 2019 (the “Agreement”); and

 

WHEREAS, the Parties wish to amend the Agreement with respect to the transferred assets, know-how and other intellectual property rights, used or necessary for use in connection with the Transferred Business, as further provided herein.

 

NOW, THEREFORE, the Parties hereby agree as follows:

 

1. Section 2.1 shall be amended and restated to read as follows:

 

“2.1. Transfer of Assets. On the terms and subject to the conditions set forth in this Agreement, at the Closing (or with respect to the patents listed under Section (a) of Schedule 2.1, the dates detailed therein), the Transferor shall transfer, assign, convey and deliver to the Transferee and the Transferee shall accept and assume from the Transferor, all of the Transferor’s rights, titles and interests in, to and under the transferred assets listed on Schedule ‎2.1 (the “Transferred Assets”), free and clear of any Liens.

 

The Transferred Assets shall include, in addition to the assets listed on Schedule ‎2.1, effective as of the Closing:

 

2.1.1. all rights and title to the severance funds maintained for or on behalf of the Transferred Employees;

 

2.1.2. all past, present and future causes of action and other enforcement rights primarily under, or on account of, the Transferee’s Business, the Products or any of the Transferred Assets, including, without limitation, all causes of action and other enforcement rights for damages, profits, royalties or other payments, injunctive relief, and any other remedies of any kind for past, current and future infringement, misappropriation or any violations of any one of the rights embodied in any of the Transferred Assets;

 

2.1.3. all of the goodwill associated with the Transferee’s Business and/or any of the Transferred Assets;

 

2.1.4. all Documents that are primarily used or relate to the Transferee’s Business or any of the Transferred Assets;

 

2.1.5. all other current assets of the Transferee’s Business; and

 

2.1.6. all know how and other intellectual property rights, used or necessary for use in connection with the Transferred Business.

 

Any rights, assets, properties and business that fall within the above definition of Transferred Assets shall be deemed a Transferred Asset, notwithstanding the failure to list the same on any of the aforementioned lists and schedules. For the avoidance of doubt, Section 2.2 of the Agreement shall apply mutatis mutandis to the assets included in Schedule 2.1.

 

 

 

 

In the event that the Transferee neglects any of the patent assets set forth in Section (a) under Schedule 2.1, the Transferee shall transfer back ownership of the patent family of such patent asset to Transferor, and such transfer shall not require additional consideration and absent any additional contingencies (the “Transfer Back”). For the purpose of this Section 2, the term neglect shall mean any act or omission, which would result in invalidation of the patent assets or cause its expiry. For the avoidance of doubt, a decision by Transferee to cease its prosecution or participation in any invalidation proceedings against the Transferred Assets vis-a-vis the applicable Patent Office, or failure to pay maintenance fees in connection with the Transferred Assets shall be deemed as neglecting such Transferred Assets. In the event that IIA Approval (as defined herein), to the extent required, cannot be reasonably obtained with respect to the Transfer Back, Transferee shall take actions which shall have the effect of achieving the closest possible result as the Transfer Back. In the event of a Transfer Back, Transferor shall extend a perpetual, royalty free, non-exclusive, transferable by way of merger, acquisition or sale of all or substantially all of assets, license to Transferee for exploiting such Transferred Assets that were subject to the Transfer Back, for the purpose of commercializing, selling, sublicensing, combining, developing, manufacturing, having manufactured with respect to any Company product or service. The Transfer Back shall occur upon 30 days prior to a deadline for an act, which if not met, would lead to invalidation of the patent assets or cause their expiry.

 

2. Schedule 2.1 attached to the Agreement shall be replaced with Schedule 2.1 attached hereto. For the avoidance of doubt, the transfer of patent family 24994 described in Schedule 2.1 hereto is subject to the prior approval of the Israel Innovation Authority (“IIA” and the “IIA Approval”). Medigus shall submit as soon as practicable following the date hereof an appropriate request for the grant of the IIA Approval and will use best efforts to obtain such approval as soon as possible. As a condition to the transfer, ScoutCam shall be obligated to execute an undertaking in the form acceptable to Medigus and the IIA pursuant to which ScoutCam agrees to comply with the obligations stipulated by the Law for Encouragement of Research and Development – 1984.

 

3. Effective as of the date hereof, Section 3.2 and Schedule 3.2 shall be deleted, and instead such Section 3.2 shall be reserved. For the avoidance of doubt, the Addendum shall not derogate from the rights and obligations derived from Section 3.2 prior to the date hereof.

 

4. Effective Date

 

This Addendum shall be in effect as of the date hereof and shall be attached to the Agreement and become an integral part thereof.

 

5. Reservation of Terms

 

Except as expressly stated in this Addendum all other terms in the Agreement shall remain unchanged unless specifically amended in accordance with the terms of the Agreement.

 

- Signature Pages Follow -

 

2

 

 

IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Amendment as of the day and year first above written.

 

  MEDIGUS LTD.   SCOUTCAM LTD.
       
 

/s/ Liron Carmel /s/ Tatiana Yosef

  /s/ Benad Goldwasser  /s/ Yaron Silberman
  Signature   Signature
       
  Liron Carmel / Tatiana Yosef   Benad Goldwasser / Yaron Silberman
  Printed Name   Printed Name
       
  CEO / CFO   Chairman / CEO
  Title   Title

 

3

 

Schedule 2.1

 

List of Transferred Assets

 

[***]

 

 

4

 

 

Exhibit 16.1

 

 

 

 

 

November 2, 2020

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by Medigus Ltd. pursuant to Item 16F of Form 20-F (copy attached), which we understand will be filed with the Securities and Exchange Commission as part of the Registration Statement on Form F-1 of Medigus Ltd. dated November 2, 2020. We agree with the statements concerning our Firm contained therein.

 

Very truly yours,

 

 

 

Tel-Aviv, Israel /s/ Kesselman & Kesselman
November 2, 2020 Certified Public Accountants (Isr.)
  A member firm of PricewaterhouseCoopers International Limited

 

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form F-1 of Medigus Ltd. of our report dated April 21, 2020 relating to the financial statements, which appears in Medigus Ltd.'s Annual Report on Form 20-F for the year ended December 31, 2019.  We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

Tel Aviv, Israel   /s/ Kesselman & Kesselman
November 2, 2020   Certified Public Accountants (Isr.)
    A member firm of PricewaterhouseCoopers International Limited

 

 

Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,

P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il

 

Exhibit 23.2

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in this Registration Statement on Form F-1 of Medigus Ltd. of our report dated April 21, 2020, which appears in Medigus Ltd.’s Annual Report on Form 20-F for the year ended December 31, 2019, relating to the consolidated financial statements of Gix Internet Ltd. (Formerly: Algomizer Ltd.) for the period from September 4, 2019 through December 31, 2019.

 

We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 

  By: /s/ Brightman Almagor Zohar & Co.
   

Brightman Almagor Zohar & Co.

Certified Public Accountants

 

 

Tel Aviv, Israel

Date: November 2, 2020

  A Firm in the Deloitte Global Network